Ranibizumab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Ranibizumab comprises 639 peer-reviewed publications across 15 journals, 91 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Macular Degeneration, Macular Edema, Pterygium, and Diabetic Retinopathy. Most recent publication: COMPARE COMBINED USE OF ANTI-VEGF DRUGS DURING OR AFTER PARS PLANA VITRECTOMY FOR DIABETIC MACULAR EDEMA GUIDED BY MICROSCOPE-INTEGRATED OPTICAL COHERENCE TOMOGRAPHY., Retina, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials.
    Ying GS, Kim BJ, Maguire MG, et al. · JAMA Ophthalmol · 2014
    PubMed: PMID 24875610 · NCT00593450 · Macular Degeneration
  2. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
    Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, et al. · JAMA · 2015
    PubMed: PMID 26565927 · NCT01489189 (Protocol S)
  3. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
    Maturi RK, Glassman AR, Liu D, et al. · JAMA Ophthalmol · 2019
    PubMed: PMID 29127949 · NCT01945866
  4. Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Maguire MG, Ying GS, Jaffe GJ, et al. · JAMA Ophthalmol · 2017
    PubMed: PMID 27099955 · NCT00593450 · Macular Degeneration
  5. Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration: A Phase 1 Dose-Escalation Study.
    Jackson TL, Boyer D, Brown DM, et al. · JAMA Ophthalmol · 2017
    PubMed: PMID 28570723 · NCT01674569 · Wet Macular Degeneration
  6. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).
    Hagstrom SA, Ying GS, Pauer GJ, et al. · JAMA Ophthalmol · 2014
    PubMed: PMID 24652518 · NCT00593450 · Macular Degeneration
  7. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
    Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. · N Engl J Med · 2015
    PubMed: PMID 25692915 · NCT01627249 (Protocol T)
  8. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.
    Diabetic Retinopathy Clinical Research Network* · JAMA Ophthalmol · 2013
    PubMed: PMID 23370902 · NCT00996437 (N) · Retinal Diseases

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT00275821
EXCITE
Macular DegenerationMean Change From Baseline in Best-corrected Visual Acuity of the Study Eye at Month 12
Baseline to Month 12
Ranibizumab 0.3 mg - 3 Times Monthly, Then Quarterly4.9 letters (±13.13 Standard Deviation)
Ranibizumab 0.3 mg Monthly8.3 letters (±11.31 Standard Deviation)
Ranibizumab 0.5 mg - 3 Times Monthly, Then Quarterly3.8 letters (±13.33 Standard Deviation)
NCT00331864Macular DegenerationPercentage of Patients With Ocular Adverse Events (AEs) in the Study Eye
Baseline through end of study (12 month treatment period)
Ranibizumab ANCHOR38.9 Percentage of Participants
Ranibizumab Non-ANCHOR48.5 Percentage of Participants
NCT00331864Macular DegenerationPercentage of Patients With Targeted Grade 3 Adverse Events (AEs) in the Study Eye
Baseline through end of study (12 month treatment period)
Ranibizumab ANCHOR0.0 Percentage of Participants
Ranibizumab Non-ANCHOR2.9 Percentage of Participants
NCT00384449Eales diseaseChange in OCT Thickness.
Baseline and 6 months
Lucentis (Ranibizumab)262 um
Lucentis (Ranibizumab)269 um
NCT00384449Eales diseaseIncidence and Severity of Ocular Adverse Events, as Identified by Eye Examination (Including Visual Acuity Testing)
Monthly through Month 6
Lucentis (Ranibizumab)0 adverse events
NCT00384449Eales diseaseIncidence and Severity of Other Adverse Events, as Identified by Physical Examination, Subject Reporting, and Changes in Vital Signs
Monthly through Month 6
Lucentis (Ranibizumab)0 adverse events
NCT00433017Macular DegenerationChange From Baseline in Best-corrected Visual Acuity (BCVA) at Month 12.
Baseline and Month 12
Ranibizumab59.4 Letters (±18.8 Standard Deviation)
Ranibizumab55.1 Letters (±12.3 Standard Deviation)
Ranibizumab4.4 Letters (±15.92 Standard Deviation)
Verteporfin + Ranibizumab54.6 Letters (±13.5 Standard Deviation)
Verteporfin + Ranibizumab2.5 Letters (±14.82 Standard Deviation)
Verteporfin + Ranibizumab57.1 Letters (±18.3 Standard Deviation)
NCT00433017Macular DegenerationPercent of Participants With a Treatment-free Interval of at Least 3 Months Following the Month 2 Visit
Month 2 to Month 11
Ranibizumab92.2 Percentage of Participants
Verteporfin + Ranibizumab95.8 Percentage of Participants
NCT00436553Macular DegenerationMean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12
Baseline and Month 12
Ranibizumab Monotherapy8.1 Letters (±15.09 Standard Deviation)
Ranibizumab Monotherapy54.8 Letters (±13.55 Standard Deviation)
Ranibizumab Monotherapy63.0 Letters (±18.88 Standard Deviation)
Verteporfin RF + Ranibizumab4.4 Letters (±15.47 Standard Deviation)
Verteporfin RF + Ranibizumab54.6 Letters (±12.78 Standard Deviation)
Verteporfin RF + Ranibizumab59.0 Letters (±18.03 Standard Deviation)
Verteporfin SF + Ranibizumab53.7 Letters (±13.52 Standard Deviation)
Verteporfin SF + Ranibizumab5.3 Letters (±15.66 Standard Deviation)
Verteporfin SF + Ranibizumab59.0 Letters (±17.47 Standard Deviation)
NCT00436553Macular DegenerationPercent of Patients With a Treatment-free Interval of at Least 3 Months Following the Month 2 Visit
Month 2 up to Month 11
Verteporfin RF + Ranibizumab83.5 Percent of participants
Verteporfin SF + Ranibizumab92.6 Percent of participants
NCT00444600
LRT for DME
Diabetic RetinopathyChange in Visual Acuity From Baseline to 1 Year Among Eyes That Had Prior Treatment for Diabetic Macular Edema
from baseline to 1 Year
0.5 mg Ranibizumab+Deferred Laser8 Letters (±12 Standard Deviation)
0.5 mg Ranibizumab+Deferred Laser11 Letters (±13 Standard Deviation)
0.5 mg Ranibizumab+Prompt Laser9 Letters (±10 Standard Deviation)
0.5 mg Ranibizumab+Prompt Laser9 Letters (±12 Standard Deviation)
4 mg Triamcinolone+Prompt Laser3 Letters (±13 Standard Deviation)
4 mg Triamcinolone+Prompt Laser5 Letters (±13 Standard Deviation)
Sham+Prompt Laser3 Letters (±13 Standard Deviation)
Sham+Prompt Laser2 Letters (±14 Standard Deviation)
NCT00444600
LRT for DME
Diabetic RetinopathyChange in Visual Acuity From Baseline to 1 Year Among Eyes That Were Pseudophakic at Baseline
from baseline to 1 Year
0.5 mg Ranibizumab+Deferred Laser7 Letters (±9 Standard Deviation)
0.5 mg Ranibizumab+Deferred Laser10 Letters (±14 Standard Deviation)
0.5 mg Ranibizumab+Prompt Laser8 Letters (±12 Standard Deviation)
0.5 mg Ranibizumab+Prompt Laser9 Letters (±10 Standard Deviation)
4 mg Triamcinolone+Prompt Laser8 Letters (±9 Standard Deviation)
4 mg Triamcinolone+Prompt Laser2 Letters (±14 Standard Deviation)
Sham+Prompt Laser4 Letters (±14 Standard Deviation)
Sham+Prompt Laser2 Letters (±13 Standard Deviation)
NCT00444600
LRT for DME
Diabetic RetinopathyChange in Visual Acuity From Baseline to 1 Year Grouped by Baseline Visual Acuity Letter Score
from baseline to 1 Year
0.5 mg Ranibizumab+Deferred Laser13 Letters (±10 Standard Deviation)
0.5 mg Ranibizumab+Deferred Laser5 Letters (±13 Standard Deviation)
0.5 mg Ranibizumab+Prompt Laser12 Letters (±11 Standard Deviation)
0.5 mg Ranibizumab+Prompt Laser6 Letters (±10 Standard Deviation)
4 mg Triamcinolone+Prompt Laser1 Letters (±11 Standard Deviation)
4 mg Triamcinolone+Prompt Laser7 Letters (±14 Standard Deviation)
Sham+Prompt Laser1 Letters (±12 Standard Deviation)
Sham+Prompt Laser5 Letters (±14 Standard Deviation)
NCT00444600
LRT for DME
Diabetic RetinopathyChange in Visual Acuity From Baseline to 1 Year Grouped by Diabetic Retinopathy Severity
from baseline to 1 Year
0.5 mg Ranibizumab+Deferred Laser9 Letters (±13 Standard Deviation)
0.5 mg Ranibizumab+Deferred Laser9 Letters (±12 Standard Deviation)
0.5 mg Ranibizumab+Prompt Laser10 Letters (±11 Standard Deviation)
0.5 mg Ranibizumab+Prompt Laser8 Letters (±10 Standard Deviation)
4 mg Triamcinolone+Prompt Laser5 Letters (±12 Standard Deviation)
4 mg Triamcinolone+Prompt Laser3 Letters (±14 Standard Deviation)
Sham+Prompt Laser3 Letters (±13 Standard Deviation)
Sham+Prompt Laser2 Letters (±15 Standard Deviation)
NCT00444600
LRT for DME
Diabetic RetinopathyChange in Visual Acuity From Baseline to 1 Year Grouped by Diffuse vs. Focal Edema as Characterized by the Investigator
from baseline to 1 Year
0.5 mg Ranibizumab+Deferred Laser8 Letters (±13 Standard Deviation)
0.5 mg Ranibizumab+Deferred Laser8 Letters (±15 Standard Deviation)
0.5 mg Ranibizumab+Deferred Laser10 Letters (±10 Standard Deviation)
0.5 mg Ranibizumab+Prompt Laser9 Letters (±12 Standard Deviation)
0.5 mg Ranibizumab+Prompt Laser10 Letters (±9 Standard Deviation)
0.5 mg Ranibizumab+Prompt Laser8 Letters (±11 Standard Deviation)
4 mg Triamcinolone+Prompt Laser3 Letters (±13 Standard Deviation)
4 mg Triamcinolone+Prompt Laser3 Letters (±11 Standard Deviation)
4 mg Triamcinolone+Prompt Laser5 Letters (±14 Standard Deviation)
Sham+Prompt Laser3 Letters (±13 Standard Deviation)
Sham+Prompt Laser3 Letters (±13 Standard Deviation)
Sham+Prompt Laser2 Letters (±14 Standard Deviation)
NCT00444600
LRT for DME
Diabetic RetinopathyChange in Visual Acuity From Baseline to 1 Year Grouped by Optical Coherence Tomography Central Subfield Thickness
from baseline to 1 Year
0.5 mg Ranibizumab+Deferred Laser11 Letters (±13 Standard Deviation)
0.5 mg Ranibizumab+Deferred Laser7 Letters (±12 Standard Deviation)
0.5 mg Ranibizumab+Prompt Laser7 Letters (±11 Standard Deviation)
0.5 mg Ranibizumab+Prompt Laser11 Letters (±10 Standard Deviation)
4 mg Triamcinolone+Prompt Laser3 Letters (±12 Standard Deviation)
4 mg Triamcinolone+Prompt Laser6 Letters (±14 Standard Deviation)
Sham+Prompt Laser3 Letters (±15 Standard Deviation)
Sham+Prompt Laser3 Letters (±11 Standard Deviation)
NCT00444600
LRT for DME
Diabetic RetinopathyDistribution of Change in Visual Acuity (Letters) From Baseline to 1 Year
from baseline to 1 Year
0.5 mg Ranibizumab+Deferred Laser36 Eyes
0.5 mg Ranibizumab+Deferred Laser4 Eyes
0.5 mg Ranibizumab+Deferred Laser2 Eyes
0.5 mg Ranibizumab+Deferred Laser5 Eyes
0.5 mg Ranibizumab+Deferred Laser35 Eyes
0.5 mg Ranibizumab+Deferred Laser54 Eyes
0.5 mg Ranibizumab+Deferred Laser52 Eyes
0.5 mg Ranibizumab+Prompt Laser3 Eyes
0.5 mg Ranibizumab+Prompt Laser57 Eyes
0.5 mg Ranibizumab+Prompt Laser38 Eyes
0.5 mg Ranibizumab+Prompt Laser34 Eyes
0.5 mg Ranibizumab+Prompt Laser38 Eyes
0.5 mg Ranibizumab+Prompt Laser14 Eyes
0.5 mg Ranibizumab+Prompt Laser3 Eyes
4 mg Triamcinolone+Prompt Laser12 Eyes
4 mg Triamcinolone+Prompt Laser15 Eyes
4 mg Triamcinolone+Prompt Laser22 Eyes
4 mg Triamcinolone+Prompt Laser32 Eyes
4 mg Triamcinolone+Prompt Laser54 Eyes
4 mg Triamcinolone+Prompt Laser39 Eyes
4 mg Triamcinolone+Prompt Laser12 Eyes
Sham+Prompt Laser38 Eyes
Sham+Prompt Laser67 Eyes
Sham+Prompt Laser23 Eyes
Sham+Prompt Laser16 Eyes
Sham+Prompt Laser86 Eyes
Sham+Prompt Laser43 Eyes
Sham+Prompt Laser20 Eyes
NCT00444600
LRT for DME
Diabetic RetinopathyMean Change in Visual Acuity (Letters) From Baseline to 1 Year Adjusted for Baseline Visual Acuity
from baseline to 1 Year
0.5 mg Ranibizumab+Deferred Laser9 Letters (±12 Standard Deviation)
0.5 mg Ranibizumab+Prompt Laser9 Letters (±11 Standard Deviation)
4 mg Triamcinolone+Prompt Laser4 Letters (±13 Standard Deviation)
Sham+Prompt Laser3 Letters (±13 Standard Deviation)
NCT00445003
LRTforDME+PRP
Diabetic RetinopathyChange in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 14 Weeks
baseline to 14 weeks
0.5mg Ranibizumab1 Letter Score (±11 Standard Deviation)
4-mg Triamcinolone Acetonided2 Letter Score (±11 Standard Deviation)
Sham Injection-4 Letter Score (±14 Standard Deviation)
NCT00473330
RISE
Macular EdemaPercentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24
Baseline to Month 24
Ranibizumab 0.3 mg44.8 Percentage of patients
Ranibizumab 0.5 mg39.2 Percentage of patients
Sham Injection18.1 Percentage of patients
NCT00473382
RIDE
Macular EdemaPercentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24
Baseline to Month 24
Ranibizumab 0.3 mg33.6 Percentage of patients
Ranibizumab 0.5 mg45.7 Percentage of patients
Sham Injection12.3 Percentage of patients
NCT00485836
CRUISE
Macular EdemaMean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months
Baseline and 6 months
Ranibizumab Injection 0.3 mg47.4 Units on a scale (±14.8 Standard Deviation)
Ranibizumab Injection 0.3 mg12.7 Units on a scale (±15.9 Standard Deviation)
Ranibizumab Injection 0.5 mg14.9 Units on a scale (±13.2 Standard Deviation)
Ranibizumab Injection 0.5 mg48.1 Units on a scale (±14.6 Standard Deviation)
Sham Injection0.8 Units on a scale (±16.2 Standard Deviation)
Sham Injection49.2 Units on a scale (±14.7 Standard Deviation)
NCT00486018
BRAVO
Macular EdemaMean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months
Baseline and 6 months
Ranibizumab Injection 0.3 mg16.6 Units on a scale (±11.0 Standard Deviation)
Ranibizumab Injection 0.3 mg56.0 Units on a scale (±12.1 Standard Deviation)
Ranibizumab Injection 0.5 mg53.0 Units on a scale (±12.5 Standard Deviation)
Ranibizumab Injection 0.5 mg18.3 Units on a scale (±13.2 Standard Deviation)
Sham Injection7.3 Units on a scale (±13.0 Standard Deviation)
Sham Injection54.7 Units on a scale (±12.2 Standard Deviation)
NCT00509795
VIEW1
Macular DegenerationPercentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)
Baseline and at week 52
IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q495.9 percentage of patients
IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q495.1 percentage of patients
IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q895.1 percentage of patients
Ranibizumab 0.5mg Q494.4 percentage of patients
Total95.1 percentage of patients
NCT00593450Macular DegenerationChange From Baseline in Visual-acuity Score (Continuous)
Baseline and 1 Year
1-Lucentis Monthly8.5 No. of Letters (±14.1 Standard Deviation)
2-Avastin Monthly8.0 No. of Letters (±15.8 Standard Deviation)
3-Lucentis as Needed6.8 No. of Letters (±13.1 Standard Deviation)
4-Avastin as Needed5.9 No. of Letters (±15.7 Standard Deviation)
NCT00626782GlaucomaAdverse Events
12 months
Treatment 1 (Ranibizumab 0.5mg)100 percentage of participants
Treatment 2 (Mitomycin C 0.4 mg/ml)16.67 percentage of participants
NCT00637377
VIEW 2
Macular DegenerationPercentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)
At week 52
Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q496.27 Percentage of participants
Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q495.62 Percentage of participants
Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q895.56 Percentage of participants
Ranibizumab 0.5mg Q494.42 Percentage of participants
NCT00680225Uveal MelanomaMean Tumor Thickness
12 mo
Lucentis Injection2.91 mm
NCT00687804
RESTORE
EdemaCore Study: Difference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline Assessments From Month 1 to Month 12
Baseline through the end of study (Month 12)
Laser0.8 Letters (±8.56 Standard Deviation)
Laser63.4 Letters (±12.26 Standard Deviation)
Laser62.6 Letters (±11.01 Standard Deviation)
Ranibizumab 0.5 mg70.8 Letters (±10.53 Standard Deviation)
Ranibizumab 0.5 mg6.1 Letters (±6.43 Standard Deviation)
Ranibizumab 0.5 mg64.7 Letters (±10.07 Standard Deviation)
Ranibizumab 0.5 mg + Laser5.9 Letters (±7.92 Standard Deviation)
Ranibizumab 0.5 mg + Laser69.2 Letters (±11.44 Standard Deviation)
Ranibizumab 0.5 mg + Laser63.4 Letters (±9.99 Standard Deviation)
NCT00687804
RESTORE
EdemaExtension Study: Percentage of Participants With Non-Ocular Adverse Events (AEs) in the 24 Month Extension Study
Extension baseline (Month 12 -end of core study) to Month 36 (end of extension study) [24 Months]
Laser With Ranibizumab in Extension37.3 Percentage of participants
Laser With Ranibizumab in Extension71.2 Percentage of participants
Laser Without Ranibizumab in Extension13.3 Percentage of participants
Laser Without Ranibizumab in Extension73.3 Percentage of participants
Ranibizumab 0.5 mg27.7 Percentage of participants
Ranibizumab 0.5 mg73.5 Percentage of participants
Ranibizumab 0.5 mg + Laser30.1 Percentage of participants
Ranibizumab 0.5 mg + Laser73.5 Percentage of participants
NCT00687804
RESTORE
EdemaExtension Study: Percentage of Participants With Ocular Adverse Events (AEs) in the Study Eye in the 24 Month Extension Study
Extension baseline (Month 12 -end of core study) to Month 36 (end of extension study) [24 Months]
Laser With Ranibizumab in Extension1.7 Percentage of participants
Laser With Ranibizumab in Extension52.5 Percentage of participants
Laser Without Ranibizumab in Extension0.0 Percentage of participants
Laser Without Ranibizumab in Extension40.0 Percentage of participants
Ranibizumab 0.5 mg56.6 Percentage of participants
Ranibizumab 0.5 mg2.4 Percentage of participants
Ranibizumab 0.5 mg + Laser56.6 Percentage of participants
Ranibizumab 0.5 mg + Laser1.2 Percentage of participants
NCT00764738—Microperimetry Mean Sensitivity
One Year
Monthly Ranibizumab6.7 dB (±0.7 Standard Error)
Monthly Ranibizumab5.5 dB (±0.8 Standard Error)
PRN Ranibizumab5.1 dB (±0.7 Standard Error)
PRN Ranibizumab7.3 dB (±0.8 Standard Error)
Ranibizumab 0.5 mg7.3 dB (±0.7 Standard Error)
Ranibizumab 0.5 mg5.7 dB (±0.7 Standard Error)
Ranibizumab 2.0 mg6.6 dB (±1.0 Standard Error)
Ranibizumab 2.0 mg4.6 dB (±0.8 Standard Error)
NCT00764738—Multifocal Electroretinography N1-P1 Amplitude
One Year
Monthly Ranibizumab3.6 nV/deg^2 (±0.4 Standard Error)
Monthly Ranibizumab3.4 nV/deg^2 (±0.4 Standard Error)
PRN Ranibizumab5.3 nV/deg^2 (±0.4 Standard Error)
PRN Ranibizumab4.7 nV/deg^2 (±0.4 Standard Error)
Ranibizumab 0.5 mg4.9 nV/deg^2 (±0.4 Standard Error)
Ranibizumab 0.5 mg4.4 nV/deg^2 (±0.4 Standard Error)
Ranibizumab 2.0 mg3.6 nV/deg^2 (±0.4 Standard Error)
Ranibizumab 2.0 mg4.0 nV/deg^2 (±0.4 Standard Error)
NCT00891735
HARBOR
Macular DegenerationChange From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12
Baseline to Month 12
Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN])8.2 Letters (±13.3 Standard Deviation)
Ranibizumab 0.5 mg Monthly10.1 Letters (±13.3 Standard Deviation)
Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])8.6 Letters (±13.8 Standard Deviation)
Ranibizumab 2.0 mg Monthly9.2 Letters (±14.6 Standard Deviation)
NCT00989989
REVEAL
EdemaAverage Change From Baseline of Best-Corrected Visual Acuity (BCVA) Over 12 Months (From Month 1 to Month 12 Compared to Baseline)
12 months
Adjunctive Treatment5.7 Letters (±7.20 Standard Deviation)
Laser Control1.4 Letters (±6.49 Standard Deviation)
Monotherapy Treatment5.9 Letters (±6.02 Standard Deviation)
NCT00996437
N
Retinal DiseasesSafety (Injected-related, Ocular Drug-related and Systemic Drug-related)
Baseline to 16 weeks
Ranibizumab13 participants
Ranibizumab4 participants
Ranibizumab0 participants
Ranibizumab0 participants
Ranibizumab10 participants
Ranibizumab1 participants
Ranibizumab1 participants
Ranibizumab0 participants
Ranibizumab8 participants
Ranibizumab16 participants
Ranibizumab8 participants
Saline Injection0 participants
Saline Injection14 participants
Saline Injection1 participants
Saline Injection19 participants
Saline Injection11 participants
Saline Injection4 participants
Saline Injection4 participants
Saline Injection11 participants
Saline Injection1 participants
Saline Injection2 participants
Saline Injection23 participants
NCT00996437
N
Retinal DiseasesTreatment or "Failure" Defined as Vitrectomy
within 112 days of randomization
Ranibizumab12 percentage of participants
Saline Injection17 percentage of participants
NCT01131585
RELATION
—Change in Best-Corrected Visual Acuity (BCVA) From Baseline to Month 12
12 months
Active Laser Photocoagulation and Ranibizumab6.5 Letters (±8.6 Standard Deviation)
Active Laser Photocoagulation and Sham Injection1.4 Letters (±7.3 Standard Deviation)
NCT01135914
RESPOND
Macular EdemaMean Change From Baseline in Best Corrected Visual Acuity- (BCVA) at Month 12
Baseline and 12 months
Combination Therapy8.2 Letters (±9.20 Standard Deviation)
Laser Monotherapy0.3 Letters (±12.47 Standard Deviation)
Ranibizumab Monotherapy8.9 Letters (±7.78 Standard Deviation)
NCT01171976
RETAIN
—Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 12
Baseline to Month 12
PRN Ranibizumab 0.5 mg71.32 Letters (±9.984 Standard Deviation)
PRN Ranibizumab 0.5 mg65.1 Letters (±10.08 Standard Deviation)
PRN Ranibizumab 0.5 mg6.20 Letters (±6.005 Standard Deviation)
TE Ranibizumab 0.5 mg Alone70.28 Letters (±10.284 Standard Deviation)
TE Ranibizumab 0.5 mg Alone6.14 Letters (±5.717 Standard Deviation)
TE Ranibizumab 0.5 mg Alone64.1 Letters (±10.52 Standard Deviation)
TE Ranibizumad 0.5 mg and Laser5.91 Letters (±5.532 Standard Deviation)
TE Ranibizumad 0.5 mg and Laser62.3 Letters (±11.50 Standard Deviation)
TE Ranibizumad 0.5 mg and Laser68.25 Letters (±11.057 Standard Deviation)
NCT01198327
RETAIN
Retinal Vein OcclusionIncidence of Serious Adverse Events.
24 mos
Ranibizumab as Needed17 number of serious adverse events
NCT01217944Choroidal NeovascularizationAverage Change From Baseline to Month 1 Through Month 3 on Visual Acuity of the Study Eye
Baseline, Month 1 through Month 3
0.5 mg Ranibizumab Driven by Stabilization Criteria66.0 Letters (±12.98 Standard Deviation)
0.5 mg Ranibizumab Driven by Stabilization Criteria55.4 Letters (±13.43 Standard Deviation)
0.5mg Ranibizumab Driven by Disease Activity66.4 Letters (±12.28 Standard Deviation)
0.5mg Ranibizumab Driven by Disease Activity55.8 Letters (±12.59 Standard Deviation)
Verteporfin PDT54.7 Letters (±13.84 Standard Deviation)
Verteporfin PDT56.9 Letters (±14.49 Standard Deviation)
NCT01396057
COMRADE-B
Macular EdemaMean Average Best Corrected Visual Acuity (BCVA) Change From Month 1 Through Month 6 to Baseline
Baseline, month 6
Dexamethasone10.1 Letters (±9.5 Standard Deviation)
Ranibizumab14.9 Letters (±9.9 Standard Deviation)
NCT01396083
COMRADE-C
Macular EdemaMean Average BCVA Change From Month 1 Through Month 6 to Baseline
Baseline, month 6
Dexamethasone4.8 Letters (±16.2 Standard Deviation)
Ranibizumab14.6 Letters (±11.8 Standard Deviation)
NCT01402544
COMPASS
Macular DegenerationNumber of Patients That Achieve Their Pre-wet Age-Related Macular Degeneration (AMD) Baseline Visual Acuity Within 12 Months
Baseline, Month 6 and Month 12
Ranibizumab 0.5 mg3 Participants
NCT01489189
Protocol S
—Mean Change in Visual Acuity From Baseline
2-years
Anti-VEGF+Deferred PRP2.8 letters
Prompt PRP0.2 letters
NCT01535261
CRYSTAL
Macular EdemaMean Change in Best Corrected Visual Acuity (BCVA) at Month 12 Compared to Baseline
Baseline to month 12
Ranibizumab Arm12.3 Letters (±16.72 Standard Deviation)
NCT01599650
BRIGHTER
Macular EdemaMean Change in Visual Acuity: BCVA Change at Month 6 Compared to Baseline in Patients With Visual Impairment Due to Branch Retinal Vein Occlusion (BRVO)
Baseline, 6 Months
1-ranibizumab Monotherapy14.8 letters (±10.70 Standard Deviation)
1-ranibizumab Monotherapy59.5 letters (±11.78 Standard Deviation)
1-ranibizumab Monotherapy74.3 letters (±12.27 Standard Deviation)
2-ranibizumab With Laser56.6 letters (±13.19 Standard Deviation)
2-ranibizumab With Laser14.8 letters (±11.13 Standard Deviation)
2-ranibizumab With Laser71.4 letters (±14.43 Standard Deviation)
3-laser Monotherapy56.8 letters (±13.86 Standard Deviation)
3-laser Monotherapy62.8 letters (±14.08 Standard Deviation)
3-laser Monotherapy6.0 letters (±14.27 Standard Deviation)
NCT01627249
Protocol T
—Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 1-year: Baseline Visual Acuity Letter Score <69
Baseline to 1-year
Aflibercept18.9 units on a scale (±11.5 Standard Deviation)
Bevacizumab11.8 units on a scale (±12.0 Standard Deviation)
Ranibizumab14.2 units on a scale (±10.6 Standard Deviation)
NCT01627249
Protocol T
—Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 1-year: Baseline Visual Acuity Letter Score 78-69
Baseline to 1-year
Aflibercept8.0 units on a scale (±7.6 Standard Deviation)
Bevacizumab7.5 units on a scale (±7.4 Standard Deviation)
Ranibizumab8.3 units on a scale (±6.8 Standard Deviation)
NCT01627249
Protocol T
—Overall Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 1-year
Baseline to 1-year
Aflibercept13.3 units on a scale (±11.1 Standard Deviation)
Bevacizumab9.7 units on a scale (±10.1 Standard Deviation)
Ranibizumab11.2 units on a scale (±9.4 Standard Deviation)
NCT01661946Macular EdemaMaximum Concentration (Cmax) of Anti-VEGF Antibody
1 month
Bevacizumab9.56 ng/mL (±2.50 Standard Error)
Ranibizumab25.22 ng/mL (±7.59 Standard Error)
NCT01748292
T-REX
Macular DegenerationMean Change in BCVA by ETDRS Letter Score From Baseline
6, 12, 18, 24, 30, and 36 months
Monthly IVT Ranibizumab8.6 ETDRS BCVA Letters (±2.8 Standard Error)
Monthly IVT Ranibizumab10.5 ETDRS BCVA Letters (±1.3 Standard Error)
Monthly IVT Ranibizumab9.2 ETDRS BCVA Letters (±1.4 Standard Error)
Monthly IVT Ranibizumab10.4 ETDRS BCVA Letters (±1.9 Standard Error)
Monthly IVT Ranibizumab10.5 ETDRS BCVA Letters (±1.9 Standard Error)
Monthly IVT Ranibizumab9.7 ETDRS BCVA Letters (±2.3 Standard Error)
Treat and Extend IVT Ranibizumab8.7 ETDRS BCVA Letters (±3.6 Standard Error)
Treat and Extend IVT Ranibizumab.95 ETDRS BCVA Letters (±4.4 Standard Error)
Treat and Extend IVT Ranibizumab10.5 ETDRS BCVA Letters (±2.0 Standard Error)
Treat and Extend IVT Ranibizumab7.3 ETDRS BCVA Letters (±1.9 Standard Error)
Treat and Extend IVT Ranibizumab9.0 ETDRS BCVA Letters (±3.2 Standard Error)
Treat and Extend IVT Ranibizumab4.1 ETDRS BCVA Letters (±4.0 Standard Error)
NCT01780935
OCTAVE
—Average Best-corrected Visual Acuity (BCVA) (Letters) Change up to Month 12
up to Month 12
RBZ 0.5 mg: VA and/or OCT (Group II)1.0 Letters correctly read (±7.25 Standard Deviation)
RBZ 0.5 mg: VA Only (Group I)0.1 Letters correctly read (±6.79 Standard Deviation)
NCT01840410Choroidal NeovascularizationChange From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye to Month 2
Baseline, Month 2
Ranibizumab9.5 letters (±0.95 Standard Error)
Sham Control-0.4 letters (±1.16 Standard Error)
NCT01846299Macular EdemaChange From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye
Baseline, Month 2
Ranibizumab5.7 letters (±0.81 Standard Error)
Sham With Ranibizumab2.9 letters (±0.89 Standard Error)
NCT01908816
ECLIPSE
Macular EdemaNumber of Participants With Adverse Events as a Measure of Safety and Tolerability
24 months
CNV (Choroidal Neovascularization)1 Participants
CNV (Choroidal Neovascularization)11 Participants
CNV (Choroidal Neovascularization)2 Participants
ME (Macular Edema)21 Participants
ME (Macular Edema)0 Participants
ME (Macular Edema)15 Participants
PDR/V14 Participants
PDR/V0 Participants
PDR/V1 Participants
RI/NVG (Rubeosis Iridis and Neovacular Glaucoma)7 Participants
RI/NVG (Rubeosis Iridis and Neovacular Glaucoma)1 Participants
RI/NVG (Rubeosis Iridis and Neovacular Glaucoma)31 Participants
NCT01922102
Brilliance
Choroidal NeovascularizationChange From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 3
From Baseline to Month 3
Group I53.7 ETDRS letters (±12.65 Standard Deviation)
Group I63.1 ETDRS letters (±12.80 Standard Deviation)
Group II63.9 ETDRS letters (±13.28 Standard Deviation)
Group II54.2 ETDRS letters (±13.01 Standard Deviation)
Group III52.6 ETDRS letters (±12.29 Standard Deviation)
Group III57.1 ETDRS letters (±13.21 Standard Deviation)
NCT01940900Macular DegenerationMean Change in Visual Acuity From Baseline to 12 Months
12 Months
E10030 + Ranibizumab9.91 letters (±0.88 Standard Error)
Sham + Ranibizumab10.36 letters (±0.87 Standard Error)
NCT01944839Macular DegenerationMean Change in Visual Acuity From Baseline to 12 Months
12 Months
E10030 + Ranibizumab10.74 letters (±0.86 Standard Error)
Sham + Ranibizumab9.82 letters (±0.86 Standard Error)
NCT01948830
TREND
Macular DegenerationChange in Best Corrected Visual Acuity (BCVA) From Baseline to Month 12
Baseline to month 12
Group I Ranibizumab 0.5 mg TER6.2 Letters (EDTRS) (±0.70 Standard Error)
Group II Ranibizumab 0.5 mg Monthly8.1 Letters (EDTRS) (±0.70 Standard Error)
NCT01976312
Camellia
Macular EdemaAverage Change in Visual Acuity (Letters) From Baseline to Month 1 Through Month 3
Baseline, 3 Months
Ranibizumab 0.5 mg11.3 Letters (±10.77 Standard Deviation)
Sham Injection-2.7 Letters (±13.92 Standard Deviation)
NCT01976338
Blossom
Macular EdemaAverage Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 1 Through Month 6
Baseline to Month 1 through Month 6
Ranibizumab 0.5 mg12.5 Letters (±8.34 Standard Deviation)
Sham Injection5.0 Letters (±9.18 Standard Deviation)
NCT02034006
OLIMPIC
Choroidal NeovascularizationChange in Central Subfield Thickness (CSFT)
Screening, Month 2, Month 6, Month 12
Ranibizumab: Re-treated Once-34.28 micromilimeter(um) (±78.01 Standard Deviation)
Ranibizumab: Re-treated Once-15.83 micromilimeter(um) (±70.74 Standard Deviation)
Ranibizumab: Re-treated Once8.64 micromilimeter(um) (±76.79 Standard Deviation)
Ranibizumab: Treated Once1.29 micromilimeter(um) (±62.55 Standard Deviation)
Ranibizumab: Treated Once-11.04 micromilimeter(um) (±61.06 Standard Deviation)
Ranibizumab: Treated Once-16.15 micromilimeter(um) (±86.65 Standard Deviation)
NCT02034006
OLIMPIC
Choroidal NeovascularizationChange in Central Subfield Volume (CSV)
Screening, Month 2, Month 6, Month 12
Ranibizumab: Re-treated Once-0.02 mm^3 (±0.06 Standard Deviation)
Ranibizumab: Re-treated Once-0.01 mm^3 (±0.07 Standard Deviation)
Ranibizumab: Re-treated Once0.01 mm^3 (±0.08 Standard Deviation)
Ranibizumab: Treated Once-0.00 mm^3 (±0.04 Standard Deviation)
Ranibizumab: Treated Once-0.00 mm^3 (±0.04 Standard Deviation)
Ranibizumab: Treated Once-0.02 mm^3 (±0.06 Standard Deviation)
NCT02034006
OLIMPIC
Choroidal NeovascularizationNumber of Patients in Different Categories of Changes From Baseline in BCVA
Baseline, Month 1, Month 2, Month 3, Month 6, Month 12
Ranibizumab: Re-treated Once97 Patients
Ranibizumab: Re-treated Once92 Patients
Ranibizumab: Re-treated Once29 Patients
Ranibizumab: Re-treated Once92 Patients
Ranibizumab: Re-treated Once30 Patients
Ranibizumab: Re-treated Once94 Patients
Ranibizumab: Re-treated Once9 Patients
Ranibizumab: Re-treated Once95 Patients
Ranibizumab: Re-treated Once25 Patients
Ranibizumab: Re-treated Once9 Patients
Ranibizumab: Re-treated Once15 Patients
Ranibizumab: Re-treated Once18 Patients
Ranibizumab: Re-treated Once7 Patients
Ranibizumab: Re-treated Once6 Patients
Ranibizumab: Re-treated Once25 Patients
Ranibizumab: Treated Once7 Patients
Ranibizumab: Treated Once51 Patients
Ranibizumab: Treated Once3 Patients
Ranibizumab: Treated Once48 Patients
Ranibizumab: Treated Once9 Patients
Ranibizumab: Treated Once5 Patients
Ranibizumab: Treated Once52 Patients
Ranibizumab: Treated Once8 Patients
Ranibizumab: Treated Once3 Patients
Ranibizumab: Treated Once50 Patients
Ranibizumab: Treated Once9 Patients
Ranibizumab: Treated Once6 Patients
Ranibizumab: Treated Once51 Patients
Ranibizumab: Treated Once8 Patients
Ranibizumab: Treated Once9 Patients
NCT02034006
OLIMPIC
Choroidal NeovascularizationNumber of Patients Treated and Re-treated Based on Improvement in Best Corrective Visual Acuity (BCVA) < 10 Letters
Baseline, Month 1, Month 2, Month 3, Month 6, Month 12
Ranibizumab: Re-treated Once27 Patients
Ranibizumab: Re-treated Once44 Patients
Ranibizumab: Re-treated Once48 Patients
Ranibizumab: Re-treated Once42 Patients
Ranibizumab: Re-treated Once50 Patients
Ranibizumab: Re-treated Once53 Patients
Ranibizumab: Re-treated Once41 Patients
Ranibizumab: Re-treated Once55 Patients
Ranibizumab: Re-treated Once70 Patients
Ranibizumab: Re-treated Once40 Patients
Ranibizumab: Treated Once23 Patients
Ranibizumab: Treated Once38 Patients
Ranibizumab: Treated Once13 Patients
Ranibizumab: Treated Once20 Patients
Ranibizumab: Treated Once30 Patients
Ranibizumab: Treated Once22 Patients
Ranibizumab: Treated Once30 Patients
Ranibizumab: Treated Once29 Patients
Ranibizumab: Treated Once19 Patients
Ranibizumab: Treated Once28 Patients
NCT02034006
OLIMPIC
Choroidal NeovascularizationNumber of Patients Treated and Re-treated Based on Improvement in Best Corrective Visual Acuity (BCVA) < 5 Letters
Baseline, Month 1, Month 2, Month 3, Month 6, Month 12
Ranibizumab: Re-treated Once25 Patients
Ranibizumab: Re-treated Once22 Patients
Ranibizumab: Re-treated Once69 Patients
Ranibizumab: Re-treated Once74 Patients
Ranibizumab: Re-treated Once20 Patients
Ranibizumab: Re-treated Once70 Patients
Ranibizumab: Re-treated Once70 Patients
Ranibizumab: Re-treated Once23 Patients
Ranibizumab: Re-treated Once28 Patients
Ranibizumab: Re-treated Once69 Patients
Ranibizumab: Treated Once40 Patients
Ranibizumab: Treated Once38 Patients
Ranibizumab: Treated Once14 Patients
Ranibizumab: Treated Once8 Patients
Ranibizumab: Treated Once37 Patients
Ranibizumab: Treated Once15 Patients
Ranibizumab: Treated Once43 Patients
Ranibizumab: Treated Once12 Patients
Ranibizumab: Treated Once8 Patients
Ranibizumab: Treated Once37 Patients
NCT02034006
OLIMPIC
Choroidal NeovascularizationNumber of Patients Treated and Re-treated Based on Presence/Absence of Active Leakage
Screening, Month 2, Month 6
Ranibizumab: Re-treated Once1 Patients
Ranibizumab: Re-treated Once61 Patients
Ranibizumab: Re-treated Once73 Patients
Ranibizumab: Re-treated Once56 Patients
Ranibizumab: Re-treated Once2 Patients
Ranibizumab: Re-treated Once2 Patients
Ranibizumab: Re-treated Once121 Patients
Ranibizumab: Re-treated Once0 Patients
Ranibizumab: Re-treated Once2 Patients
Ranibizumab: Re-treated Once40 Patients
Ranibizumab: Treated Once0 Patients
Ranibizumab: Treated Once1 Patients
Ranibizumab: Treated Once4 Patients
Ranibizumab: Treated Once55 Patients
Ranibizumab: Treated Once0 Patients
Ranibizumab: Treated Once3 Patients
Ranibizumab: Treated Once58 Patients
Ranibizumab: Treated Once0 Patients
Ranibizumab: Treated Once61 Patients
Ranibizumab: Treated Once3 Patients
NCT02034006
OLIMPIC
Choroidal NeovascularizationNumber of Patients Treated and Re-treated Based on Presence/Absence of Clinically Significant Abnormalities
Baseline, Month 1, Month 2, Month 3, Month 6, Month 12
Ranibizumab: Re-treated Once1 Patients
Ranibizumab: Re-treated Once24 Patients
Ranibizumab: Re-treated Once116 Patients
Ranibizumab: Re-treated Once0 Patients
Ranibizumab: Re-treated Once18 Patients
Ranibizumab: Re-treated Once106 Patients
Ranibizumab: Re-treated Once103 Patients
Ranibizumab: Re-treated Once110 Patients
Ranibizumab: Re-treated Once2 Patients
Ranibizumab: Re-treated Once20 Patients
Ranibizumab: Re-treated Once2 Patients
Ranibizumab: Re-treated Once12 Patients
Ranibizumab: Re-treated Once2 Patients
Ranibizumab: Re-treated Once0 Patients
Ranibizumab: Re-treated Once103 Patients
Ranibizumab: Re-treated Once26 Patients
Ranibizumab: Re-treated Once27 Patients
Ranibizumab: Re-treated Once108 Patients
Ranibizumab: Treated Once59 Patients
Ranibizumab: Treated Once3 Patients
Ranibizumab: Treated Once4 Patients
Ranibizumab: Treated Once60 Patients
Ranibizumab: Treated Once61 Patients
Ranibizumab: Treated Once56 Patients
Ranibizumab: Treated Once2 Patients
Ranibizumab: Treated Once60 Patients
Ranibizumab: Treated Once61 Patients
Ranibizumab: Treated Once7 Patients
Ranibizumab: Treated Once5 Patients
Ranibizumab: Treated Once6 Patients
Ranibizumab: Treated Once7 Patients
Ranibizumab: Treated Once9 Patients
Ranibizumab: Treated Once8 Patients
Ranibizumab: Treated Once0 Patients
Ranibizumab: Treated Once7 Patients
Ranibizumab: Treated Once5 Patients
NCT02034006
OLIMPIC
Choroidal NeovascularizationNumber of Patients Treated and Re-treated Based on Presence/Absence of Cysts
Screening, Month 2, Month 6, Month 12
Ranibizumab: Re-treated Once2 Patients
Ranibizumab: Re-treated Once98 Patients
Ranibizumab: Re-treated Once32 Patients
Ranibizumab: Re-treated Once0 Patients
Ranibizumab: Re-treated Once26 Patients
Ranibizumab: Re-treated Once50 Patients
Ranibizumab: Re-treated Once97 Patients
Ranibizumab: Re-treated Once79 Patients
Ranibizumab: Re-treated Once1 Patients
Ranibizumab: Re-treated Once1 Patients
Ranibizumab: Re-treated Once94 Patients
Ranibizumab: Re-treated Once27 Patients
Ranibizumab: Re-treated Once1 Patients
Ranibizumab: Treated Once60 Patients
Ranibizumab: Treated Once27 Patients
Ranibizumab: Treated Once1 Patients
Ranibizumab: Treated Once1 Patients
Ranibizumab: Treated Once3 Patients
Ranibizumab: Treated Once57 Patients
Ranibizumab: Treated Once1 Patients
Ranibizumab: Treated Once2 Patients
Ranibizumab: Treated Once41 Patients
Ranibizumab: Treated Once57 Patients
Ranibizumab: Treated Once0 Patients
Ranibizumab: Treated Once1 Patients
Ranibizumab: Treated Once2 Patients
NCT02034006
OLIMPIC
Choroidal NeovascularizationNumber of Patients Treated and Re-treated Based on Presence/Absence of Intra-retinal Fluid
Screening, Month 2, Month 6, Month 12
Ranibizumab: Re-treated Once77 Patients
Ranibizumab: Re-treated Once38 Patients
Ranibizumab: Re-treated Once85 Patients
Ranibizumab: Re-treated Once2 Patients
Ranibizumab: Re-treated Once2 Patients
Ranibizumab: Re-treated Once90 Patients
Ranibizumab: Re-treated Once37 Patients
Ranibizumab: Re-treated Once50 Patients
Ranibizumab: Re-treated Once2 Patients
Ranibizumab: Re-treated Once26 Patients
Ranibizumab: Re-treated Once96 Patients
Ranibizumab: Re-treated Once3 Patients
Ranibizumab: Treated Once19 Patients
Ranibizumab: Treated Once1 Patients
Ranibizumab: Treated Once49 Patients
Ranibizumab: Treated Once58 Patients
Ranibizumab: Treated Once1 Patients
Ranibizumab: Treated Once1 Patients
Ranibizumab: Treated Once7 Patients
Ranibizumab: Treated Once1 Patients
Ranibizumab: Treated Once55 Patients
Ranibizumab: Treated Once57 Patients
Ranibizumab: Treated Once2 Patients
Ranibizumab: Treated Once2 Patients
NCT02034006
OLIMPIC
Choroidal NeovascularizationNumber of Patients Treated and Re-treated Based on Presence/Absence of Macular Edema
Screening, Month 2, Month 6, Month 12
Ranibizumab: Re-treated Once15 Patients
Ranibizumab: Re-treated Once108 Patients
Ranibizumab: Re-treated Once1 Patients
Ranibizumab: Re-treated Once1 Patients
Ranibizumab: Re-treated Once24 Patients
Ranibizumab: Re-treated Once2 Patients
Ranibizumab: Re-treated Once103 Patients
Ranibizumab: Re-treated Once65 Patients
Ranibizumab: Re-treated Once101 Patients
Ranibizumab: Re-treated Once24 Patients
Ranibizumab: Re-treated Once1 Patients
Ranibizumab: Re-treated Once63 Patients
Ranibizumab: Treated Once1 Patients
Ranibizumab: Treated Once1 Patients
Ranibizumab: Treated Once4 Patients
Ranibizumab: Treated Once56 Patients
Ranibizumab: Treated Once2 Patients
Ranibizumab: Treated Once57 Patients
Ranibizumab: Treated Once1 Patients
Ranibizumab: Treated Once3 Patients
Ranibizumab: Treated Once59 Patients
Ranibizumab: Treated Once3 Patients
Ranibizumab: Treated Once28 Patients
Ranibizumab: Treated Once38 Patients
NCT02034006
OLIMPIC
Choroidal NeovascularizationNumber of Patients Treated and Re-treated Based on Presence/Absence of Sub-retinal Fluid
Screening, Month 2, Month 6, Month 12
Ranibizumab: Re-treated Once3 Patients
Ranibizumab: Re-treated Once14 Patients
Ranibizumab: Re-treated Once113 Patients
Ranibizumab: Re-treated Once3 Patients
Ranibizumab: Re-treated Once8 Patients
Ranibizumab: Re-treated Once61 Patients
Ranibizumab: Re-treated Once65 Patients
Ranibizumab: Re-treated Once3 Patients
Ranibizumab: Re-treated Once17 Patients
Ranibizumab: Re-treated Once108 Patients
Ranibizumab: Re-treated Once4 Patients
Ranibizumab: Re-treated Once109 Patients
Ranibizumab: Treated Once58 Patients
Ranibizumab: Treated Once1 Patients
Ranibizumab: Treated Once3 Patients
Ranibizumab: Treated Once58 Patients
Ranibizumab: Treated Once0 Patients
Ranibizumab: Treated Once2 Patients
Ranibizumab: Treated Once60 Patients
Ranibizumab: Treated Once0 Patients
Ranibizumab: Treated Once1 Patients
Ranibizumab: Treated Once2 Patients
Ranibizumab: Treated Once43 Patients
Ranibizumab: Treated Once25 Patients
NCT02259088
REFINE
Macular EdemaMean Average Change From Baseline in Best-Corrected Visual Acuity (BCVA) (Letters) to Month 1 Through 12
Baseline, Monthly from Month 1 through Month 12
Laser1.1 letters (±7.73 Standard Deviation)
Ranibizumab (RFB002)6.8 letters (±6.58 Standard Deviation)
NCT02375971
RAINBOW
Retinopathy of PrematurityPercentage of Participants With Absence of Active ROP and Absence of Unfavorable Structural Outcomes in Both Eyes at Week 24
Week 24
Laser Therapy66.2 Percentage of Participants
Ranibizumab 0.1 mg75.0 Percentage of Participants
Ranibizumab 0.2 mg80.0 Percentage of Participants
NCT02462486Macular DegenerationPercentage of Participants With Stable Vision at Week 52
Baseline to Week 52
Abicipar Pegol 2 mg (2Q12)91.3 percentage of participants
Abicipar Pegol 2 mg (2Q8)94.8 percentage of participants
Ranibizumab (rQ4)96.0 percentage of participants
NCT02462928
CEDAR
Macular DegenerationPercentage of Participants With Stable Vision at Week 52
Baseline to Week 52
Abicipar Pegol 2 mg (2Q12)91.2 percentage of participants
Abicipar Pegol 2 mg (2Q8)91.7 percentage of participants
Ranibizumab 0.5 mg (rQ4)95.5 percentage of participants
NCT02611778
COLUMBUS-AMD
Macular DegenerationChange From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 8 Weeks
Baseline and Week 8
FYB2015.1 letters (±7.52 Standard Deviation)
Lucentis5.6 letters (±8.63 Standard Deviation)
Total5.4 letters (±8.10 Standard Deviation)
NCT02623426
MERIT
Macular EdemaProportion of Baseline Central Subfield Thickness Observed at 12 Weeks
At 12-week visit
Intravitreal Methotrexate 400 µg in 0.1 mL 0.9% Sodium Chloride Solution, Preservative-free0.88 Proportion of baseline retinal thickness
Intravitreal Ranibizumab (Lucentis) 0.5 mg in 0.05 mL0.79 Proportion of baseline retinal thickness
Ozurdex (0.7 mg Dexamethasone Pellet) Delivered Via Intravitreal Injection0.65 Proportion of baseline retinal thickness
NCT02640664
RainbowExt
Retinopathy of PrematurityVisual Acuity (VA) of the Better-seeing Eye at the Participant's Fifth Birthday Visit - Comparison Between Treatment Arms
at the participant's fifth birthday visit (maximum 5 years and 4 months post core baseline visit)
Laser Therapy62.1 Score on a scale (±2.18 Standard Error)
Ranibizumab 0.1 mg64.6 Score on a scale (±2.00 Standard Error)
Ranibizumab 0.2 mg66.8 Score on a scale (±1.95 Standard Error)
NCT02698566Macular EdemaPercentage of PFS Usage Errors on Essential Tasks
Day 1
Ranibizumab PFS0 percentage of usage errors
NCT02698566Macular EdemaPercentage of PFS Usage Errors on Safety Critical Tasks
Day 1
Ranibizumab PFS0 percentage of usage errors
NCT02698566Macular EdemaPercentage of Successful Task Completions
Day 1
Ranibizumab PFS100 percentage of tasks
Ranibizumab PFS100 percentage of tasks
Ranibizumab PFS100 percentage of tasks
Ranibizumab PFS100 percentage of tasks
Ranibizumab PFS100 percentage of tasks
Ranibizumab PFS100 percentage of tasks
Ranibizumab PFS100 percentage of tasks
Ranibizumab PFS100 percentage of tasks
Ranibizumab PFS100 percentage of tasks
Ranibizumab PFS100 percentage of tasks
Ranibizumab PFS100 percentage of tasks
Ranibizumab PFS100 percentage of tasks
NCT03150589Macular DegenerationChange From Baseline in Best Corrected Visual Acuity (BCVA)
Baseline and Week 8
Lucentis (Ranibizumab)7.08 letters (±0.51 Standard Error)
SB11 (Proposed Ranibizumab Biosimilar)6.26 letters (±0.51 Standard Error)
NCT03150589Macular DegenerationChange From Baseline in Central Subfield Thickness (CST)
Baseline and Week 4
Lucentis (Ranibizumab)-100.05 μm (±4.64 Standard Error)
SB11 (Proposed Ranibizumab Biosimilar)-108.40 μm (±4.65 Standard Error)
NCT03677934
Archway
—Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score at the Average of Week 36 and Week 40, as Assessed Using the ETDRS Visual Acuity Chart at a Starting Distance of 4 Meters
Baseline, and the average of Week 36 and Week 40
Intravitreal Arm0.5 letters
PDS Implant Arm0.2 letters
NCT03805100
XPLORE
Macular DegenerationChange in Best Corrected Visual Acuity (BCVA)
Baseline and Week 8
Lucentis (Ranibizumab)6.37 Letters
Xlucane (Proposed Ranibizumab Biosimilar)4.57 Letters
NCT04503551
PAVILION
Diabetic RetinopathyPercentage of Participants With a ≥2-Step Improvement From Baseline on the Early Treatment Diabetic Retinopathy Study-Diabetic Retinopathy Severity Scale (ETDRS-DRSS) at Week 52
Baseline, Week 52
Comparator Arm9.0 percentage of participants
PDS With Ranibizumab 100 mg/mL80.1 percentage of participants
NCT04690556—Mean Change in BCVA From Baseline in the Study Eye at the End of 12 Months
Baseline and 12 Months
LUBT010 (Proposed Ranibizumab Biosimilar)11.17 Letters (±0.689 Standard Error)
Lucentis (Ranibizumab)11.14 Letters (±0.680 Standard Error)
NCT04757610
ShORe
—Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) Letters
Baseline to Week 52
0.5 mg Ranibizumab With Extended Dosing 2.0 mg OPT-30212.41 Letters read (±0.731 Standard Error)
0.5 mg Ranibizumab With Sham14.30 Letters read (±0.719 Standard Error)
0.5 mg Ranibizumab With Standard Dosing 2.0 mg OPT-30213.20 Letters read (±0.728 Standard Error)

Publications by year

1969–2026: 639 publications.

1969
1
1979
2
1983
1
1985
1
1986
1
1987
1
1988
1
1989
2
1990
2
1991
3
1992
2
1993
1
1994
5
1995
4
1996
4
1997
10
1998
5
1999
4
2000
3
2001
8
2002
10
2003
10
2004
12
2005
16
2006
27
2007
19
2008
14
2009
20
2010
24
2011
32
2012
36
2013
42
2014
35
2015
44
2016
29
2017
35
2018
16
2019
25
2020
29
2021
33
2022
33
2023
18
2024
8
2025
7
2026
4

Publications by indication

Macular Degeneration (208)

  • Six-year findings of polypoidal choroidal vasculopathy in the EVEREST II study: Japanese subgroup analysis.
    Jpn J Ophthalmol · 2025 · PMID 40504425 · NCT01846273
  • Interim Results of the Phase III Portal Extension Trial of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular Degeneration.
    Ophthalmol Retina · 2025 · PMID 39209113 · NCT02510794
  • RELATIONSHIP BETWEEN OPTICAL COHERENCE TOMOGRAPHY BIOMARKERS AND NUMBER OF INTRAVITREAL RANIBIZUMAB INJECTIONS IN EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE HARBOR STUDY.
    Retina · 2024 · PMID 39287532 · NCT00891735
  • Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the EVEREST II Study.
    Ophthalmol Ther · 2024 · PMID 38308746 · NCT01846273
  • Tissue Plasminogen Activator or Perfluoropropane for Submacular Hemorrhage in Age-Related Macular Degeneration: A Factorial Randomized Clinical Trial.
    JAMA Ophthalmol · 2024 · PMID 39418015 · NCT01835067

Macular Edema (105)

  • Clinically Meaningful Change Estimates for the National Eye Institute Visual Function Questionnaire-25 in Patients With Diabetic Macular Edema.
    Transl Vis Sci Technol · 2024 · PMID 39680390 · NCT00473382
  • Predictors of As-Needed Ranibizumab Injection Frequency in Patients With Macular Edema Following Retinal Vein Occlusion.
    Am J Ophthalmol · 2023 · PMID 36646240 · NCT01277302
  • Baseline Diabetic Retinopathy Severity and Time to Diabetic Macular Edema Resolution with Ranibizumab Treatment: A Meta-Analysis.
    Ophthalmol Retina · 2023 · PMID 36774994 · NCT00473330
  • Multi-ancestry GWAS analysis identifies two novel loci associated with diabetic eye disease and highlights APOL1 as a high risk locus in patients with diabetic macular edema.
    PLoS Genet · 2023 · PMID 37585454 · NCT00473382
  • Intravitreal Therapy for Uveitic Macular Edema-Ranibizumab versus Methotrexate versus the Dexamethasone Implant: The MERIT Trial Results.
    Ophthalmology · 2023 · PMID 37318415 · NCT02623426

Pterygium (35)

  • Subconjunctival bevacizumab in the impending recurrent pterygia.
    Int Ophthalmol · 2015 · PMID 24026871 · NCT02342392
  • VEGF mRNA assessment in human pterygium: a new 'scope' for a future hope.
    Ophthalmic Res · 2015 · PMID 25300614 · NCT02342392
  • Efficacy of intralesional bevacizumab administration in primary pterygium: a quantitative analysis.
    Eye Contact Lens · 2014 · PMID 24335454 · NCT02342392
  • The effect of different doses of subconjunctival bevacizumab on the recurrence rate of excised primary pterygium.
    Bull Soc Belge Ophtalmol · 2014 · PMID 24923077 · NCT02342392
  • Subconjunctival bevacizumab for primary pterygium excision; a randomized clinical trial.
    J Ophthalmic Vis Res · 2014 · PMID 24982728 · NCT02342392

Diabetic Retinopathy (31)

  • COMPARE COMBINED USE OF ANTI-VEGF DRUGS DURING OR AFTER PARS PLANA VITRECTOMY FOR DIABETIC MACULAR EDEMA GUIDED BY MICROSCOPE-INTEGRATED OPTICAL COHERENCE TOMOGRAPHY.
    Retina · 2026 · PMID 41687084 · NCT05138029
  • Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial.
    JAMA Ophthalmol · 2025 · PMID 40048178 · NCT04503551
  • Evaluation of the Effect of Repeated Intravitreal Bevacizumab Injections on the Macular Microvasculature of a Diabetic Patient Using Optical Coherence Tomography Angiography.
    Case Rep Ophthalmol Med · 2022 · PMID 31139483 · NCT04991350
  • Evaluation of Changes in Macular Perfusion Detected by Optical Coherence Tomography Angiography following 3 Intravitreal Monthly Bevacizumab Injections for Diabetic Macular Edema in the IMPACT Study.
    J Ophthalmol · 2022 · PMID 32411431 · NCT04991350
  • Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis.
    Clin Ophthalmol · 2022 · PMID 33519187 · NCT04018833

Choroidal Neovascularization (25)

  • Hyperreflective Material Boundary Remodeling in Neovascular Age-Related Macular Degeneration: A Post Hoc Analysis of the AVENUE Trial.
    Ophthalmol Retina · 2023 · PMID 37422192 · NCT02484690
  • Machine Learning to Predict Faricimab Treatment Outcome in Neovascular Age-Related Macular Degeneration.
    Ophthalmol Sci · 2023 · PMID 37868796 · NCT02484690
  • Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
    JAMA Ophthalmol · 2021 · PMID 32729888 · NCT02484690
  • Accuracy of a Machine-Learning Algorithm for Detecting and Classifying Choroidal Neovascularization on Spectral-Domain Optical Coherence Tomography.
    J Pers Med · 2021 · PMID 34201045 · NCT02484690
  • OLIMPIC: a 12-month study on the criteria driving retreatment with ranibizumab in patients with visual impairment due to myopic choroidal neovascularization.
    Graefes Arch Clin Exp Ophthalmol · 2019 · PMID 30680452 · NCT02034006

Retinopathy of Prematurity (20)

  • Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomised trial.
    EClinicalMedicine · 2024 · PMID 38638400 · NCT02640664
  • Time Course of Retinopathy of Prematurity Regression and Reactivation After Treatment with Ranibizumab or Laser in the RAINBOW Trial.
    Ophthalmol Retina · 2022 · PMID 35202890 · NCT02375971
  • Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age.
    J Ophthalmol · 2022 · PMID 29713524 · NCT03334513
  • 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial.
    Lancet Child Adolesc Health · 2021 · PMID 34391532 · NCT02640664
  • Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial.
    Lancet · 2019 · PMID 31522845 · NCT02375971

Publications by journal

  • Ophthalmology140 papers
  • JAMA Ophthalmol52 papers
  • Am J Ophthalmol41 papers
  • Br J Ophthalmol40 papers
  • Retina40 papers
  • Arch Ophthalmol30 papers
  • Invest Ophthalmol Vis Sci24 papers
  • Ophthalmol Retina21 papers
  • N Engl J Med14 papers
  • Graefes Arch Clin Exp Ophthalmol13 papers

Trial-results highlights

For patients with macular degeneration, clinical trials evaluated the effects of ranibizumab on visual acuity. In NCT00275821, the mean change from baseline in best-corrected visual acuity at Month 12 was 4.9 letters for the ranibizumab 0.3 mg - 3 times monthly, then quarterly arm, 8.3 letters for the ranibizumab 0.3 mg monthly arm, and 3.8 letters for the ranibizumab 0.5 mg - 3 times monthly, then quarterly arm. Another study, NCT00433017, reported a mean change from baseline in best-corrected visual acuity at Month 12 of 4.4 letters for the ranibizumab arm and 2.5 letters for the verteporfin + ranibizumab arm.

Adverse events and treatment intervals were also reported for macular degeneration. In NCT00331864, the percentage of participants with ocular adverse events in the study eye over a 12-month treatment period was 38.9% for the ranibizumab ANCHOR arm and 48.5% for the ranibizumab Non-ANCHOR arm. For targeted Grade 3 adverse events in the study eye, 0.0% of participants were reported in the ranibizumab ANCHOR arm and 2.9% in the ranibizumab Non-ANCHOR arm. In NCT00433017, the percentage of participants with a treatment-free interval of at least 3 months following the Month 2 visit was 92.2% for the ranibizumab arm and 95.8% for the verteporfin + ranibizumab arm.

For Eales disease, a study (NCT00384449) investigated ranibizumab (Lucentis). OCT thickness measurements were reported as 262 um and 269 um. The incidence of ocular adverse events, as identified by eye examination monthly through Month 6, was 0 adverse events for the Lucentis (ranibizumab) arm. Similarly, the incidence of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs monthly through Month 6, was also 0 adverse events for the Lucentis (ranibizumab) arm.

All values presented are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Ranibizumab publications (639)

2026 (4 papers)

  1. COMPARE COMBINED USE OF ANTI-VEGF DRUGS DURING OR AFTER PARS PLANA VITRECTOMY FOR DIABETIC MACULAR EDEMA GUIDED BY MICROSCOPE-INTEGRATED OPTICAL COHERENCE TOMOGRAPHY.
    Zhu J, Liu J, Chen YX, et al. · Retina · 2026 · Derived
    PubMed: PMID 41687084 · NCT05138029 · Diabetic Retinopathy
  2. Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized Clinical Trial.
    Sharma S, Lin P, Hu A, et al. · JAMA Ophthalmol · 2026 · Derived
    PubMed: PMID 41954903 · NCT06771271 (DOVETAIL)
  3. Impact of AI-enhanced three-dimensional OCT scans on disease activity assessment in patients with nAMD: the RAZORBILL study.
    Kortuem KU, Zarranz-Ventura J, Bandello F, et al. · Br J Ophthalmol · 2026 · Derived
    PubMed: PMID 42082322 · NCT04662944 (RAZORBILL)
  4. Assessing the Safety and Efficacy of Agonistic Monoclonal Antibody against Robo4 versus Ranibizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Phase I, Open-Label, Multicenter Study.
    Afridi R, Senaldi G, Hwang JJ, et al. · Ophthalmol Sci · 2026 · Derived
    PubMed: PMID 42064470 · NCT02530918

2025 (7 papers)

  1. Six-year findings of polypoidal choroidal vasculopathy in the EVEREST II study: Japanese subgroup analysis.
    Yanagi Y, Mori R, Teo KYC, et al. · Jpn J Ophthalmol · 2025 · Derived
    PubMed: PMID 40504425 · NCT01846273 (EVEREST II) · Macular Degeneration
  2. Retinal Fluid and Thickness Fluctuations in Archway Trial for Port Delivery System with Ranibizumab versus Monthly Ranibizumab Injections.
    Sheth VS, Holekamp NM, Khanani AM, et al. · Ophthalmol Retina · 2025 · Derived
    PubMed: PMID 39447871 · NCT03677934 (Archway)
  3. Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial.
    Pieramici DJ, Awh CC, Chang M, et al. · JAMA Ophthalmol · 2025 · Derived
    PubMed: PMID 40048178 · NCT04503551 (PAVILION) · Diabetic Retinopathy
  4. Interventions for central serous chorioretinopathy: a network meta-analysis.
    Lange CA, Qureshi R, Pauleikhoff L, et al. · Cochrane Database Syst Rev · 2025 · Derived
    PubMed: PMID 40522203 · NCT01325181
  5. Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial.
    Khanani AM, Campochiaro PA, Graff JM, et al. · JAMA Ophthalmol · 2025 · Derived
    PubMed: PMID 40048197 · NCT04108156 (Pagoda)
  6. Endophthalmitis in Eyes Treated with the Port Delivery System with Ranibizumab: Summary of Cases during Clinical Trial Development.
    Eichenbaum DA, Freeman WR, Chang MA, et al. · Ophthalmol Retina · 2025 · Derived
    PubMed: PMID 39154860 · NCT03677934 (Archway)
  7. Interim Results of the Phase III Portal Extension Trial of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular Degeneration.
    Campochiaro PA, Eichenbaum D, Chang MA, et al. · Ophthalmol Retina · 2025 · Derived
    PubMed: PMID 39209113 · NCT02510794 (LADDER) · Macular Degeneration

2024 (8 papers)

  1. RELATIONSHIP BETWEEN OPTICAL COHERENCE TOMOGRAPHY BIOMARKERS AND NUMBER OF INTRAVITREAL RANIBIZUMAB INJECTIONS IN EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE HARBOR STUDY.
    Tong N, Fan W, Su L, et al. · Retina · 2024 · Derived
    PubMed: PMID 39287532 · NCT00891735 (HARBOR) · Macular Degeneration
  2. Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the EVEREST II Study.
    Teo KYC, Park KH, Ngah NF, et al. · Ophthalmol Ther · 2024 · Derived
    PubMed: PMID 38308746 · NCT01846273 (EVEREST II) · Macular Degeneration
  3. Oct biomarkers for early prognosis in diabetic macular edema treatment with ranibizumab.
    Pessoa B, Leite J, Ferreira A, et al. · Eur J Ophthalmol · 2024 · Derived
    PubMed: PMID 37919940 · NCT04387604 (DEVITRA)
  4. Supplemental Intravitreal Ranibizumab Injections in Eyes Treated with the Port Delivery System with Ranibizumab in the Archway Trial.
    Nielsen JS, Chang A, Holekamp NM, et al. · Ophthalmol Retina · 2024 · Derived
    PubMed: PMID 38914294 · NCT03677934 (Archway)
  5. Tissue Plasminogen Activator or Perfluoropropane for Submacular Hemorrhage in Age-Related Macular Degeneration: A Factorial Randomized Clinical Trial.
    Murphy GSP, Saleh A, Ayis S, et al. · JAMA Ophthalmol · 2024 · Derived
    PubMed: PMID 39418015 · NCT01835067 (TAPAS) · Macular Degeneration
  6. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomised trial.
    Marlow N, Reynolds JD, Lepore D, et al. · EClinicalMedicine · 2024 · Derived
    PubMed: PMID 38638400 · NCT02640664 (RainbowExt) · Retinopathy of Prematurity
  7. Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial.
    Jackson TL, Desai R, Wafa HA, et al. · Lancet · 2024 · Derived
    PubMed: PMID 38876132 · NCT02243878 (STAR) · Macular Degeneration
  8. Clinically Meaningful Change Estimates for the National Eye Institute Visual Function Questionnaire-25 in Patients With Diabetic Macular Edema.
    Bressler N, Haskova Z, Kapre A, et al. · Transl Vis Sci Technol · 2024 · Derived
    PubMed: PMID 39680390 · NCT00473382 (RIDE) · Macular Edema

2023 (18 papers)

  1. Hyperreflective Material Boundary Remodeling in Neovascular Age-Related Macular Degeneration: A Post Hoc Analysis of the AVENUE Trial.
    Yu S, Bachmeier I, Hernandez-Sanchez J, et al. · Ophthalmol Retina · 2023 · Derived
    PubMed: PMID 37422192 · NCT02484690 (AVENUE) · Choroidal Neovascularization
  2. Predictors of As-Needed Ranibizumab Injection Frequency in Patients With Macular Edema Following Retinal Vein Occlusion.
    Yiu G, Huang D, Wang Y, et al. · Am J Ophthalmol · 2023 · Derived
    PubMed: PMID 36646240 · NCT01277302 · Macular Edema
  3. Baseline Diabetic Retinopathy Severity and Time to Diabetic Macular Edema Resolution with Ranibizumab Treatment: A Meta-Analysis.
    Talcott KE, Valentim CCS, Hill L, et al. · Ophthalmol Retina · 2023 · Derived
    PubMed: PMID 36774994 · NCT00473330 (RISE) · Macular Edema
  4. Multi-ancestry GWAS analysis identifies two novel loci associated with diabetic eye disease and highlights APOL1 as a high risk locus in patients with diabetic macular edema.
    Stockwell AD, Chang MC, Mahajan A, et al. · PLoS Genet · 2023 · Derived
    PubMed: PMID 37585454 · NCT00473382 (RIDE) · Macular Edema
  5. Characteristics that Correlate with Macular Atrophy in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration.
    Staurenghi G, Cozzi M, Sadda S, et al. · Ophthalmol Retina · 2023 · Derived
    PubMed: PMID 36372347 · NCT00891735 (HARBOR) · Macular Degeneration
  6. Anti-vascular endothelial growth factor for neovascular glaucoma.
    Rittiphairoj T, Roberti G, Michelessi M, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 37010901 · NCT02914626 · Glaucoma, Neovascular
  7. Intravitreal Therapy for Uveitic Macular Edema-Ranibizumab versus Methotrexate versus the Dexamethasone Implant: The MERIT Trial Results.
    Multicenter Uveitis Steroid Treatment Trial (MUST) Research Group, Writing Committee:, Acharya NR, Vitale AT, et al. · Ophthalmology · 2023 · Derived
    PubMed: PMID 37318415 · NCT02623426 (MERIT) · Macular Edema
  8. Predicting the immediate impact of national lockdown on neovascular age-related macular degeneration and associated visual morbidity: an INSIGHT Health Data Research Hub for Eye Health report.
    Mollan SP, Fu DJ, Chuo CY, et al. · Br J Ophthalmol · 2023 · Derived
    PubMed: PMID 34518162 · NCT00056836 · Macular Degeneration
  9. Seven-year outcomes following intensive anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration.
    Lukacs R, Schneider M, Nagy ZZ, et al. · BMC Ophthalmol · 2023 · Derived
    PubMed: PMID 36932356 · NCT00637377 (VIEW 2) · Macular Degeneration
  10. Rare CIDEC coding variants enriched in age-related macular degeneration patients with small low-luminance deficit cause lipid droplet and fat storage defects.
    Kim S, Stockwell A, Qin H, et al. · PLoS One · 2023 · Derived
    PubMed: PMID 37079518 · NCT00891735 (HARBOR) · Macular Degeneration
  11. Machine Learning to Predict Faricimab Treatment Outcome in Neovascular Age-Related Macular Degeneration.
    Kikuchi Y, Kawczynski MG, Anegondi N, et al. · Ophthalmol Sci · 2023 · Derived
    PubMed: PMID 37868796 · NCT02484690 (AVENUE) · Choroidal Neovascularization
  12. Epimacular brachytherapy for previously treated neovascular age-related macular degeneration: month 36 results of the MERLOT randomised controlled trial.
    Jackson TL, Soare C, Petrarca C, et al. · Br J Ophthalmol · 2023 · Derived
    PubMed: PMID 35217515 · NCT01006538 (MERLOT) · Macular Degeneration
  13. A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration.
    Jackson TL, Slakter J, Buyse M, et al. · Ophthalmology · 2023 · Derived
    PubMed: PMID 36754174 · NCT03345082
  14. Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy.
    Dervenis P, Dervenis N, Smith JM, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 37260074 · NCT00516464
  15. Thiazolidinedione use and retinal fluid in the comparison of age-related macular degeneration treatments trials.
    Core JQ, Hua P, Daniel E, et al. · Br J Ophthalmol · 2023 · Derived
    PubMed: PMID 35428655 · NCT00593450 · Macular Degeneration
  16. Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and Pharmacokinetics: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial.
    Bressler NM, Kim T, Oh I, et al. · JAMA Ophthalmol · 2023 · Derived
    PubMed: PMID 36520462 · NCT03150589 · Macular Degeneration
  17. Prevalence of Macular Atrophy in the MARINA Study of Ranibizumab versus Sham for Neovascular Age-Related Macular Degeneration.
    Blodi BA, Domalpally A, Corkery E, et al. · Ophthalmol Retina · 2023 · Derived
    PubMed: PMID 37086257 · NCT00056836 · Macular Degeneration
  18. PATTERNS OF SUBRETINAL AND/OR INTRARETINAL FLUID RECURRENCE IN PATIENTS WHO RECEIVED AS-NEEDED RANIBIZUMAB THERAPY IN THE HARBOR TRIAL.
    Adrean SD, Chaili S, Hill L, et al. · Retina · 2023 · Derived
    PubMed: PMID 36729084 · NCT00891735 (HARBOR) · Macular Degeneration

2022 (33 papers)

  1. Conversion of Central Subfield Thickness Measurements of Diabetic Macular Edema Across Cirrus and Spectralis Optical Coherence Tomography Instruments.
    Sun JK, Josic K, Melia M, et al. · Transl Vis Sci Technol · 2022 · Trial result
    PubMed: PMID 34967834 · NCT01610557
  2. Intravitreous treatment of severe ocular von Hippel-Lindau disease using a combination of the VEGF inhibitor, ranibizumab and PDGF inhibitor, E10030: Results from a phase 1/2 clinical trial.
    Hwang CK, Chew EY, Cukras CA, et al. · Clin Exp Ophthalmol · 2022 · Trial result
    PubMed: PMID 34549489 · NCT02859441 · von Hippel-Lindau Disease
  3. Evaluation of the Effect of Repeated Intravitreal Bevacizumab Injections on the Macular Microvasculature of a Diabetic Patient Using Optical Coherence Tomography Angiography.
    Elnahry AG, Abdel-Kader AA, Raafat KA, et al. · Case Rep Ophthalmol Med · 2022 · Trial result
    PubMed: PMID 31139483 · NCT04991350 (REBEL) · Diabetic Retinopathy
  4. Evaluation of Changes in Macular Perfusion Detected by Optical Coherence Tomography Angiography following 3 Intravitreal Monthly Bevacizumab Injections for Diabetic Macular Edema in the IMPACT Study.
    Elnahry AG, Abdel-Kader AA, Raafat KA, et al. · J Ophthalmol · 2022 · Trial result
    PubMed: PMID 32411431 · NCT04991350 (REBEL) · Diabetic Retinopathy
  5. Two-year results for ranibizumab for radiation retinopathy (RRR): a randomized, prospective trial.
    Yu HJ, Fuller D, Anand R, et al. · Graefes Arch Clin Exp Ophthalmol · 2022 · Derived
    PubMed: PMID 34463842 · NCT02222610 (RRR)
  6. In-vitro characterization of ranibizumab release from the Port Delivery System.
    Yohe S, Maass KF, Horvath J, et al. · J Control Release · 2022 · Derived
    PubMed: PMID 35248647 · NCT02510794 (LADDER) · Macular Degeneration
  7. Pharmacokinetics of the Port Delivery System with Ranibizumab in the Ladder Phase 2 Trial for Neovascular Age-Related Macular Degeneration.
    Wykoff CC, Campochiaro PA, Pieramici DJ, et al. · Ophthalmol Ther · 2022 · Derived
    PubMed: PMID 35759124 · NCT02510794 (LADDER) · Macular Degeneration
  8. Predictors of Early Diabetic Retinopathy Regression with Ranibizumab in the RIDE and RISE Clinical Trials.
    Singer M, Liu M, Schlottmann PG, et al. · Clin Ophthalmol · 2022 · Derived
    PubMed: PMID 32606578 · NCT00473330 (RISE) · Macular Edema
  9. Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis.
    Sheth V, D'Rozario M, Gune S, et al. · BMJ Open Ophthalmol · 2022 · Derived
    PubMed: PMID 35342822 · NCT00891735 (HARBOR) · Macular Degeneration
  10. Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment.
    Pongsachareonnont P, Mak MYK, Hurst CP, et al. · Clin Ophthalmol · 2022 · Derived
    PubMed: PMID 30310267 · NCT02218177 · Macular Degeneration
  11. Choroidal Blood Flow After Intravitreal Ranibizumab in Vitrectomized and Non-Vitrectomized Eyes with Diabetic Macular Edema.
    Pessoa B, Marques JH, Leite J, et al. · Clin Ophthalmol · 2022 · Derived
    PubMed: PMID 34675476 · NCT04387604 (DEVITRA)
  12. Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis.
    Pessoa B, Malheiro L, Carneiro I, et al. · Clin Ophthalmol · 2022 · Derived
    PubMed: PMID 33519187 · NCT04018833 (SWITCH) · Diabetic Retinopathy
  13. Vitrectomized versus non-vitrectomized eyes in diabetic macular edema response to ranibizumab-retinal layers thickness as prognostic biomarkers.
    Pessoa B, Leite J, Heitor J, et al. · Sci Rep · 2022 · Derived
    PubMed: PMID 34845300 · NCT04387604 (DEVITRA)
  14. SYSTEMATIC CORRELATION OF CENTRAL SUBFIELD THICKNESS WITH RETINAL FLUID VOLUMES QUANTIFIED BY DEEP LEARNING IN THE MAJOR EXUDATIVE MACULAR DISEASES.
    Pawloff M, Bogunovic H, Gruber A, et al. · Retina · 2022 · Derived
    PubMed: PMID 34934034 · NCT01627249 (Protocol T)
  15. Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema.
    Nguyen QD, Sepah YJ, Berger B, et al. · Int J Retina Vitreous · 2022 · Derived
    PubMed: PMID 31388454 · NCT02302079 (VIDI) · Diabetes Mellitus
  16. The efficacy of micropulse laser combined with ranibizumab in diabetic macular edema treatment: study protocol for a randomized controlled trial.
    Mi X, Gu X, Yu X, et al. · Trials · 2022 · Derived
    PubMed: PMID 36056443 · NCT03690947
  17. Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical Trial.
    Maguire MG, Liu D, Bressler SB, et al. · JAMA Ophthalmol · 2022 · Derived
    PubMed: PMID 34673898 · NCT01489189 (Protocol S)
  18. Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study.
    Leys AM, Ramboer E, Favreau M, et al. · Clin Ophthalmol · 2022 · Derived
    PubMed: PMID 32581505 · NCT01318941 (LUMINOUS) · Macular Degeneration
  19. Subretinal Fluid Resolution and Visual Acuity in Patients with Neovascular Age-Related Macular Degeneration: A HARBOR Post Hoc Analysis.
    Lally DR, Hill L, Amador-Patarroyo MJ, et al. · Ophthalmol Retina · 2022 · Derived
    PubMed: PMID 35654363 · NCT00891735 (HARBOR) · Macular Degeneration
  20. Mental Status and Feasibility of an Intravitreal Ranibizumab Treat-and-Extend Regimen in Patients with Neovascular Age-Related Macular Degeneration.
    Kato A, Yasukawa T, Sugita I, et al. · Adv Ther · 2022 · Derived
    PubMed: PMID 35112307 · NCT02321839
  21. Effect of Residual Retinal Fluid on Visual Function in Ranibizumab-Treated Neovascular Age-Related Macular Degeneration.
    Holekamp NM, Sadda S, Sarraf D, et al. · Am J Ophthalmol · 2022 · Derived
    PubMed: PMID 34289338 · NCT00891735 (HARBOR) · Macular Degeneration
  22. Effect of less aggressive treatment on diabetic retinopathy severity scale scores: analyses of the RIDE and RISE open-label extension.
    Goldberg RA, Hill L, Davis T, et al. · BMJ Open Ophthalmol · 2022 · Derived
    PubMed: PMID 36161830 · NCT00473330 (RISE) · Macular Edema
  23. Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR.
    Freund KB, Staurenghi G, Jung JJ, et al. · Graefes Arch Clin Exp Ophthalmol · 2022 · Derived
    PubMed: PMID 35239009 · NCT00891735 (HARBOR) · Macular Degeneration
  24. Time Course of Retinopathy of Prematurity Regression and Reactivation After Treatment with Ranibizumab or Laser in the RAINBOW Trial.
    Fleck BW, Reynolds JD, Zhu Q, et al. · Ophthalmol Retina · 2022 · Derived
    PubMed: PMID 35202890 · NCT02375971 (RAINBOW) · Retinopathy of Prematurity
  25. RETINAL VASCULAR BED AREA IN EYES WITH RETINAL VEIN OCCLUSION ON ULTRA-WIDEFIELD FLUORESCEIN ANGIOGRAPHY: WAVE Study.
    Fan W, Fleming A, Hemert JV, et al. · Retina · 2022 · Derived
    PubMed: PMID 35976232 · NCT01710839 (WAVE) · Macular Edema
  26. Predominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials.
    Core JQ, Pistilli M, Hua P, et al. · Ophthalmol Retina · 2022 · Derived
    PubMed: PMID 35405352 · NCT00593450 · Macular Degeneration
  27. Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age.
    Chen YC, Chen SN, Yang BC, et al. · J Ophthalmol · 2022 · Derived
    PubMed: PMID 29713524 · NCT03334513 · Retinopathy of Prematurity
  28. Patient Preference and Treatment Satisfaction With a Port Delivery System for Ranibizumab vs Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
    Chang MA, Kapre A, Kaufman D, et al. · JAMA Ophthalmol · 2022 · Derived
    PubMed: PMID 35708706 · NCT03677934 (Archway)
  29. Association Between Cilioretinal Arteries and Advanced Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT).
    Bavinger JC, Ying GS, Daniel E, et al. · JAMA Ophthalmol · 2022 · Derived
    PubMed: PMID 31513262 · NCT00593450 · Macular Degeneration
  30. Management of Key Ocular Adverse Events in Patients Implanted with the Port Delivery System with Ranibizumab.
    Awh CC, Barteselli G, Makadia S, et al. · Ophthalmol Retina · 2022 · Derived
    PubMed: PMID 35589078 · NCT02510794 (LADDER) · Macular Degeneration
  31. Basis and Design of a Randomized Clinical Trial to Evaluate the Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema.
    Robles-Osorio ML, García-Franco R, Núñez-Amaro CD, et al. · Front Endocrinol (Lausanne) · 2022 · Background
    PubMed: PMID 29896154 · NCT03161652 · Macular Edema
  32. Early DMO: a predictor of poor outcomes following cataract surgery in diabetic patients. The DICAT-II study.
    Panozzo G, Mura GD, Franzolin E, et al. · Eye (Lond) · 2022 · Background
    PubMed: PMID 34345028 · NCT05080803
  33. Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial.
    Bressler NM, Odia I, Maguire M, et al. · JAMA Ophthalmol · 2022 · Background
    PubMed: PMID 31246237 · NCT01627249 (Protocol T)

2021 (33 papers)

  1. Mean macular intercapillary area in eyes with diabetic macular oedema after anti-vascular endothelial growth factor therapy and its association with treatment response.
    Sorour OA, Elsheikh M, Chen S, et al. · Clin Exp Ophthalmol · 2021 · Trial result
    PubMed: PMID 34189816 · NCT04991350 (REBEL) · Diabetic Retinopathy
  2. Automated Image Alignment for Comparing Microvascular Changes Detected by Fluorescein Angiography and Optical Coherence Tomography Angiography in Diabetic Retinopathy.
    Elnahry AG, Ramsey DJ · Semin Ophthalmol · 2021 · Trial result
    PubMed: PMID 33784213 · NCT04991350 (REBEL) · Diabetic Retinopathy
  3. Optical Coherence Tomography Angiography of Macular Perfusion Changes after Anti-VEGF Therapy for Diabetic Macular Edema: A Systematic Review.
    Elnahry AG, Elnahry GA · J Diabetes Res · 2021 · Trial result
    PubMed: PMID 34124270 · NCT04991350 (REBEL) · Diabetic Retinopathy
  4. Review on Recent Trials Evaluating the Effect of Intravitreal Injections of Anti-VEGF Agents on the Macular Perfusion of Diabetic Patients with Diabetic Macular Edema.
    Elnahry AG, Abdel-Kader AA, Habib AE, et al. · Rev Recent Clin Trials · 2021 · Trial result
    PubMed: PMID 32427087 · NCT04991350 (REBEL) · Diabetic Retinopathy
  5. Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
    Woo SJ, Veith M, Hamouz J, et al. · JAMA Ophthalmol · 2021 · Derived
    PubMed: PMID 33211076 · NCT03150589 · Macular Degeneration
  6. Efficacy and Safety of Ranibizumab in Asian Patients with Branch Retinal Vein Occlusion: Results from the Randomized BLOSSOM Study.
    Wei W, Weisberger A, Zhu L, et al. · Ophthalmol Retina · 2021 · Derived
    PubMed: PMID 31902472 · NCT01976338 (Blossom) · Macular Edema
  7. Effect of posterior vitreous detachment on treat-and-extend versus monthly ranibizumab for neovascular age-related macular degeneration.
    Waldstein SM, Coulibaly L, Riedl S, et al. · Br J Ophthalmol · 2021 · Derived
    PubMed: PMID 31563866 · NCT01948830 (TREND) · Macular Degeneration
  8. Combination of Ranibizumab with macular laser for macular edema secondary to branch retinal vein occlusion: one-year results from a randomized controlled double-blind trial.
    Song S, Yu X, Zhang P, et al. · BMC Ophthalmol · 2021 · Derived
    PubMed: PMID 32560639 · NCT03054766 · Retinal Vein Occlusion
  9. Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
    Sahni J, Dugel PU, Patel SS, et al. · JAMA Ophthalmol · 2021 · Derived
    PubMed: PMID 32729888 · NCT02484690 (AVENUE) · Choroidal Neovascularization
  10. Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial.
    Roberts PK, Vogl WD, Gerendas BS, et al. · JAMA Ophthalmol · 2021 · Derived
    PubMed: PMID 32722799 · NCT01627249 (Protocol T)
  11. Evaluation of contrast sensitivity in non-high-risk proliferative diabetic retinopathy treated with panretinal photocoagulation with and without intravitreal injections of ranibizumab.
    Rentiya ZS, Ferraz DA, Hutnik R, et al. · Arq Bras Oftalmol · 2021 · Derived
    PubMed: PMID 34586227 · NCT01746563 · Diabetic Retinopathy
  12. Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results.
    Payne JF, Wykoff CC, Clark WL, et al. · Br J Ophthalmol · 2021 · Derived
    PubMed: PMID 32303499 · NCT01934556 (TREX-DME)
  13. Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration?
    Patel Y, Miller DM, Fung AE, et al. · Ophthalmol Retina · 2021 · Derived
    PubMed: PMID 31735634 · NCT00891735 (HARBOR) · Macular Degeneration
  14. Changes in neovascular activity following fixed dosing with an anti-vascular endothelial growth factor agent over 52 weeks in the phase III VIEW 1 and VIEW 2 studies.
    Moshfeghi DM, Thompson D, Saroj N, et al. · Br J Ophthalmol · 2021 · Derived
    PubMed: PMID 31826853 · NCT00637377 (VIEW 2) · Macular Degeneration
  15. Accuracy of a Machine-Learning Algorithm for Detecting and Classifying Choroidal Neovascularization on Spectral-Domain Optical Coherence Tomography.
    Maunz A, Benmansour F, Li Y, et al. · J Pers Med · 2021 · Derived
    PubMed: PMID 34201045 · NCT02484690 (AVENUE) · Choroidal Neovascularization
  16. 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial.
    Marlow N, Stahl A, Lepore D, et al. · Lancet Child Adolesc Health · 2021 · Derived
    PubMed: PMID 34391532 · NCT02640664 (RainbowExt) · Retinopathy of Prematurity
  17. Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.
    Lim TH, Lai TYY, Takahashi K, et al. · JAMA Ophthalmol · 2021 · Derived
    PubMed: PMID 32672800 · NCT01846273 (EVEREST II) · Macular Degeneration
  18. Anatomical and functional responses in eyes with diabetic macular edema treated with "1 + PRN" ranibizumab: one-year outcomes in population of mainland China.
    Lai K, Huang C, Li L, et al. · BMC Ophthalmol · 2021 · Derived
    PubMed: PMID 32539744 · NCT03973138 (IVRDME) · Macular Edema
  19. BETA-PERIPAPILLARY ATROPHY AND GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS.
    Kolomeyer AM, Smith E, Daniel E, et al. · Retina · 2021 · Derived
    PubMed: PMID 32383840 · NCT00593450 · Macular Degeneration
  20. Agreement of Spectral-Domain OCT with Fluorescein Leakage in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study.
    Khurana RN, Hill L, Ghanekar A, et al. · Ophthalmol Retina · 2021 · Derived
    PubMed: PMID 32353536 · NCT00891735 (HARBOR) · Macular Degeneration
  21. The Value of Prior Response to Anti-Vascular Endothelial Growth Factor for Age-Related Macular Degeneration: A HARBOR Subanalysis.
    Khurana RN, Chang LK, Hill LF, et al. · Ophthalmol Retina · 2021 · Derived
    PubMed: PMID 31416763 · NCT00891735 (HARBOR) · Macular Degeneration
  22. Timing of Peak Vision Gains in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab.
    Khurana RN, Chang L, Day BM, et al. · Ophthalmol Retina · 2021 · Derived
    PubMed: PMID 32387055 · NCT00891735 (HARBOR) · Macular Degeneration
  23. Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.
    Khanani AM, Patel SS, Ferrone PJ, et al. · JAMA Ophthalmol · 2021 · Derived
    PubMed: PMID 32729897 · NCT03038880 (STAIRWAY) · Macular Degeneration
  24. Changes in Treatment-Naive Pigment Epithelial Detachments Associated With the Initial Anti-Vascular Endothelial Growth Factor Injection: A Post Hoc Analysis From the HARBOR Trial.
    Javaheri M, Hill L, Ghanekar A, et al. · JAMA Ophthalmol · 2021 · Derived
    PubMed: PMID 33331859 · NCT00891735 (HARBOR) · Macular Degeneration
  25. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial.
    Jackson TL, Soare C, Petrarca C, et al. · JAMA Ophthalmol · 2021 · Derived
    PubMed: PMID 32644148 · NCT01006538 (MERLOT) · Macular Degeneration
  26. Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study.
    Holz FG, Minnella AM, Tuli R, et al. · PLoS One · 2021 · Derived
    PubMed: PMID 33378369 · NCT01318941 (LUMINOUS) · Macular Degeneration
  27. A custom virtual reality training solution for ophthalmologic surgical clinical trials.
    Heimann F, Barteselli G, Brand A, et al. · Adv Simul (Lond) · 2021 · Derived
    PubMed: PMID 33863399 · NCT03677934 (Archway)
  28. Panretinal Photocoagulation for Diabetic Retinopathy in the RIDE and RISE Trials: Not "1 and Done".
    Gonzalez VH, Wang PW, Ruiz CQ, et al. · Ophthalmology · 2021 · Derived
    PubMed: PMID 31668888 · NCT00473382 (RIDE) · Macular Edema
  29. Efficacy of combining intravitreal injections of ranibizumab with micropulse diode laser versus intravitreal injections of ranibizumab alone in diabetic macular edema (ReCaLL): a single center, randomised, controlled, non-inferiority clinical trial.
    Furashova O, Strassburger P, Becker KA, et al. · BMC Ophthalmol · 2021 · Derived
    PubMed: PMID 32727496 · NCT02059772 (ReCaLL)
  30. Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial.
    Daniel E, Maguire MG, Grunwald JE, et al. · JAMA Ophthalmol · 2021 · Derived
    PubMed: PMID 32191267 · NCT00593450 · Macular Degeneration
  31. ETDRS panretinal photocoagulation combined with intravitreal ranibizumab versus PASCAL panretinal photocoagulation with intravitreal ranibizumab versus intravitreal ranibizumab alone for the treatment of proliferative diabetic retinopathy.
    Barroso RMP, Messias K, Garcia DM, et al. · Arq Bras Oftalmol · 2021 · Derived
    PubMed: PMID 33470281 · NCT02005432 · Retinal Neovascularization
  32. Oxidative Stress Induces a VEGF Autocrine Loop in the Retina: Relevance for Diabetic Retinopathy.
    Rossino MG, Lulli M, Amato R, et al. · Cells · 2021 · Background
    PubMed: PMID 32545222 · NCT04878835
  33. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
    Hutton DW, Stein JD, Glassman AR, et al. · JAMA Ophthalmol · 2021 · Background
    PubMed: PMID 31647496 · NCT01489189 (Protocol S)

2020 (29 papers)

  1. One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial.
    Wang F, Yuan Y, Wang L, et al. · J Ophthalmol · 2020 · Derived
    PubMed: PMID 31687203 · NCT02810808 (ARTIS)
  2. Distribution of OCT Features within Areas of Macular Atrophy or Scar after 2 Years of Anti-VEGF Treatment for Neovascular AMD in CATT.
    Toth CA, Tai V, Pistilli M, et al. · Ophthalmol Retina · 2020 · Derived
    PubMed: PMID 31014683 · NCT00593450 · Macular Degeneration
  3. Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-Label Extension of RIDE and RISE Studies.
    Sun JK, Wang PW, Taylor S, et al. · Ophthalmology · 2020 · Derived
    PubMed: PMID 30419298 · NCT00473382 (RIDE) · Macular Edema
  4. Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration - results from the randomized, phase IIIb OCTAVE study.
    Staurenghi G, Garweg JG, Gerendas BS, et al. · BMC Ophthalmol · 2020 · Derived
    PubMed: PMID 31918685 · NCT01780935 (OCTAVE)
  5. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Shalchi Z, Mahroo O, Bunce C, et al. · Cochrane Database Syst Rev · 2020 · Derived
    PubMed: PMID 32633861 · NCT01396057 (COMRADE-B) · Macular Edema
  6. Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical Trial.
    Scoles D, Ying GS, Pan W, et al. · JAMA Ophthalmol · 2020 · Derived
    PubMed: PMID 31999297 · NCT00593450 · Macular Degeneration
  7. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.
    Sahni J, Patel SS, Dugel PU, et al. · Ophthalmology · 2020 · Derived
    PubMed: PMID 30905643 · NCT02699450 (BOULEVARD)
  8. Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Sadda SR, Abdelfattah NS, Lei J, et al. · Ophthalmology · 2020 · Derived
    PubMed: PMID 32402555 · NCT00891735 (HARBOR) · Macular Degeneration
  9. Intravitreal steroids for macular edema in diabetes.
    Rittiphairoj T, Mir TA, Li T, et al. · Cochrane Database Syst Rev · 2020 · Derived
    PubMed: PMID 33206392 · NCT01492400 · Macular Edema
  10. Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial.
    Ramakrishnan MS, Yu Y, VanderBeek BL, et al. · JAMA Ophthalmol · 2020 · Derived
    PubMed: PMID 32027349 · NCT00593450 · Macular Degeneration
  11. Real-world outcomes with ranibizumab in branch retinal vein occlusion: The prospective, global, LUMINOUS study.
    Pearce I, Clemens A, Brent MH, et al. · PLoS One · 2020 · Derived
    PubMed: PMID 32555630 · NCT01318941 (LUMINOUS) · Macular Degeneration
  12. Emerging PEGylated non-biologic drugs.
    Park EJ, Choi J, Lee KC, et al. · Expert Opin Emerg Drugs · 2020 · Derived
    PubMed: PMID 30957581 · NCT01944839 · Macular Degeneration
  13. OCT Risk Factors for Development of Late Age-Related Macular Degeneration in the Fellow Eyes of Patients Enrolled in the HARBOR Study.
    Nassisi M, Lei J, Abdelfattah NS, et al. · Ophthalmology · 2020 · Derived
    PubMed: PMID 31281056 · NCT00891735 (HARBOR) · Macular Degeneration
  14. Effectiveness and safety of ranibizumab 0.5 mg in treatment-naïve patients with diabetic macular edema: Results from the real-world global LUMINOUS study.
    Mitchell P, Sheidow TG, Farah ME, et al. · PLoS One · 2020 · Derived
    PubMed: PMID 32492069 · NCT01318941 (LUMINOUS) · Macular Degeneration
  15. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
    Li E, Donati S, Lindsley KB, et al. · Cochrane Database Syst Rev · 2020 · Derived
    PubMed: PMID 32374423 · NCT00891735 (HARBOR) · Macular Degeneration
  16. Imaging, Genetic, and Demographic Factors Associated With Conversion to Neovascular Age-Related Macular Degeneration: Secondary Analysis of a Randomized Clinical Trial.
    Hallak JA, de Sisternes L, Osborne A, et al. · JAMA Ophthalmol · 2020 · Derived
    PubMed: PMID 31021381 · NCT00891735 (HARBOR) · Macular Degeneration
  17. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
    Gillies MC, Hunyor AP, Arnold JJ, et al. · JAMA Ophthalmol · 2020 · Derived
    PubMed: PMID 30676617 · NCT02130024 (RIVAL) · Macular Degeneration
  18. Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study.
    Gale RP, Pearce I, Eter N, et al. · Br J Ophthalmol · 2020 · Derived
    PubMed: PMID 31383649 · NCT02161575 (SAFARI) · Macular Degeneration
  19. Radiotherapy for neovascular age-related macular degeneration.
    Evans JR, Igwe C, Jackson TL, et al. · Cochrane Database Syst Rev · 2020 · Derived
    PubMed: PMID 32844399 · NCT01006538 (MERLOT) · Macular Degeneration
  20. Five-Year Follow-up of Nonfibrotic Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Daniel E, Ying GS, Kim BJ, et al. · Ophthalmology · 2020 · Derived
    PubMed: PMID 30476517 · NCT00593450 · Macular Degeneration
  21. An optical coherence tomography-based grading of diabetic maculopathy proposed by an international expert panel: The European School for Advanced Studies in Ophthalmology classification.
    Panozzo G, Cicinelli MV, Augustin AJ, et al. · Eur J Ophthalmol · 2020 · Background
    PubMed: PMID 31718271 · NCT05080803
  22. Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy.
    Maguire MG, Liu D, Glassman AR, et al. · JAMA Ophthalmol · 2020 · Background
    PubMed: PMID 31999300 · NCT01489189 (Protocol S)
  23. PANRETINAL PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Comparison of Peripapillary Retinal Nerve Fiber Layer Thickness in a Randomized Clinical Trial.
    Jampol LM, Odia I, Glassman AR, et al. · Retina · 2020 · Background
    PubMed: PMID 29135802 · NCT01489189 (Protocol S)
  24. Effect of telephone calls from a centralized coordinating center on participant retention in a randomized clinical trial.
    Glassman AR, Beaulieu WT, Stockdale CR, et al. · Clin Trials · 2020 · Background
    PubMed: PMID 31984762 · NCT01489189 (Protocol S)
  25. Combined Phacoemulsification and Intravitreal Dexamethasone Implant (Ozurdex®) in Diabetic Patients with Coexisting Cataract and Diabetic Macular Edema.
    Furino C, Boscia F, Niro A, et al. · J Ophthalmol · 2020 · Background
    PubMed: PMID 28884024 · NCT03832179 (STAMP) · Cataract
  26. Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration.
    Callanan D, Kunimoto D, Maturi RK, et al. · J Ocul Pharmacol Ther · 2020 · Background
    PubMed: PMID 30412448 · NCT01397409 · Macular Degeneration
  27. Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial.
    Bressler SB, Odia I, Maguire MG, et al. · JAMA Ophthalmol · 2020 · Background
    PubMed: PMID 30676635 · NCT01627249 (Protocol T)
  28. PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Should Baseline Characteristics Affect Choice of Treatment?
    Bressler SB, Beaulieu WT, Glassman AR, et al. · Retina · 2020 · Background
    PubMed: PMID 30807516 · NCT01489189 (Protocol S)
  29. Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices.
    Abràmoff MD, Lavin PT, Birch M, et al. · NPJ Digit Med · 2020 · Background
    PubMed: PMID 31304320 · NCT06205979

2019 (25 papers)

  1. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
    Maturi RK, Glassman AR, Liu D, et al. · JAMA Ophthalmol · 2019 · Trial result
    PubMed: PMID 29127949 · NCT01945866
  2. Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial.
    Wykoff CC, Ou WC, Croft DE, et al. · Br J Ophthalmol · 2019 · Derived
    PubMed: PMID 28779006 · NCT01748292 (T-REX) · Macular Degeneration
  3. Ranibizumab Induces Regression of Diabetic Retinopathy in Most Patients at High Risk of Progression to Proliferative Diabetic Retinopathy.
    Wykoff CC, Eichenbaum DA, Roth DB, et al. · Ophthalmol Retina · 2019 · Derived
    PubMed: PMID 31047503 · NCT00473330 (RISE) · Macular Edema
  4. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial.
    Stahl A, Lepore D, Fielder A, et al. · Lancet · 2019 · Derived
    PubMed: PMID 31522845 · NCT02375971 (RAINBOW) · Retinopathy of Prematurity
  5. Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial.
    Stahl A, Krohne TU, Eter N, et al. · JAMA Pediatr · 2019 · Derived
    PubMed: PMID 29309486 · NCT02134457 (CARE-ROP) · Retinopathy of Prematurity
  6. OLIMPIC: a 12-month study on the criteria driving retreatment with ranibizumab in patients with visual impairment due to myopic choroidal neovascularization.
    Ricci F, Staurenghi G, Varano M, et al. · Graefes Arch Clin Exp Ophthalmol · 2019 · Derived
    PubMed: PMID 30680452 · NCT02034006 (OLIMPIC) · Choroidal Neovascularization
  7. Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE.
    Reddy RK, Pieramici DJ, Gune S, et al. · Ophthalmology · 2019 · Derived
    PubMed: PMID 29752001 · NCT00473382 (RIDE) · Macular Edema
  8. Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema.
    Payne JF, Clark WL, Bruce BB, et al. · Ophthalmology · 2019 · Derived
    PubMed: PMID 29729809 · NCT01934556 (TREX-DME)
  9. Impact of Cataract Surgery during Treatment with Ranibizumab in Patients with Diabetic Macular Edema.
    Moshfeghi AA, Shapiro H, Lemmon LA, et al. · Ophthalmol Retina · 2019 · Derived
    PubMed: PMID 31047350 · NCT00473330 (RISE) · Macular Edema
  10. Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion.
    Lloyd Clark W, Liu M, Kitchens J, et al. · BMC Ophthalmol · 2019 · Derived
    PubMed: PMID 30621653 · NCT01277302 · Macular Edema
  11. Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study.
    Larsen M, Waldstein SM, Priglinger S, et al. · Ophthalmol Retina · 2019 · Derived
    PubMed: PMID 31047340 · NCT01535261 (CRYSTAL) · Macular Edema
  12. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials.
    Jaffe GJ, Ying GS, Toth CA, et al. · Ophthalmology · 2019 · Derived
    PubMed: PMID 30189282 · NCT00593450 · Macular Degeneration
  13. A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema.
    Gale JD, Berger B, Gilbert S, et al. · Invest Ophthalmol Vis Sci · 2019 · Derived
    PubMed: PMID 29847672 · NCT01994291 · Macular Edema
  14. Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Daniel E, Pan W, Ying GS, et al. · Ophthalmology · 2019 · Derived
    PubMed: PMID 29454660 · NCT00593450 · Macular Degeneration
  15. Molecular Mechanisms Mediating Diabetic Retinal Neurodegeneration: Potential Research Avenues and Therapeutic Targets.
    Chakravarthy H, Devanathan V · J Mol Neurosci · 2019 · Derived
    PubMed: PMID 30293228 · NCT01492400 · Macular Edema
  16. Usability of the Ranibizumab 0.5 mg Prefilled Syringe: Human Factors Studies to Evaluate Critical Task Completion by Healthcare Professionals.
    Antoszyk AN, Baker C, Calzada J, et al. · PDA J Pharm Sci Technol · 2019 · Derived
    PubMed: PMID 29853609 · NCT02698566 · Macular Edema
  17. Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy.
    Sun JK, Glassman AR, Beaulieu WT, et al. · Ophthalmology · 2019 · Background
    PubMed: PMID 30096354 · NCT01489189 (Protocol S)
  18. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
    Jampol LM, Glassman AR, Liu D, et al. · Ophthalmology · 2019 · Background
    PubMed: PMID 29525602 · NCT01627249 (Protocol T)
  19. Sequential Dexamethasone and Aflibercept Treatment in Patients with Diabetic Macular Edema: Structural and Functional Outcomes at 52 Weeks.
    Hernández-Bel L, Cervera-Taulet E, Navarro-Palop C, et al. · Ophthalmologica · 2019 · Background
    PubMed: PMID 29996128 · NCT03784443 (CASSIE) · Macular Edema
  20. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
    Gross JG, Glassman AR, Liu D, et al. · JAMA Ophthalmol · 2019 · Background
    PubMed: PMID 30043039 · NCT01489189 (Protocol S)
  21. Reply.
    Glassman AR, Duh EJ, Liu D, et al. · Ophthalmology · 2019 · Background
    PubMed: PMID 30318048 · NCT01627249 (Protocol T)
  22. CHANGES IN DIABETIC RETINOPATHY SEVERITY WHEN TREATING DIABETIC MACULAR EDEMA WITH RANIBIZUMAB: DRCR.net Protocol I 5-Year Report.
    Bressler SB, Odia I, Glassman AR, et al. · Retina · 2019 · Background
    PubMed: PMID 30234859 · NCT00444600 (LRT for DME) · Diabetic Retinopathy
  23. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.
    Bressler SB, Beaulieu WT, Glassman AR, et al. · Ophthalmology · 2019 · Background
    PubMed: PMID 29980333 · NCT01489189 (Protocol S)
  24. Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T.
    Bressler NM, Beaulieu WT, Maguire MG, et al. · Am J Ophthalmol · 2019 · Background
    PubMed: PMID 30077569 · NCT01627249 (Protocol T)
  25. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
    Bressler NM, Beaulieu WT, Glassman AR, et al. · JAMA Ophthalmol · 2019 · Background
    PubMed: PMID 29392288 · NCT01627249 (Protocol T)

2018 (16 papers)

  1. Ranibizumab pretreatment in diabetic vitrectomy: a pilot randomised controlled trial (the RaDiVit study).
    Comyn O, Wickham L, Charteris DG, et al. · Eye (Lond) · 2018 · Trial result
    PubMed: PMID 28498374 · NCT04464694
  2. Peripheral Laser for Recalcitrant Macular Edema Owing to Retinal Vein Occlusion: The WAVE Trial.
    Wykoff CC, Ou WC, Wang R, et al. · Ophthalmology · 2018 · Derived
    PubMed: PMID 28318636 · NCT01710839 (WAVE) · Macular Edema
  3. StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): study protocol for a randomised controlled clinical trial.
    Neffendorf JE, Desai R, Wang Y, et al. · Trials · 2018 · Derived
    PubMed: PMID 27881184 · NCT02243878 (STAR) · Macular Degeneration
  4. Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen.
    Lai K, Li Y, Zhou L, et al. · BMC Ophthalmol · 2018 · Derived
    PubMed: PMID 29925341 · NCT03459144 · Polypoidal Choroidal Vasculopathy
  5. Response of vascular pigment epithelium detachment due to age-related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study.
    Clemens CR, Wolf A, Alten F, et al. · Acta Ophthalmol · 2018 · Derived
    PubMed: PMID 28084038 · NCT00976222 · Retinal Detachment
  6. Reply.
    Wells JA, Glassman AR, Jampol LM, et al. · Ophthalmology · 2018 · Background
    PubMed: PMID 28219510 · NCT01627249 (Protocol T)
  7. Reply.
    Wells JA, Glassman AR, Bressler NM, et al. · Ophthalmology · 2018 · Background
    PubMed: PMID 28335949 · NCT01627249 (Protocol T)
  8. Reply.
    Wells JA, Glassman AR, Ayala AR, et al. · Ophthalmology · 2018 · Background
    PubMed: PMID 27993277 · NCT01627249 (Protocol T)
  9. Long-term efficacy and safety of anti-VEGF therapy in retinitis pigmentosa: a case report.
    Miyata M, Oishi A, Oishi M, et al. · BMC Ophthalmol · 2018 · Background
    PubMed: PMID 30217183 · NCT03763227 · Retinal Dystrophies
  10. Vascular endothelial growth factor signaling in development and disease.
    Karaman S, Leppänen VM, Alitalo K, et al. · Development · 2018 · Background
    PubMed: PMID 30030240 · NCT04878835
  11. Panretinal Photocoagulation vs Anti-Vascular Endothelial Growth Factor for Proliferative Diabetic Retinopathy-Reply.
    Gross JG, Glassman AR · JAMA Ophthalmol · 2018 · Background
    PubMed: PMID 27101313 · NCT01489189 (Protocol S)
  12. Interim Safety Data Comparing Ranibizumab With Panretinal Photocoagulation Among Participants With Proliferative Diabetic Retinopathy.
    Gross JG, Glassman AR, Klein MJ, et al. · JAMA Ophthalmol · 2018 · Background
    PubMed: PMID 28492921 · NCT01489189 (Protocol S)
  13. Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
    Glassman AR, Liu D, Jampol LM, et al. · Invest Ophthalmol Vis Sci · 2018 · Background
    PubMed: PMID 29625440 · NCT01627249 (Protocol T)
  14. EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY.
    Calvo P, Ferreras A, Al Adel F, et al. · Retina · 2018 · Background
    PubMed: PMID 28196056 · NCT03832179 (STAMP) · Cataract
  15. Controversies in Using Off-Label Intravitreous Bevacizumab for Patients With Diabetic Macular Edema-Reply.
    Bressler NM, Glassman AR, Hutton DW, et al. · JAMA Ophthalmol · 2018 · Background
    PubMed: PMID 28152135 · NCT01627249 (Protocol T)
  16. A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion.
    Bandello F, Augustin A, Tufail A, et al. · Eur J Ophthalmol · 2018 · Background
    PubMed: PMID 29631435 · NCT01427751 · Macular Edema

2017 (35 papers)

  1. Pseudodrusen and Incidence of Late Age-Related Macular Degeneration in Fellow Eyes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Zhou Q, Daniel E, Maguire MG, et al. · Ophthalmology · 2017 · Trial result
    PubMed: PMID 27040149 · NCT00593450 · Macular Degeneration
  2. Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Maguire MG, Ying GS, Jaffe GJ, et al. · JAMA Ophthalmol · 2017 · Trial result
    PubMed: PMID 27099955 · NCT00593450 · Macular Degeneration
  3. Short-term efficacy and safety of ranibizumab for macular oedema secondary to retinal vein occlusion in Japanese patients.
    Kamei M, Terasaki H, Yoshimura N, et al. · Acta Ophthalmol · 2017 · Trial result
    PubMed: PMID 27654837 · NCT01377597 (RVO in Japan) · Macular Edema
  4. Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration: A Phase 1 Dose-Escalation Study.
    Jackson TL, Boyer D, Brown DM, et al. · JAMA Ophthalmol · 2017 · Trial result
    PubMed: PMID 28570723 · NCT01674569 · Wet Macular Degeneration
  5. Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER.
    Tadayoni R, Waldstein SM, Boscia F, et al. · Ophthalmology · 2017 · Derived
    PubMed: PMID 27039022 · NCT01599650 (BRIGHTER) · Macular Edema
  6. Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study.
    Tadayoni R, Waldstein SM, Boscia F, et al. · Ophthalmology · 2017 · Derived
    PubMed: PMID 28807635 · NCT01599650 (BRIGHTER) · Macular Edema
  7. The Impact of Systemic Factors on Clinical Response to Ranibizumab for Diabetic Macular Edema.
    Singh RP, Habbu K, Ehlers JP, et al. · Ophthalmology · 2017 · Derived
    PubMed: PMID 27234930 · NCT00473382 (RIDE) · Macular Edema
  8. Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study.
    Sarraf D, London NJ, Khurana RN, et al. · Ophthalmology · 2017 · Derived
    PubMed: PMID 27566855 · NCT00891735 (HARBOR) · Macular Degeneration
  9. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study.
    Prünte C, Fajnkuchen F, Mahmood S, et al. · Br J Ophthalmol · 2017 · Derived
    PubMed: PMID 26453639 · NCT01171976 (RETAIN)
  10. Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE.
    Pieramici DJ, Wang PW, Ding B, et al. · Ophthalmology · 2017 · Derived
    PubMed: PMID 26992841 · NCT00473382 (RIDE) · Macular Edema
  11. Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes.
    Payne JF, Wykoff CC, Clark WL, et al. · Ophthalmology · 2017 · Derived
    PubMed: PMID 27836430 · NCT01934556 (TREX-DME)
  12. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
    Koh A, Lai TYY, Takahashi K, et al. · JAMA Ophthalmol · 2017 · Derived
    PubMed: PMID 28983556 · NCT01846273 (EVEREST II) · Macular Degeneration
  13. Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study.
    Holz FG, Tadayoni R, Beatty S, et al. · Br J Ophthalmol · 2017 · Derived
    PubMed: PMID 27030279 · NCT01447043 (AURA) · Macular Degeneration
  14. Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials.
    Grunwald JE, Pistilli M, Daniel E, et al. · Ophthalmology · 2017 · Derived
    PubMed: PMID 28079023 · NCT00593450 · Macular Degeneration
  15. Predicting vision gains with anti-VEGF therapy in neovascular age-related macular degeneration patients by using low-luminance vision.
    Frenkel RE, Shapiro H, Stoilov I, et al. · Br J Ophthalmol · 2017 · Derived
    PubMed: PMID 26541435 · NCT00891735 (HARBOR) · Macular Degeneration
  16. Association of Circulating Markers With Outcome Parameters in the Bevacizumab and Ranibizumab in Diabetic Macular Edema Trial.
    Fickweiler W, Klaassen I, Vogels IM, et al. · Invest Ophthalmol Vis Sci · 2017 · Derived
    PubMed: PMID 27842163 · NCT01635790 (BRDME)
  17. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times.
    Fauser S, Muether PS · Br J Ophthalmol · 2017 · Derived
    PubMed: PMID 26888975 · NCT01213667 (RESPONSE) · Macular Degeneration
  18. Optical Coherence Tomography Angiography in Central Retinal Vein Occlusion: Correlation Between the Foveal Avascular Zone and Visual Acuity.
    Casselholmde Salles M, Kvanta A, Amrén U, et al. · Invest Ophthalmol Vis Sci · 2017 · Derived
    PubMed: PMID 27409478 · NCT02274259 · Retinal Vein Occlusion
  19. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
    Wells JA, Glassman AR, Ayala AR, et al. · Ophthalmology · 2017 · Background
    PubMed: PMID 26935357 · NCT01627249 (Protocol T)
  20. Reduction in the frequency of intravitreal bevacizumab administrations achieved by posterior subtenon injection of triamcinolone acetonide in patients with diffuse diabetic macular edema.
    Shimura M, Yasuda K, Minezaki T, et al. · Jpn J Ophthalmol · 2017 · Background
    PubMed: PMID 27306783 · NCT03784443 (CASSIE) · Macular Edema
  21. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
    Ross EL, Hutton DW, Stein JD, et al. · JAMA Ophthalmol · 2017 · Background
    PubMed: PMID 27280850 · NCT01627249 (Protocol T)
  22. The Intraocular Cytokine Profile and Therapeutic Response in Persistent Neovascular Age-Related Macular Degeneration.
    Rezar-Dreindl S, Sacu S, Eibenberger K, et al. · Invest Ophthalmol Vis Sci · 2017 · Background
    PubMed: PMID 27537264 · NCT02976194 (CyPov) · Polypoidal Choroidal Vasculopathy
  23. Characterization of Intraocular Pressure Increases and Management Strategies Following Treatment With Fluocinolone Acetonide Intravitreal Implants in the FAME Trials.
    Parrish RK, Campochiaro PA, Pearson PA, et al. · Ophthalmic Surg Lasers Imaging Retina · 2017 · Background
    PubMed: PMID 27183546 · NCT03784443 (CASSIE) · Macular Edema
  24. Prolactin protects retinal pigment epithelium by inhibiting sirtuin 2-dependent cell death.
    Meléndez García R, Arredondo Zamarripa D, Arnold E, et al. · EBioMedicine · 2017 · Background
    PubMed: PMID 27322457 · NCT03161652 · Macular Edema
  25. Diabetic Macular Edema at the time of Cataract Surgery trial: a prospective, randomized clinical trial of intravitreous bevacizumab versus triamcinolone in patients with diabetic macular oedema at the time of cataract surgery - preliminary 6 month results.
    Lim LL, Morrison JL, Constantinou M, et al. · Clin Exp Ophthalmol · 2017 · Background
    PubMed: PMID 26871700 · NCT03832179 (STAMP) · Cataract
  26. Ranibizumab for persistent diabetic macular edema after bevacizumab treatment.
    Katz G, Moisseiev E, Goldenberg D, et al. · Eur J Ophthalmol · 2017 · Background
    PubMed: PMID 27445070 · NCT06205979
  27. Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.
    Jampol LM, Glassman AR, Bressler NM, et al. · JAMA Ophthalmol · 2017 · Background
    PubMed: PMID 27711918 · NCT01627249 (Protocol T)
  28. Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.
    Hutton DW, Stein JD, Bressler NM, et al. · JAMA Ophthalmol · 2017 · Background
    PubMed: PMID 28492920 · NCT01489189 (Protocol S)
  29. Molecular Basis of Pterygium Development.
    Cárdenas-Cantú E, Zavala J, Valenzuela J, et al. · Semin Ophthalmol · 2017 · Background
    PubMed: PMID 25415268 · NCT04878835
  30. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG, Loewenstein A, Patel SS, et al. · Graefes Arch Clin Exp Ophthalmol · 2017 · Background
    PubMed: PMID 27632215 · NCT01492400 · Macular Edema
  31. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
    Bressler SB, Liu D, Glassman AR, et al. · JAMA Ophthalmol · 2017 · Background
    PubMed: PMID 28448655 · NCT01627249 (Protocol T)
  32. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
    Bressler SB, Beaulieu WT, Glassman AR, et al. · Ophthalmology · 2017 · Background
    PubMed: PMID 28161147 · NCT01489189 (Protocol S)
  33. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial.
    Beaulieu WT, Bressler NM, Melia M, et al. · Am J Ophthalmol · 2017 · Background
    PubMed: PMID 27523491 · NCT01489189 (Protocol S)
  34. Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature.
    Ashraf M, Souka A, Adelman R, et al. · Br J Ophthalmol · 2017 · Background
    PubMed: PMID 27231313 · NCT06205979
  35. Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group.
    Arevalo JF, Lasave AF, Wu L, et al. · Br J Ophthalmol · 2017 · Background
    PubMed: PMID 26912377 · NCT03784443 (CASSIE) · Macular Edema

2016 (29 papers)

  1. Association between Antiplatelet or Anticoagulant Drugs and Retinal or Subretinal Hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Ying GS, Maguire MG, Daniel E, et al. · Ophthalmology · 2016 · Trial result
    PubMed: PMID 26545320 · NCT00593450 · Macular Degeneration
  2. Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT).
    Ying GS, Maguire MG, Daniel E, et al. · Ophthalmology · 2016 · Trial result
    PubMed: PMID 26383996 · NCT00593450 · Macular Degeneration
  3. A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.
    Wiley HE, Thompson DJ, Bailey C, et al. · Ophthalmology · 2016 · Trial result
    PubMed: PMID 26875003 · NCT01610557
  4. An updated review of long-term outcomes from randomized controlled trials in approved pharmaceuticals for diabetic macular edema.
    Wang JK, Huang TL, Su PY, et al. · Eye Sci · 2016 · Trial result
    PubMed: PMID 27215008 · NCT04089605
  5. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Sharma S, Toth CA, Daniel E, et al. · Ophthalmology · 2016 · Trial result
    PubMed: PMID 26783095 · NCT00593450 · Macular Degeneration
  6. Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Shah N, Maguire MG, Martin DF, et al. · Ophthalmology · 2016 · Trial result
    PubMed: PMID 26778329 · NCT00593450 · Macular Degeneration
  7. Ranibizumab versus mitomycin C in primary trabeculectomy--a pilot study.
    Pro MJ, Freidl KB, Neylan CJ, et al. · Curr Eye Res · 2016 · Trial result
    PubMed: PMID 25019269 · NCT00626782 · Glaucoma
  8. Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
    Daniel E, Shaffer J, Ying GS, et al. · Ophthalmology · 2016 · Trial result
    PubMed: PMID 26681392 · NCT00593450 · Macular Degeneration
  9. Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema.
    Bressler SB, Glassman AR, Almukhtar T, et al. · Am J Ophthalmol · 2016 · Trial result
    PubMed: PMID 26802783 · NCT00444600 (LRT for DME) · Diabetic Retinopathy
  10. Intravitreal Ranibizumab Injection as an Adjuvant in the Treatment of Neovascular Glaucoma Accompanied by Vitreous Hemorrhage after Diabetic Vitrectomy.
    Shen X, Chen Y, Wang Y, et al. · J Ophthalmol · 2016 · Derived
    PubMed: PMID 27293875 · NCT02647515 · Diabetic Retinopathy
  11. A model of the ocular pharmacokinetics involved in the therapy of neovascular age-related macular degeneration with ranibizumab.
    Saunders DJ, Muether PS, Fauser S, et al. · Br J Ophthalmol · 2016 · Derived
    PubMed: PMID 25957377 · NCT01213667 (RESPONSE) · Macular Degeneration
  12. Bevacizumab Versus Ranibizumab in the Treatment of Macular Edema Due to Retinal Vein Occlusion: 6-Month Results of the CRAVE Study.
    Rajagopal R, Shah GK, Blinder KJ, et al. · Ophthalmic Surg Lasers Imaging Retina · 2016 · Derived
    PubMed: PMID 26431300 · NCT01428388 (CRAVE) · Macular Edema
  13. Three-year patient-reported visual function outcomes in diabetic macular edema managed with ranibizumab: the RESTORE extension study.
    Mitchell P, Massin P, Bressler S, et al. · Curr Med Res Opin · 2016 · Derived
    PubMed: PMID 26327116 · NCT00687804 (RESTORE) · Edema
  14. Ranibizumab for High-Risk Proliferative Diabetic Retinopathy: An Exploratory Randomized Controlled Trial.
    Figueira J, Silva R, Henriques J, et al. · Ophthalmologica · 2016 · Derived
    PubMed: PMID 26630400 · NCT01280929
  15. Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study).
    Dhoot DS, Pieramici DJ, Nasir M, et al. · Eye (Lond) · 2016 · Derived
    PubMed: PMID 25633882 · NCT01292798 (REEF) · Diabetes Mellitus
  16. Effect of Ranibizumab on the Decision to Drive and Vision Function Relevant to Driving in Patients With Diabetic Macular Edema: Report From RESTORE, RIDE, and RISE Trials.
    Bressler NM, Varma R, Mitchell P, et al. · JAMA Ophthalmol · 2016 · Derived
    PubMed: PMID 26584450 · NCT00473330 (RISE) · Macular Edema
  17. Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials.
    Boyer DS, Nguyen QD, Brown DM, et al. · Ophthalmology · 2016 · Derived
    PubMed: PMID 26452713 · NCT00473382 (RIDE) · Macular Edema
  18. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study.
    Arnold JJ, Markey CM, Kurstjens NP, et al. · BMC Ophthalmol · 2016 · Derived
    PubMed: PMID 27009515 · NCT01972789 (FLUID)
  19. Comparison of Perioperative Ranibizumab Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery.
    Yumuşak E, Örnek K · J Ophthalmol · 2016 · Background
    PubMed: PMID 27493795 · NCT03832179 (STAMP) · Cataract
  20. Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
    Wells JA, Glassman AR, Jampol LM, et al. · JAMA Ophthalmol · 2016 · Background
    PubMed: PMID 26605836 · NCT01627249 (Protocol T)
  21. Intravitreal aflibercept (Eylea) injection for cystoid macular edema secondary to retinitis pigmentosa - a first case report and short review of the literature.
    Moustafa GA, Moschos MM · BMC Ophthalmol · 2016 · Background
    PubMed: PMID 25925748 · NCT03763227 · Retinal Dystrophies
  22. Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial.
    Kuppermann BD, Goldstein M, Maturi RK, et al. · Ophthalmologica · 2016 · Background
    PubMed: PMID 26088793 · NCT00511706 · Macular Degeneration
  23. Cataract surgery and age-related macular degeneration. An evidence-based update.
    Kessel L, Erngaard D, Flesner P, et al. · Acta Ophthalmol · 2016 · Background
    PubMed: PMID 25601333 · NCT03944070 · Wet Macular Degeneration
  24. The Features of Inflammation Factors Concentrations in Aqueous Humor of Polypoidal Choroidal Vasculopathy.
    Hu J, Leng X, Hu Y, et al. · PLoS One · 2016 · Background
    PubMed: PMID 26799405 · NCT02976194 (CyPov) · Polypoidal Choroidal Vasculopathy
  25. A Novel Treatment for Proliferative Diabetic Retinopathy: Anti-Vascular Endothelial Growth Factor Therapy.
    Gross JG, Glassman AR · JAMA Ophthalmol · 2016 · Background
    PubMed: PMID 26583372 · NCT01489189 (Protocol S)
  26. Elevated Intraocular Pressure After Intravitreal Steroid Injection in Diabetic Macular Edema: Monitoring and Management.
    Goñi FJ, Stalmans I, Denis P, et al. · Ophthalmol Ther · 2016 · Background
    PubMed: PMID 27164896 · NCT03784443 (CASSIE) · Macular Edema
  27. Diabetes enhances the efficacy of AAV2 vectors in the retina: therapeutic effect of AAV2 encoding vasoinhibin and soluble VEGF receptor 1.
    Díaz-Lezama N, Wu Z, Adán-Castro E, et al. · Lab Invest · 2016 · Background
    PubMed: PMID 26568297 · NCT03161652 · Macular Edema
  28. RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Bressler SB, Melia M, Glassman AR, et al. · Retina · 2016 · Background
    PubMed: PMID 26035510 · NCT00444600 (LRT for DME) · Diabetic Retinopathy
  29. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment.
    Bressler SB, Ayala AR, Bressler NM, et al. · JAMA Ophthalmol · 2016 · Background
    PubMed: PMID 26746868 · NCT06205979

2015 (44 papers)

  1. EXTEND II: an open-label phase III multicentre study to evaluate efficacy and safety of ranibizumab in Chinese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Zhao J, Li X, Tang S, et al. · BioDrugs · 2015 · Trial result
    PubMed: PMID 25012926 · NCT00826371 (EXTEND II) · Macular Degeneration
  2. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
    Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, et al. · JAMA · 2015 · Trial result
    PubMed: PMID 26565927 · NCT01489189 (Protocol S)
  3. Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Willoughby AS, Ying GS, Toth CA, et al. · Ophthalmology · 2015 · Trial result
    PubMed: PMID 26143666 · NCT00593450 · Macular Degeneration
  4. IDENTIFICATION OF FLUID ON OPTICAL COHERENCE TOMOGRAPHY BY TREATING OPHTHALMOLOGISTS VERSUS A READING CENTER IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS.
    Toth CA, Decroos FC, Ying GS, et al. · Retina · 2015 · Trial result
    PubMed: PMID 26102433 · NCT00593450 · Macular Degeneration
  5. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.
    Moja L, Lucenteforte E, Kwag KH, et al. · Cochrane Database Syst Rev · 2015 · Trial result
    PubMed: PMID 25220133 · NCT00593450 · Macular Degeneration
  6. Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT).
    Meredith TA, McCannel CA, Barr C, et al. · Ophthalmology · 2015 · Trial result
    PubMed: PMID 25600198 · NCT00593450 · Macular Degeneration
  7. Outer retinal tubulation in the comparison of age-related macular degeneration treatments trials (CATT).
    Lee JY, Folgar FA, Maguire MG, et al. · Ophthalmology · 2015 · Trial result
    PubMed: PMID 25064723 · NCT00593450 · Macular Degeneration
  8. VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.
    Hagstrom SA, Ying GS, Maguire MG, et al. · Ophthalmology · 2015 · Trial result
    PubMed: PMID 26028346 · NCT00593450 · Macular Degeneration
  9. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials.
    Grunwald JE, Pistilli M, Ying GS, et al. · Ophthalmology · 2015 · Trial result
    PubMed: PMID 25542520 · NCT00593450 · Macular Degeneration
  10. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results.
    Elman MJ, Ayala A, Bressler NM, et al. · Ophthalmology · 2015 · Trial result
    PubMed: PMID 25439614 · NCT00444600 (LRT for DME) · Diabetic Retinopathy
  11. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
    Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. · N Engl J Med · 2015 · Trial result
    PubMed: PMID 25692915 · NCT01627249 (Protocol T)
  12. Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Ciulla TA, Ying GS, Maguire MG, et al. · Ophthalmology · 2015 · Trial result
    PubMed: PMID 25824327 · NCT00593450 · Macular Degeneration
  13. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab.
    Chen SN, Lian I, Hwang YC, et al. · Retina · 2015 · Trial result
    PubMed: PMID 25462435 · NCT03334513 · Retinopathy of Prematurity
  14. Subconjunctival bevacizumab in the impending recurrent pterygia.
    Bayar SA, Kucukerdonmez C, Oner O, et al. · Int Ophthalmol · 2015 · Trial result
    PubMed: PMID 24026871 · NCT02342392 · Pterygium
  15. Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).
    Altaweel MM, Daniel E, Martin DF, et al. · Ophthalmology · 2015 · Trial result
    PubMed: PMID 25307130 · NCT00593450 · Macular Degeneration
  16. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.
    Yuzawa M, Fujita K, Wittrup-Jensen KU, et al. · Ophthalmology · 2015 · Derived
    PubMed: PMID 25439429 · NCT00509795 (VIEW1) · Macular Degeneration
  17. Progressive retinal nonperfusion in ischemic central retinal vein occlusion.
    Wykoff CC, Brown DM, Croft DE, et al. · Retina · 2015 · Derived
    PubMed: PMID 25102193 · NCT01225146 (RAVE2) · Retinal Vein Occlusion
  18. EVEREST study report 2: imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy.
    Tan CS, Ngo WK, Chen JP, et al. · Br J Ophthalmol · 2015 · Derived
    PubMed: PMID 25758601 · NCT00674323 (PCV) · Macular Degeneration
  19. Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy.
    Ritter M, Simader C, Bolz M, et al. · Br J Ophthalmol · 2015 · Derived
    PubMed: PMID 25079064 · NCT00433017 · Macular Degeneration
  20. Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial.
    Pielen A, Mirshahi A, Feltgen N, et al. · Acta Ophthalmol · 2015 · Derived
    PubMed: PMID 25042729 · NCT00562406 (RABAMES) · Macular Edema
  21. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.
    Pearce I, Banerjee S, Burton BJ, et al. · Ophthalmology · 2015 · Derived
    PubMed: PMID 26150052 · NCT01257815 (RELIGHT) · Macular Edema
  22. Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study.
    Ogura Y, Terasaki H, Gomi F, et al. · Br J Ophthalmol · 2015 · Derived
    PubMed: PMID 25107900 · NCT00637377 (VIEW 2) · Macular Degeneration
  23. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease.
    Menke MN, Framme C, Nelle M, et al. · BMC Ophthalmol · 2015 · Derived
    PubMed: PMID 25886603 · NCT02164604 · Retinopathy of Prematurity
  24. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration.
    Holz FG, Tadayoni R, Beatty S, et al. · Br J Ophthalmol · 2015 · Derived
    PubMed: PMID 25193672 · NCT01447043 (AURA) · Macular Degeneration
  25. A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy.
    Ferraz DA, Vasquez LM, Preti RC, et al. · Retina · 2015 · Derived
    PubMed: PMID 25272318 · NCT01746563 · Diabetic Retinopathy
  26. Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration.
    Chan CK, Abraham P, Sarraf D, et al. · Eye (Lond) · 2015 · Derived
    PubMed: PMID 25277305 · NCT00749021 · Choroidal Neovascularization
  27. Visual acuity outcome in RADIANCE study patients with dome-shaped macular features.
    Ceklic L, Wolf-Schnurrbusch U, Gekkieva M, et al. · Ophthalmology · 2015 · Derived
    PubMed: PMID 25109929 · NCT01217944 · Choroidal Neovascularization
  28. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE.
    Bressler NM, Varma R, Suñer IJ, et al. · Ophthalmology · 2015 · Derived
    PubMed: PMID 25148789 · NCT00687804 (RESTORE) · Edema
  29. Influence of Glycosylated Hemoglobin on the Efficacy of Ranibizumab for Diabetic Macular Edema: A Post Hoc Analysis of the RIDE/RISE Trials.
    Bansal AS, Khurana RN, Wieland MR, et al. · Ophthalmology · 2015 · Derived
    PubMed: PMID 26050541 · NCT00473382 (RIDE) · Macular Edema
  30. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD.
    Avery RL, Castellarin AA, Steinle NC, et al. · Br J Ophthalmol · 2015 · Derived
    PubMed: PMID 25001321 · NCT02118831 · Macular Degeneration
  31. Targeting the Effect of VEGF in Diabetic Macular Edema.
    Wells JA, Glassman AR, Jampol LM, et al. · N Engl J Med · 2015 · Background
    PubMed: PMID 26222565 · NCT01627249 (Protocol T)
  32. The effects of cataract surgery on patients with wet macular degeneration.
    Saraf SS, Ryu CL, Ober MD, et al. · Am J Ophthalmol · 2015 · Background
    PubMed: PMID 26095263 · NCT03944070 · Wet Macular Degeneration
  33. Aqueous humor cytokine levels in patients with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration.
    Sakurada Y, Nakamura Y, Yoneyama S, et al. · Ophthalmic Res · 2015 · Background
    PubMed: PMID 25472810 · NCT02976194 (CyPov) · Polypoidal Choroidal Vasculopathy
  34. VEGF mRNA assessment in human pterygium: a new 'scope' for a future hope.
    Poenaru Sava MG, Raica ML, Cimpean AM, et al. · Ophthalmic Res · 2015 · Background
    PubMed: PMID 25300614 · NCT02342392 · Pterygium
  35. A review of anti-VEGF agents for proliferative diabetic retinopathy.
    Osaadon P, Fagan XJ, Lifshitz T, et al. · Eye (Lond) · 2015 · Background
    PubMed: PMID 24525867 · NCT02979665
  36. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema.
    Mesquida M, Molins B, Llorenç V, et al. · Ophthalmology · 2015 · Background
    PubMed: PMID 25204610 · NCT02511067 (READ-4)
  37. Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema.
    Mehta H, Gillies M, Fraser-Bell S, et al. · Ther Adv Chronic Dis · 2015 · Background
    PubMed: PMID 26336592 · NCT03784443 (CASSIE) · Macular Edema
  38. One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization.
    Kung YH, Wu TT, Huang YH, et al. · Acta Ophthalmol · 2015 · Background
    PubMed: PMID 24924911 · NCT03042871 (SMILE) · Choroidal Neovascularization
  39. Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network.
    Jampol LM, Glassman AR, Bressler NM, et al. · JAMA Ophthalmol · 2015 · Background
    PubMed: PMID 26087135 · NCT01627249 (Protocol T)
  40. High-dose (2.0 mg) intravitreal ranibizumab for recalcitrant radiation retinopathy.
    Finger PT, Chin KJ · Eur J Ophthalmol · 2015 · Background
    PubMed: PMID 23813109 · NCT02222610 (RRR)
  41. Aqueous cytokines as predictors of macular edema in patients with diabetes following uncomplicated phacoemulsification cataract surgery.
    Dong N, Xu B, Wang B, et al. · Biomed Res Int · 2015 · Background
    PubMed: PMID 25811020 · NCT03832179 (STAMP) · Cataract
  42. Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion: The RELATE Trial.
    Campochiaro PA, Hafiz G, Mir TA, et al. · Ophthalmology · 2015 · Background
    PubMed: PMID 25972260 · NCT04062370 · Retinal Vein Occlusion
  43. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment.
    Bressler SB, Almukhtar T, Bhorade A, et al. · JAMA Ophthalmol · 2015 · Background
    PubMed: PMID 25719991 · NCT00444600 (LRT for DME) · Diabetic Retinopathy
  44. Causes of vision loss worldwide, 1990-2010: a systematic analysis.
    Bourne RR, Stevens GA, White RA, et al. · Lancet Glob Health · 2015 · Background
    PubMed: PMID 25104599 · NCT02511067 (READ-4)

2014 (35 papers)

  1. Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials.
    Ying GS, Kim BJ, Maguire MG, et al. · JAMA Ophthalmol · 2014 · Trial result
    PubMed: PMID 24875610 · NCT00593450 · Macular Degeneration
  2. Diabetic macular edema: New promising therapies.
    Shamsi HN, Masaud JS, Ghazi NG, et al. · World J Diabetes · 2014 · Trial result
    PubMed: PMID 24379924 · NCT02447185 (aiRTo-PDR)
  3. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
    Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. · Ophthalmology · 2014 · Trial result
    PubMed: PMID 24084500 · NCT00637377 (VIEW 2) · Macular Degeneration
  4. Efficacy of intralesional bevacizumab administration in primary pterygium: a quantitative analysis.
    Sarac O, Demirel S, Oltulu R, et al. · Eye Contact Lens · 2014 · Trial result
    PubMed: PMID 24335454 · NCT02342392 · Pterygium
  5. The effect of different doses of subconjunctival bevacizumab on the recurrence rate of excised primary pterygium.
    Razeghinejad R, Banifatemi M, Hosseini H, et al. · Bull Soc Belge Ophtalmol · 2014 · Trial result
    PubMed: PMID 24923077 · NCT02342392 · Pterygium
  6. Subconjunctival bevacizumab for primary pterygium excision; a randomized clinical trial.
    Razeghinejad MR, Banifatemi M · J Ophthalmic Vis Res · 2014 · Trial result
    PubMed: PMID 24982728 · NCT02342392 · Pterygium
  7. Randomized, controlled trial of conjunctival autografting combined with subconjunctival bevacizumab for primary pterygium treatment: 1-year follow-up.
    Nava-Castañeda A, Olvera-Morales O, Ramos-Castellon C, et al. · Clin Exp Ophthalmol · 2014 · Trial result
    PubMed: PMID 23777441 · NCT02342392 · Pterygium
  8. Vascular endothelial growth factor suppression times in patients with diabetic macular oedema treated with ranibizumab.
    Muether PS, Droege KM, Fauser S, et al. · Br J Ophthalmol · 2014 · Trial result
    PubMed: PMID 24227804 · NCT04089605
  9. Subconjunctival bevacizumab injection in the surgery of primary pterygium: comparison with intraoperative mitomycin-C.
    Kocabora SM, Fazil K, Ozsutcu M, et al. · Bull Soc Belge Ophtalmol · 2014 · Trial result
    PubMed: PMID 24923076 · NCT02342392 · Pterygium
  10. Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
    Kim BJ, Ying GS, Huang J, et al. · Am J Ophthalmol · 2014 · Trial result
    PubMed: PMID 24727261 · NCT00593450 · Macular Degeneration
  11. Does topical bevacizumab prevent postoperative recurrence after pterygium surgery with conjunctival autografting?
    Karalezli A, Kucukerdonmez C, Akova YA, et al. · Int J Ophthalmol · 2014 · Trial result
    PubMed: PMID 24967201 · NCT02342392 · Pterygium
  12. Bevacizumab in the treatment of pterygium: a meta-analysis.
    Hu Q, Qiao Y, Nie X, et al. · Cornea · 2014 · Trial result
    PubMed: PMID 24326333 · NCT02342392 · Pterygium
  13. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).
    Hagstrom SA, Ying GS, Pauer GJ, et al. · JAMA Ophthalmol · 2014 · Trial result
    PubMed: PMID 24652518 · NCT00593450 · Macular Degeneration
  14. Surgical management of diabetic retinopathy.
    Gupta V, Arevalo JF · Middle East Afr J Ophthalmol · 2014 · Trial result
    PubMed: PMID 24339677 · NCT02447185 (aiRTo-PDR)
  15. The use of a vascular endothelial growth factor inhibitor (ranibizumab) in macular edema due to eales disease.
    Gupta SR, Flaxel CJ · Retin Cases Brief Rep · 2014 · Trial result
    PubMed: PMID 25390730 · NCT00384449 · Eales disease
  16. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials.
    Grunwald JE, Daniel E, Huang J, et al. · Ophthalmology · 2014 · Trial result
    PubMed: PMID 24084496 · NCT00593450 · Macular Degeneration
  17. Delayed patchy choroidal filling in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
    Gewaily DY, Grunwald JE, Pistilli M, et al. · Am J Ophthalmol · 2014 · Trial result
    PubMed: PMID 24949820 · NCT00593450 · Macular Degeneration
  18. Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials.
    Folgar FA, Jaffe GJ, Ying GS, et al. · Ophthalmology · 2014 · Trial result
    PubMed: PMID 24835760 · NCT00593450 · Macular Degeneration
  19. Risk of scar in the comparison of age-related macular degeneration treatments trials.
    Daniel E, Toth CA, Grunwald JE, et al. · Ophthalmology · 2014 · Trial result
    PubMed: PMID 24314839 · NCT00593450 · Macular Degeneration
  20. Common variant in VEGFA and response to anti-VEGF therapy for neovascular age-related macular degeneration.
    Zhao L, Grob S, Avery R, et al. · Curr Mol Med · 2014 · Derived
    PubMed: PMID 23745581 · NCT01464723 (SEAGUL2) · Macular Degeneration
  21. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.
    Wolf S, Balciuniene VJ, Laganovska G, et al. · Ophthalmology · 2014 · Derived
    PubMed: PMID 24326106 · NCT01217944 · Choroidal Neovascularization
  22. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials.
    Thach AB, Yau L, Hoang C, et al. · Ophthalmology · 2014 · Derived
    PubMed: PMID 24424249 · NCT00061594 · Macular Degeneration
  23. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.
    Schmidt-Erfurth U, Lang GE, Holz FG, et al. · Ophthalmology · 2014 · Derived
    PubMed: PMID 24491642 · NCT00687804 (RESTORE) · Edema
  24. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).
    Schmidt-Erfurth U, Chong V, Loewenstein A, et al. · Br J Ophthalmol · 2014 · Derived
    PubMed: PMID 25136079 · NCT01318941 (LUMINOUS) · Macular Degeneration
  25. Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma--results from a prospective interventional case series.
    Lüke J, Nassar K, Lüke M, et al. · Graefes Arch Clin Exp Ophthalmol · 2014 · Derived
    PubMed: PMID 23893090 · NCT01370135 (LucNVG0108) · Glaucoma, Neovascular
  26. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema.
    Campochiaro PA, Wykoff CC, Shapiro H, et al. · Ophthalmology · 2014 · Derived
    PubMed: PMID 24768239 · NCT00473330 (RISE) · Macular Edema
  27. Anti-vascular endothelial growth factor for diabetic macular oedema.
    Virgili G, Parravano M, Menchini F, et al. · Cochrane Database Syst Rev · 2014 · Background
    PubMed: PMID 25342124 · NCT03784443 (CASSIE) · Macular Edema
  28. Retinal morphologic changes and concentrations of cytokines in eyes with diabetic macular edema.
    Sonoda S, Sakamoto T, Yamashita T, et al. · Retina · 2014 · Background
    PubMed: PMID 23975003 · NCT02511067 (READ-4)
  29. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema.
    Cunha-Vaz J, Ashton P, Iezzi R, et al. · Ophthalmology · 2014 · Background
    PubMed: PMID 24935282 · NCT03784443 (CASSIE) · Macular Edema
  30. Green or yellow laser treatment for diabetic macular edema: exploratory assessment within the Diabetic Retinopathy Clinical Research Network.
    Bressler SB, Almukhtar T, Aiello LP, et al. · Retina · 2014 · Background
    PubMed: PMID 23792486 · NCT00445003 (LRTforDME+PRP) · Diabetic Retinopathy
  31. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema.
    Boyer DS, Yoon YH, Belfort R, et al. · Ophthalmology · 2014 · Background
    PubMed: PMID 24907062 · NCT02511067 (READ-4)
  32. Evaluation of results 1 year following short-term use of ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy.
    Bhavsar AR, Torres K, Glassman AR, et al. · JAMA Ophthalmol · 2014 · Background
    PubMed: PMID 25010170 · NCT00996437 (N) · Retinal Diseases
  33. Vasoinhibins regulate the inner and outer blood-retinal barrier and limit retinal oxidative stress.
    Arredondo Zamarripa D, Díaz-Lezama N, Meléndez García R, et al. · Front Cell Neurosci · 2014 · Background
    PubMed: PMID 25368550 · NCT03161652 · Macular Edema
  34. The hormone prolactin is a novel, endogenous trophic factor able to regulate reactive glia and to limit retinal degeneration.
    Arnold E, Thebault S, Baeza-Cruz G, et al. · J Neurosci · 2014 · Background
    PubMed: PMID 24478366 · NCT03161652 · Macular Edema
  35. Diabetic macular edema: changing treatment paradigms.
    Arevalo JF · Curr Opin Ophthalmol · 2014 · Background
    PubMed: PMID 25211039 · NCT02511067 (READ-4)

2013 (42 papers)

  1. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.
    Ying GS, Huang J, Maguire MG, et al. · Ophthalmology · 2013 · Trial result
    PubMed: PMID 23047002 · NCT00593450 · Macular Degeneration
  2. Correlation between reflectivity of subretinal fluid in OCT images and concentration of intravitreal VEGF in eyes with diabetic macular edema.
    Sonoda S, Sakamoto T, Shirasawa M, et al. · Invest Ophthalmol Vis Sci · 2013 · Trial result
    PubMed: PMID 23860753 · NCT04089605
  3. Intraoperative subconjunctival bevacizumab as an adjunctive treatment in primary pterygium: a preliminary report.
    Shahin MM, Elbendary AM, Elwan MM, et al. · Ophthalmic Surg Lasers Imaging · 2013 · Trial result
    PubMed: PMID 22882007 · NCT02342392 · Pterygium
  4. Topical application of bevacizumab as an adjunct to recurrent pterygium surgery.
    Ozgurhan EB, Agca A, Kara N, et al. · Cornea · 2013 · Trial result
    PubMed: PMID 23187164 · NCT02342392 · Pterygium
  5. Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.
    Maguire MG, Daniel E, Shah AR, et al. · Ophthalmology · 2013 · Trial result
    PubMed: PMID 23706946 · NCT00593450 · Macular Degeneration
  6. EXTEND III: efficacy and safety of ranibizumab in South Korean and Taiwanese patients with subfoveal CNV secondary to AMD.
    Kwon OW, Lee FL, Chung H, et al. · Graefes Arch Clin Exp Ophthalmol · 2013 · Trial result
    PubMed: PMID 22382503 · NCT00470678 · Macular Degeneration
  7. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.
    Jaffe GJ, Martin DF, Toth CA, et al. · Ophthalmology · 2013 · Trial result
    PubMed: PMID 23642377 · NCT00593450 · Macular Degeneration
  8. Single and multiple injections of subconjunctival ranibizumab for early, recurrent pterygium.
    Hurmeric V, Vaddavalli P, Galor A, et al. · Clin Ophthalmol · 2013 · Trial result
    PubMed: PMID 23486999 · NCT02342392 · Pterygium
  9. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
    Heier JS, Brown DM, Chong V, et al. · Ophthalmology · 2013 · Trial result
    PubMed: PMID 23084240 · NCT00637377 (VIEW 2) · Macular Degeneration
  10. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).
    Hagstrom SA, Ying GS, Pauer GJT, et al. · Ophthalmology · 2013 · Trial result
    PubMed: PMID 23337555 · NCT00593450 · Macular Degeneration
  11. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results.
    Diabetic Retinopathy Clinical Research Network, Elman MJ, Qin H, et al. · Ophthalmology · 2013 · Trial result
    PubMed: PMID 22999634 · NCT00444600 (LRT for DME) · Diabetic Retinopathy
  12. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.
    Diabetic Retinopathy Clinical Research Network* · JAMA Ophthalmol · 2013 · Trial result
    PubMed: PMID 23370902 · NCT00996437 (N) · Retinal Diseases
  13. Intravitreal ranibizumab as an adjunct for Ahmed valve surgery in open-angle glaucoma: a pilot study.
    Desai RU, Singh K, Lin SC, et al. · Clin Exp Ophthalmol · 2013 · Trial result
    PubMed: PMID 22712537 · NCT00644280 · Glaucoma
  14. Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials.
    DeCroos FC, Toth CA, Stinnett SS, et al. · Ophthalmology · 2013 · Trial result
    PubMed: PMID 22939114 · NCT00593450 · Macular Degeneration
  15. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach.
    Xu L, Lu T, Tuomi L, et al. · Invest Ophthalmol Vis Sci · 2013 · Derived
    PubMed: PMID 23361508 · NCT00056823 · Macular Degeneration
  16. Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD.
    Wykoff CC, Brown DM, Croft DE, et al. · Ophthalmology · 2013 · Derived
    PubMed: PMID 24001533 · NCT00406471 · Bites and Stings
  17. Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials.
    Weinberg DV, Shapiro H, Ehrlich JS, et al. · Ophthalmology · 2013 · Derived
    PubMed: PMID 23453513 · NCT00061594 · Macular Degeneration
  18. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study.
    Tufail A, Narendran N, Patel PJ, et al. · Ophthalmology · 2013 · Derived
    PubMed: PMID 24001532 · NCT01037348 (REPAIR) · Choroidal Neovascularization
  19. Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
    Suñer IJ, Bressler NM, Varma R, et al. · JAMA Ophthalmol · 2013 · Derived
    PubMed: PMID 23699977 · NCT00486018 (BRAVO) · Macular Edema
  20. Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion.
    Sophie R, Hafiz G, Scott AW, et al. · Am J Ophthalmol · 2013 · Derived
    PubMed: PMID 24053892 · NCT00407355 (LVO) · Macular Edema
  21. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration.
    Silva R, Axer-Siegel R, Eldem B, et al. · Ophthalmology · 2013 · Derived
    PubMed: PMID 23021093 · NCT00504959 · Macular Degeneration
  22. Ranibizumab versus photodynamic therapy for presumed ocular histoplasmosis syndrome.
    Ramaiya KJ, Blinder KJ, Ciulla T, et al. · Ophthalmic Surg Lasers Imaging Retina · 2013 · Derived
    PubMed: PMID 23410808 · NCT00546936 · Histoplasmosis
  23. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema.
    Nepomuceno AB, Takaki E, Paes de Almeida FP, et al. · Am J Ophthalmol · 2013 · Derived
    PubMed: PMID 23795985 · NCT01487629 (IBERA-DME) · Macular Edema
  24. FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity.
    Monés J, Biarnés M, Trindade F, et al. · Graefes Arch Clin Exp Ophthalmol · 2013 · Derived
    PubMed: PMID 22527314 · NCT01500915 (FUSION)
  25. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial.
    Mitchell P, Bressler N, Tolley K, et al. · JAMA Ophthalmol · 2013 · Derived
    PubMed: PMID 23974915 · NCT00687804 (RESTORE) · Edema
  26. Intravitreal ranibizumab for polypoidal choroidal vasculopathy in non-Asian patients.
    Marcus DM, Singh H, Lott MN, et al. · Retina · 2013 · Derived
    PubMed: PMID 22990319 · NCT00837330 · Choroidal Neovascularization
  27. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.
    Krebs I, Schmetterer L, Boltz A, et al. · Br J Ophthalmol · 2013 · Derived
    PubMed: PMID 23292928 · NCT00710229 (MANTA) · Macular Degeneration
  28. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography.
    Jackson TL, Dugel PU, Bebchuk JD, et al. · Ophthalmology · 2013 · Derived
    PubMed: PMID 23490325 · NCT01006538 (MERLOT) · Macular Degeneration
  29. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment.
    Do DV, Nguyen QD, Khwaja AA, et al. · JAMA Ophthalmol · 2013 · Derived
    PubMed: PMID 23544200 · NCT00407381
  30. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Busbee BG, Ho AC, Brown DM, et al. · Ophthalmology · 2013 · Derived
    PubMed: PMID 23352196 · NCT00891735 (HARBOR) · Macular Degeneration
  31. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
    Brown DM, Nguyen QD, Marcus DM, et al. · Ophthalmology · 2013 · Derived
    PubMed: PMID 23706949 · NCT00473382 (RIDE) · Macular Edema
  32. Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab.
    Bressler NM, Chang TS, Varma R, et al. · Ophthalmology · 2013 · Derived
    PubMed: PMID 23009891 · NCT00061594 · Macular Degeneration
  33. Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography.
    Bhisitkul RB, Campochiaro PA, Shapiro H, et al. · Ophthalmology · 2013 · Derived
    PubMed: PMID 23415775 · NCT00486018 (BRAVO) · Macular Edema
  34. Prolactin and vasoinhibins: Endogenous players in diabetic retinopathy.
    Triebel J, Macotela Y, de la Escalera GM, et al. · IUBMB Life · 2013 · Background
    PubMed: PMID 21913303 · NCT03161652 · Macular Edema
  35. High prevalence of myopia and high myopia in 5060 Chinese university students in Shanghai.
    Sun J, Zhou J, Zhao P, et al. · Invest Ophthalmol Vis Sci · 2013 · Background
    PubMed: PMID 23060137 · NCT03042871 (SMILE) · Choroidal Neovascularization
  36. Ocular hypertension following intravitreal anti-vascular endothelial growth factor agents.
    Singh RS, Kim JE · Drugs Aging · 2013 · Background
    PubMed: PMID 23179897 · NCT02979665
  37. Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema.
    Rauen PI, Ribeiro JA, Almeida FP, et al. · Retina · 2013 · Background
    PubMed: PMID 22495327 · NCT03832179 (STAMP) · Cataract
  38. Recurrence of retinopathy of prematurity following bevacizumab monotherapy: is it only the tip of the iceberg?
    Mireskandari K, Adams GG, Tehrani NN, et al. · JAMA Ophthalmol · 2013 · Background
    PubMed: PMID 23579608 · NCT04539106 · Retinopathy of Prematurity
  39. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration.
    Mathalone N, Arodi-Golan A, Sar S, et al. · Graefes Arch Clin Exp Ophthalmol · 2013 · Background
    PubMed: PMID 22434210 · NCT02979665
  40. High vitreous concentration of IL-6 and IL-8, but not of adhesion molecules in relation to plasma concentrations in proliferative diabetic retinopathy.
    Koskela UE, Kuusisto SM, Nissinen AE, et al. · Ophthalmic Res · 2013 · Background
    PubMed: PMID 23257933 · NCT02511067 (READ-4)
  41. Comparative analysis of aqueous humor cytokine levels between patients with exudative age-related macular degeneration and normal controls.
    Cha DM, Woo SJ, Kim HJ, et al. · Invest Ophthalmol Vis Sci · 2013 · Background
    PubMed: PMID 24106111 · NCT02976194 (CyPov) · Polypoidal Choroidal Vasculopathy
  42. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial.
    Bressler SB, Qin H, Melia M, et al. · JAMA Ophthalmol · 2013 · Background
    PubMed: PMID 23807371 · NCT00444600 (LRT for DME) · Diabetic Retinopathy

2012 (36 papers)

  1. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration.
    Park SS, Daftari I, Phillips T, et al. · Retina · 2012 · Trial result
    PubMed: PMID 22183743 · NCT00517010 · Macular Degeneration
  2. Bevacizumab: not as good with more adverse reactions? Response.
    Martin DF, Maguire MG, Fine SL, et al. · Clin Exp Ophthalmol · 2012 · Trial result
    PubMed: PMID 22452699 · NCT00593450 · Macular Degeneration
  3. Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: a pilot study.
    Lekhanont K, Patarakittam T, Thongphiew P, et al. · Cornea · 2012 · Trial result
    PubMed: PMID 22081150 · NCT02342392 · Pterygium
  4. Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Grunwald JE, Daniel E, Ying GS, et al. · Ophthalmology · 2012 · Trial result
    PubMed: PMID 22512984 · NCT00593450 · Macular Degeneration
  5. Refractory squamous cell carcinoma of the conjunctiva treated with subconjunctival ranibizumab (Lucentis): a two-year study.
    Finger PT, Chin KJ · Ophthalmic Plast Reconstr Surg · 2012 · Trial result
    PubMed: PMID 22186988 · NCT00456495 · Conjunctival Neoplasms
  6. Pars plana vitrectomy with internal limiting membrane peeling for refractory diffuse diabetic macular edema.
    Dehghan MH, Salehipour M, Naghib J, et al. · J Ophthalmic Vis Res · 2012 · Trial result
    PubMed: PMID 22737351 · NCT02447185 (aiRTo-PDR)
  7. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
    Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, et al. · Ophthalmology · 2012 · Trial result
    PubMed: PMID 22555112 · NCT00593450 · Macular Degeneration
  8. Transconjunctival 25-gauge pars plana vitrectomy and internal limiting membrane peeling for chronic macular edema.
    Cho M, D'Amico DJ · Clin Ophthalmol · 2012 · Trial result
    PubMed: PMID 22848140 · NCT02447185 (aiRTo-PDR)
  9. Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study.
    Benayoun Y, Adenis JP, Casse G, et al. · Cornea · 2012 · Trial result
    PubMed: PMID 22357391 · NCT02342392 · Pterygium
  10. Refractory diabetic macular edema.
    Bainbridge J · J Ophthalmic Vis Res · 2012 · Trial result
    PubMed: PMID 22737347 · NCT02447185 (aiRTo-PDR)
  11. Combination therapy with low-dose transpupillary thermotherapy and intravitreal ranibizumab for neovascular age-related macular degeneration: a 24-month prospective randomised clinical study.
    Söderberg AC, Algvere PV, Hengstler JC, et al. · Br J Ophthalmol · 2012 · Derived
    PubMed: PMID 22241923 · NCT00599222 · Macular Degeneration
  12. Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy.
    Messias A, Ramos Filho JA, Messias K, et al. · Doc Ophthalmol · 2012 · Derived
    PubMed: PMID 22457045 · NCT00993525 (INIPE) · Diabetic Retinopathy
  13. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results.
    Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. · Ophthalmology · 2012 · Derived
    PubMed: PMID 22424834 · NCT00433017 · Macular Degeneration
  14. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.
    Koh A, Lee WK, Chen LJ, et al. · Retina · 2012 · Derived
    PubMed: PMID 22426346 · NCT00674323 (PCV) · Macular Degeneration
  15. Subjective perception versus objective outcome after intravitreal ranibizumab for exudative AMD.
    Koch KR, Muether PS, Hermann MM, et al. · Graefes Arch Clin Exp Ophthalmol · 2012 · Derived
    PubMed: PMID 21901296 · NCT01213667 (RESPONSE) · Macular Degeneration
  16. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
    Kaiser PK, Boyer DS, Cruess AF, et al. · Ophthalmology · 2012 · Derived
    PubMed: PMID 22444829 · NCT00436553 · Macular Degeneration
  17. Long-term effects of ranibizumab on diabetic retinopathy severity and progression.
    Ip MS, Domalpally A, Hopkins JJ, et al. · Arch Ophthalmol · 2012 · Derived
    PubMed: PMID 22965590 · NCT00473382 (RIDE) · Macular Edema
  18. The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study (an American Ophthalmological Society thesis).
    Francis PJ · Trans Am Ophthalmol Soc · 2012 · Derived
    PubMed: PMID 22253485 · NCT00469352 · Macular Degeneration
  19. A new epidemiological aid in deciding whether to continue or stop a treatment.
    Elshout M, van der Reis MI, Webers CA, et al. · Invest Ophthalmol Vis Sci · 2012 · Derived
    PubMed: PMID 22661474 · NCT00056836 · Macular Degeneration
  20. Global prevalence and major risk factors of diabetic retinopathy.
    Yau JW, Rogers SL, Kawasaki R, et al. · Diabetes Care · 2012 · Background
    PubMed: PMID 22301125 · NCT03784443 (CASSIE) · Macular Edema
  21. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
    Shienbaum G, Gupta OP, Fecarotta C, et al. · Am J Ophthalmol · 2012 · Background
    PubMed: PMID 21996309 · NCT01748292 (T-REX) · Macular Degeneration
  22. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies.
    Shibuya M · Genes Cancer · 2012 · Background
    PubMed: PMID 22866201 · NCT04878835
  23. Vasoinhibin gene transfer by adenoassociated virus type 2 protects against VEGF- and diabetes-induced retinal vasopermeability.
    Ramírez M, Wu Z, Moreno-Carranza B, et al. · Invest Ophthalmol Vis Sci · 2012 · Background
    PubMed: PMID 22003113 · NCT03161652 · Macular Edema
  24. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
    Nguyen QD, Brown DM, Marcus DM, et al. · Ophthalmology · 2012 · Background
    PubMed: PMID 22330964 · NCT02511067 (READ-4)
  25. Prevalence of diabetic macular oedema and related health and social care resource use in England.
    Minassian DC, Owens DR, Reidy A, et al. · Br J Ophthalmol · 2012 · Background
    PubMed: PMID 21602478 · NCT03784443 (CASSIE) · Macular Edema
  26. Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease?
    Manousaridis K, Talks J · Br J Ophthalmol · 2012 · Background
    PubMed: PMID 22250209 · NCT04991350 (REBEL) · Diabetic Retinopathy
  27. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans.
    Krohne TU, Liu Z, Holz FG, et al. · Am J Ophthalmol · 2012 · Background
    PubMed: PMID 22818800 · NCT04539106 · Retinopathy of Prematurity
  28. The prevalence and impact of high myopia.
    Jones D, Luensmann D · Eye Contact Lens · 2012 · Background
    PubMed: PMID 22495679 · NCT03042871 (SMILE) · Choroidal Neovascularization
  29. Detection of 8-hydroxydeoxyguanosine enzyme in recurrent pterygium raising a question on its role on recurrence.
    Ismaeel OM, Jaafar H, Ibrahim M, et al. · Int J Ophthalmol · 2012 · Background
    PubMed: PMID 22553564 · NCT04878835
  30. Evaluation of masking study participants to intravitreal injections in a randomized clinical trial.
    Glassman AR, Stockdale CR, Beck RW, et al. · Arch Ophthalmol · 2012 · Background
    PubMed: PMID 22332211 · NCT00445003 (LRTforDME+PRP) · Diabetic Retinopathy
  31. Intravitreal anti-VEGF bevacizumab (Avastin) for external beam related radiation retinopathy.
    Finger PT, Mukkamala SK · Eur J Ophthalmol · 2012 · Background
    PubMed: PMID 21218391 · NCT02222610 (RRR)
  32. Antivascular endothelial growth factor bevacizumab for radiation optic neuropathy: secondary to plaque radiotherapy.
    Finger PT, Chin KJ · Int J Radiat Oncol Biol Phys · 2012 · Background
    PubMed: PMID 21277107 · NCT02222610 (RRR)
  33. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema.
    Diabetic Retinopathy Clinical Research Network, Writing Committee, Aiello LP, et al. · Ophthalmology · 2012 · Background
    PubMed: PMID 22136692 · NCT00445003 (LRTforDME+PRP) · Diabetic Retinopathy
  34. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema.
    Campochiaro PA, Brown DM, Pearson A, et al. · Ophthalmology · 2012 · Background
    PubMed: PMID 22727177 · NCT03784443 (CASSIE) · Macular Edema
  35. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab.
    Bressler SB, Qin H, Beck RW, et al. · Arch Ophthalmol · 2012 · Background
    PubMed: PMID 22965591 · NCT00444600 (LRT for DME) · Diabetic Retinopathy
  36. Diabetic retinopathy.
    Antonetti DA, Klein R, Gardner TW, et al. · N Engl J Med · 2012 · Background
    PubMed: PMID 22455417 · NCT03784443 (CASSIE) · Macular Edema

2011 (32 papers)

  1. A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy.
    Zhao LQ, Zhu H, Zhao PQ, et al. · Br J Ophthalmol · 2011 · Trial result
    PubMed: PMID 21278146 · NCT04464694
  2. Effects of combination therapy with verteporfin photodynamic therapy and ranibizumab in patients with age-related macular degeneration.
    Wolf-Schnurrbusch UE, Brinkmann CK, Berger L, et al. · Acta Ophthalmol · 2011 · Trial result
    PubMed: PMID 19878113 · NCT00413829 · Macular Degeneration
  3. Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study.
    Tano Y, Ohji M, EXTEND-I Study Group, et al. · Acta Ophthalmol · 2011 · Trial result
    PubMed: PMID 21232078 · NCT00284089
  4. Subconjunctival bevacizumab immediately after excision of primary pterygium: the first clinical trial.
    Shenasi A, Mousavi F, Shoa-Ahari S, et al. · Cornea · 2011 · Trial result
    PubMed: PMID 21955635 · NCT02342392 · Pterygium
  5. Managing diabetic macular edema: The leading cause of diabetes blindness.
    Romero-Aroca P · World J Diabetes · 2011 · Trial result
    PubMed: PMID 21860693 · NCT02447185 (aiRTo-PDR)
  6. The effect of subconjunctival ranibizumab on primary pterygium: a pilot study.
    Mandalos A, Tsakpinis D, Karayannopoulou G, et al. · Cornea · 2011 · Trial result
    PubMed: PMID 20856107 · NCT02342392 · Pterygium
  7. Efficacy of intralesional bevacizumab injection in decreasing pterygium size.
    Fallah Tafti MR, Khosravifard K, Mohammadpour M, et al. · Cornea · 2011 · Trial result
    PubMed: PMID 20885313 · NCT02342392 · Pterygium
  8. A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: preliminary results.
    Enkvetchakul O, Thanathanee O, Rangsin R, et al. · Cornea · 2011 · Trial result
    PubMed: PMID 21915047 · NCT02342392 · Pterygium
  9. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
    Elman MJ, Bressler NM, Qin H, et al. · Ophthalmology · 2011 · Trial result
    PubMed: PMID 21459214 · NCT00445003 (LRTforDME+PRP) · Diabetic Retinopathy
  10. Ranibizumab and bevacizumab for AMD.
    Cheung CM, Wong TY · N Engl J Med · 2011 · Trial result
    PubMed: PMID 22150050 · NCT00593450 · Macular Degeneration
  11. Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
    CATT Research Group, Martin DF, Maguire MG, et al. · N Engl J Med · 2011 · Trial result
    PubMed: PMID 21526923 · NCT00593450 · Macular Degeneration
  12. Subconjunctival bevacizumab injection in treatment of pterygium.
    Besharati MR, Manaviat MR, Souzani A, et al. · Acta Med Iran · 2011 · Trial result
    PubMed: PMID 21681707 · NCT02342392 · Pterygium
  13. Pattern electroretinography in age-related macular degeneration.
    Sheybani A, Brantley MA, Apte RS, et al. · Arch Ophthalmol · 2011 · Derived
    PubMed: PMID 21555610 · NCT00500344 (CAPTAIN) · Macular Degeneration
  14. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials.
    Rosenfeld PJ, Shapiro H, Tuomi L, et al. · Ophthalmology · 2011 · Derived
    PubMed: PMID 20920825 · NCT00061594 · Macular Degeneration
  15. Cataract surgery in ranibizumab-treated patients with neovascular age-related macular degeneration from the phase 3 ANCHOR and MARINA trials.
    Rosenfeld PJ, Shapiro H, Ehrlich JS, et al. · Am J Ophthalmol · 2011 · Derived
    PubMed: PMID 21794843 · NCT00056836 · Macular Degeneration
  16. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.
    Mitchell P, Bandello F, Schmidt-Erfurth U, et al. · Ophthalmology · 2011 · Derived
    PubMed: PMID 21459215 · NCT00687804 (RESTORE) · Edema
  17. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study.
    Massin P, Bandello F, Garweg JG, et al. · Diabetes Care · 2011 · Derived
    PubMed: PMID 20980427 · NCT00284050 (RESOLVE)
  18. Patient-reported outcomes among sham vs no-treatment controls from randomized trials.
    Hawkins BS, Bressler NM, Reynolds SM, et al. · Arch Ophthalmol · 2011 · Derived
    PubMed: PMID 21320967 · NCT00056836 · Macular Degeneration
  19. Comparison of film and digital fundus photographs in eyes of individuals with diabetes mellitus.
    Gangaputra S, Almukhtar T, Glassman AR, et al. · Invest Ophthalmol Vis Sci · 2011 · Derived
    PubMed: PMID 21571677 · NCT00444600 (LRT for DME) · Diabetic Retinopathy
  20. Monthly ranibizumab for choroidal neovascularizations secondary to angioid streaks in pseudoxanthoma elasticum: a one-year prospective study.
    Finger RP, Charbel Issa P, Hendig D, et al. · Am J Ophthalmol · 2011 · Derived
    PubMed: PMID 21704964 · NCT00510965 · Choroidal Neovascularization
  21. Structure-function correlation of the human central retina.
    Charbel Issa P, Troeger E, Finger R, et al. · PLoS One · 2011 · Derived
    PubMed: PMID 20877651 · NCT00504400
  22. Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study.
    Charbel Issa P, Finger RP, Kruse K, et al. · Am J Ophthalmol · 2011 · Derived
    PubMed: PMID 21334595 · NCT00504400
  23. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy.
    Bae SH, Heo JW, Kim C, et al. · Am J Ophthalmol · 2011 · Derived
    PubMed: PMID 21742303 · NCT01325181
  24. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.
    Schmidt-Erfurth U, Eldem B, Guymer R, et al. · Ophthalmology · 2011 · Background
    PubMed: PMID 21146229 · NCT01748292 (T-REX) · Macular Degeneration
  25. Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up.
    Pece A, Isola V, Piermarocchi S, et al. · Br J Ophthalmol · 2011 · Background
    PubMed: PMID 20601660 · NCT03054766 · Retinal Vein Occlusion
  26. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration.
    Oubraham H, Cohen SY, Samimi S, et al. · Retina · 2011 · Background
    PubMed: PMID 20890246 · NCT01748292 (T-REX) · Macular Degeneration
  27. Characteristics of periconus choroidal neovascularization in pathologic myopia.
    Nagaoka N, Shimada N, Hayashi W, et al. · Am J Ophthalmol · 2011 · Background
    PubMed: PMID 21696698 · NCT03042871 (SMILE) · Choroidal Neovascularization
  28. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.
    Mintz-Hittner HA, Kennedy KA, Chuang AZ, et al. · N Engl J Med · 2011 · Background
    PubMed: PMID 21323540 · NCT04539106 · Retinopathy of Prematurity
  29. Hemodilution therapy using automated erythrocytapheresis in central retinal vein occlusion: results of a multicenter randomized controlled study.
    Glacet-Bernard A, Atassi M, Fardeau C, et al. · Graefes Arch Clin Exp Ophthalmol · 2011 · Background
    PubMed: PMID 20953877 · NCT01448018 (CHIC-3) · Retinal Vein Occlusion
  30. Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes.
    Campochiaro PA, Hafiz G, Channa R, et al. · Ophthalmology · 2011 · Background
    PubMed: PMID 20630595 · NCT01198327 (RETAIN) · Retinal Vein Occlusion
  31. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.
    Campochiaro PA, Brown DM, Awh CC, et al. · Ophthalmology · 2011 · Background
    PubMed: PMID 21715011 · NCT01710839 (WAVE) · Macular Edema
  32. Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C.
    Alkawas AA, Shahien EA, Hussein AM, et al. · J Glaucoma · 2011 · Background
    PubMed: PMID 20179624 · NCT01922154 · Retinal Vein Occlusion

2010 (24 papers)

  1. EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Tano Y, Ohji M, EXTEND-I Study Group, et al. · Acta Ophthalmol · 2010 · Trial result
    PubMed: PMID 20163368 · NCT00284089
  2. [Combined surgical and pharmacological treatment of diabetic maculopathy].
    Robaszkiewicz J, Chmielewska K, Wierzbowska J, et al. · Klin Oczna · 2010 · Trial result
    PubMed: PMID 20572497 · NCT02447185 (aiRTo-PDR)
  3. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results.
    Kokame GT, Yeung L, Lai JC, et al. · Br J Ophthalmol · 2010 · Trial result
    PubMed: PMID 19726427 · NCT00424710 (PEARL) · Choroidal Neovascularization
  4. Subclinical choroidal detachment at sclerotomy sites after 23-gauge vitrectomy: analysis by anterior segment optical coherence tomography.
    Guthoff R, Riederle H, Meinhardt B, et al. · Ophthalmologica · 2010 · Trial result
    PubMed: PMID 20332654 · NCT02447185 (aiRTo-PDR)
  5. Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoing pterygium surgery.
    Galor A, Yoo SH, Piccoli FV, et al. · Am J Ophthalmol · 2010 · Trial result
    PubMed: PMID 20417925 · NCT02342392 · Pterygium
  6. Intravitreous ranibizumab (lucentis) for radiation maculopathy.
    Finger PT, Chin KJ · Arch Ophthalmol · 2010 · Trial result
    PubMed: PMID 20142553 · NCT00750399 · Retinal Diseases
  7. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
    Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, et al. · Ophthalmology · 2010 · Trial result
    PubMed: PMID 20427088 · NCT00444600 (LRT for DME) · Diabetic Retinopathy
  8. Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration.
    Chang MA, Do DV, Bressler SB, et al. · Retina · 2010 · Trial result
    PubMed: PMID 20827138 · NCT00363168 · Choroidal Neovascularization
  9. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study.
    Kinge B, Stordahl PB, Forsaa V, et al. · Am J Ophthalmol · 2010 · Derived
    PubMed: PMID 20591399 · NCT00567697 · Macular Edema
  10. Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: a pilot study.
    Kahook MY · Am J Ophthalmol · 2010 · Derived
    PubMed: PMID 20570237 · NCT00661583 (OCTOPUS) · Glaucoma
  11. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR.
    Bressler NM, Chang TS, Suñer IJ, et al. · Ophthalmology · 2010 · Derived
    PubMed: PMID 20189654 · NCT00056836 · Macular Degeneration
  12. Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials.
    Barbazetto IA, Saroj N, Shapiro H, et al. · Am J Ophthalmol · 2010 · Derived
    PubMed: PMID 20378094 · NCT00056836 · Macular Degeneration
  13. Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab.
    Barbazetto I, Saroj N, Shapiro H, et al. · Retina · 2010 · Derived
    PubMed: PMID 20683380 · NCT00056836 · Macular Degeneration
  14. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2.
    Abraham P, Yue H, Wilson L, et al. · Am J Ophthalmol · 2010 · Derived
    PubMed: PMID 20598667 · NCT00090623 · Macular Degeneration
  15. Preliminary results of subconjunctival bevacizumab in primary pterygium excision.
    Razeghinejad MR, Hosseini H, Ahmadi F, et al. · Ophthalmic Res · 2010 · Background
    PubMed: PMID 19887878 · NCT02342392 · Pterygium
  16. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.
    Michaelides M, Kaines A, Hamilton RD, et al. · Ophthalmology · 2010 · Background
    PubMed: PMID 20416952 · NCT04991350 (REBEL) · Diabetic Retinopathy
  17. Identifying and eliminating the roadblocks to comparative-effectiveness research.
    Martin DF, Maguire MG, Fine SL, et al. · N Engl J Med · 2010 · Background
    PubMed: PMID 20519677 · NCT00593450 · Macular Degeneration
  18. Changes in diabetic macular oedema after phacoemulsification surgery.
    Hayashi K, Igarashi C, Hirata A, et al. · Eye (Lond) · 2010 · Background
    PubMed: PMID 17962820 · NCT03832179 (STAMP) · Cataract
  19. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact.
    Gupta OP, Shienbaum G, Patel AH, et al. · Ophthalmology · 2010 · Background
    PubMed: PMID 20591490 · NCT01748292 (T-REX) · Macular Degeneration
  20. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.
    Campochiaro PA, Heier JS, Feiner L, et al. · Ophthalmology · 2010 · Background
    PubMed: PMID 20398941 · NCT01198327 (RETAIN) · Retinal Vein Occlusion
  21. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.
    Brown DM, Campochiaro PA, Singh RP, et al. · Ophthalmology · 2010 · Background
    PubMed: PMID 20381871 · NCT01710839 (WAVE) · Macular Edema
  22. Intravitreal ranibizumab in the treatment of cystoid macular edema associated with retinitis pigmentosa.
    Artunay O, Yuzbasioglu E, Rasier R, et al. · J Ocul Pharmacol Ther · 2010 · Background
    PubMed: PMID 20028262 · NCT03763227 · Retinal Dystrophies
  23. High levels of serum prolactin protect against diabetic retinopathy by increasing ocular vasoinhibins.
    Arnold E, Rivera JC, Thebault S, et al. · Diabetes · 2010 · Background
    PubMed: PMID 20823101 · NCT03161652 · Macular Edema
  24. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema.
    Aiello LP, Edwards AR, Beck RW, et al. · Ophthalmology · 2010 · Background
    PubMed: PMID 20122739 · NCT01552408 (DAVE) · Macular Edema

2009 (20 papers)

  1. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials.
    Suñer IJ, Kokame GT, Yu E, et al. · Invest Ophthalmol Vis Sci · 2009 · Trial result
    PubMed: PMID 19255158 · NCT00056836 · Macular Degeneration
  2. Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin).
    Lo WR, Kim SJ, Aaberg TM, et al. · Retina · 2009 · Trial result
    PubMed: PMID 19584650 · NCT04464694
  3. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM, Michels M, Kaiser PK, et al. · Ophthalmology · 2009 · Trial result
    PubMed: PMID 19118696 · NCT00061594 · Macular Degeneration
  4. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial.
    Bressler NM, Chang TS, Fine JT, et al. · Arch Ophthalmol · 2009 · Trial result
    PubMed: PMID 19139332 · NCT00061594 · Macular Degeneration
  5. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
    Boyer DS, Heier JS, Brown DM, et al. · Ophthalmology · 2009 · Trial result
    PubMed: PMID 19643495 · NCT00251459 · Macular Degeneration
  6. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
    Lalwani GA, Rosenfeld PJ, Fung AE, et al. · Am J Ophthalmol · 2009 · Derived
    PubMed: PMID 19376495 · NCT00344227 · Macular Degeneration
  7. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials.
    Bhavsar AR, Googe JM, Stockdale CR, et al. · Arch Ophthalmol · 2009 · Derived
    PubMed: PMID 20008710 · NCT00444600 (LRT for DME) · Diabetic Retinopathy
  8. Intravitreal bevacizumab (Avastin) injection in retinitis pigmentosa.
    Yuzbasioglu E, Artunay O, Rasier R, et al. · Curr Eye Res · 2009 · Background
    PubMed: PMID 19274531 · NCT03763227 · Retinal Dystrophies
  9. Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium.
    Wu PC, Kuo HK, Tai MH, et al. · Cornea · 2009 · Background
    PubMed: PMID 19092418 · NCT02342392 · Pterygium
  10. Effect of subconjunctival bevacizumab on primary pterygium.
    Teng CC, Patel NN, Jacobson L, et al. · Cornea · 2009 · Background
    PubMed: PMID 19411971 · NCT02342392 · Pterygium
  11. Effect of focal/grid photocoagulation on visual acuity and retinal thickening in eyes with non-center-involved diabetic macular edema.
    Scott IU, Danis RP, Bressler SB, et al. · Retina · 2009 · Background
    PubMed: PMID 19373126 · NCT01552408 (DAVE) · Macular Edema
  12. Treatment of inflamed pterygia or residual pterygial bed.
    Mansour AM · Br J Ophthalmol · 2009 · Background
    PubMed: PMID 19553512 · NCT02342392 · Pterygium
  13. Incidence of retinopathy of prematurity in the United States: 1997 through 2005.
    Lad EM, Hernandez-Boussard T, Morton JM, et al. · Am J Ophthalmol · 2009 · Background
    PubMed: PMID 19541285 · NCT04539106 · Retinopathy of Prematurity
  14. The clinical role of vascular endothelial growth factor (VEGF) system in the pathogenesis of retinopathy of prematurity.
    Kwinta P, Bik-Multanowski M, Mitkowska Z, et al. · Graefes Arch Clin Exp Ophthalmol · 2009 · Background
    PubMed: PMID 18546007 · NCT04539106 · Retinopathy of Prematurity
  15. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes.
    Klein R, Knudtson MD, Lee KE, et al. · Ophthalmology · 2009 · Background
    PubMed: PMID 19167079 · NCT01610557
  16. Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma.
    Kitnarong N, Chindasub P, Metheetrairut A, et al. · Adv Ther · 2009 · Background
    PubMed: PMID 18425438 · NCT01922154 · Retinal Vein Occlusion
  17. Long-term visual acuity results of treated and untreated radiation retinopathy (an AOS thesis).
    Kinyoun JL · Trans Am Ophthalmol Soc · 2009 · Background
    PubMed: PMID 19277244 · NCT02222610 (RRR)
  18. Aqueous vascular endothelial growth factor as a predictor of macular thickening following cataract surgery in patients with diabetes mellitus.
    Hartnett ME, Tinkham N, Paynter L, et al. · Am J Ophthalmol · 2009 · Background
    PubMed: PMID 19837384 · NCT03832179 (STAMP) · Cataract
  19. "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation.
    Engelbert M, Zweifel SA, Freund KB, et al. · Retina · 2009 · Background
    PubMed: PMID 19898180 · NCT01748292 (T-REX) · Macular Degeneration
  20. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema.
    Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, et al. · Arch Ophthalmol · 2009 · Background
    PubMed: PMID 19273785 · NCT01552408 (DAVE) · Macular Edema

2008 (14 papers)

  1. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.
    Regillo CD, Brown DM, Abraham P, et al. · Am J Ophthalmol · 2008 · Trial result
    PubMed: PMID 18222192 · NCT00090623 · Macular Degeneration
  2. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.
    Kaiser PK, Brown DM, Zhang K, et al. · Am J Ophthalmol · 2008 · Trial result
    PubMed: PMID 17949673 · NCT00061594 · Macular Degeneration
  3. Rapid improvement of radiation-induced neovascular glaucoma and exudative retinal detachment after a single intravitreal ranibizumab injection.
    Dunavoelgyi R, Zehetmayer M, Simader C, et al. · Clin Exp Ophthalmol · 2008 · Trial result
    PubMed: PMID 18173426 · NCT01922154 · Retinal Vein Occlusion
  4. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.
    Bahar I, Kaiserman I, McAllum P, et al. · Curr Eye Res · 2008 · Trial result
    PubMed: PMID 18214740 · NCT02342392 · Pterygium
  5. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.
    Antoszyk AN, Tuomi L, Chung CY, et al. · Am J Ophthalmol · 2008 · Derived
    PubMed: PMID 18321465 · NCT00056823 · Macular Degeneration
  6. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression.
    Wang K, Wang Y, Gao L, et al. · Biol Pharm Bull · 2008 · Background
    PubMed: PMID 18670086 · NCT03784443 (CASSIE) · Macular Edema
  7. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy.
    Simó R, Hernández C · Diabetologia · 2008 · Background
    PubMed: PMID 18404258 · NCT02979665
  8. Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin).
    Gupta A, Muecke JS · Retina · 2008 · Background
    PubMed: PMID 18698298 · NCT02222610 (RRR)
  9. Intravitreal steroids for macular edema in diabetes.
    Grover D, Li TJ, Chong CC, et al. · Cochrane Database Syst Rev · 2008 · Background
    PubMed: PMID 18254088 · NCT03784443 (CASSIE) · Macular Edema
  10. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control.
    Gilbert C · Early Hum Dev · 2008 · Background
    PubMed: PMID 18234457 · NCT04539106 · Retinopathy of Prematurity
  11. Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation.
    García C, Aranda J, Arnold E, et al. · J Clin Invest · 2008 · Background
    PubMed: PMID 18497878 · NCT03161652 · Macular Edema
  12. Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin).
    Finger PT · Int J Radiat Oncol Biol Phys · 2008 · Background
    PubMed: PMID 18313522 · NCT00750399 · Retinal Diseases
  13. Vasoinhibins: novel inhibitors of ocular angiogenesis.
    Clapp C, Thebault S, Arnold E, et al. · Am J Physiol Endocrinol Metab · 2008 · Background
    PubMed: PMID 18544641 · NCT03161652 · Macular Edema
  14. Causes of blind certifications in England and Wales: April 1999-March 2000.
    Bunce C, Wormald R · Eye (Lond) · 2008 · Background
    PubMed: PMID 17332762 · NCT03784443 (CASSIE) · Macular Edema

2007 (19 papers)

  1. Evaluation of the efficacy of vitrectomy for persistent diabetic macular edema and associated factors predicting outcome.
    Song SJ, Sohn JH, Park KH, et al. · Korean J Ophthalmol · 2007 · Trial result
    PubMed: PMID 17804919 · NCT02447185 (aiRTo-PDR)
  2. Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia.
    Hosseini H, Nejabat M, Khalili MR, et al. · Med Hypotheses · 2007 · Trial result
    PubMed: PMID 17367957 · NCT02342392 · Pterygium
  3. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial.
    Chang TS, Bressler NM, Fine JT, et al. · Arch Ophthalmol · 2007 · Derived
    PubMed: PMID 17998507 · NCT00056836 · Macular Degeneration
  4. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema.
    Writing Committee for the Diabetic Retinopathy Clinical Research Network, Fong DS, Strauber SF, et al. · Arch Ophthalmol · 2007 · Background
    PubMed: PMID 17420366 · NCT01552408 (DAVE) · Macular Edema
  5. Ranibizumab according to need: a treatment for age-related macular degeneration.
    Spaide R · Am J Ophthalmol · 2007 · Background
    PubMed: PMID 17386275 · NCT01748292 (T-REX) · Macular Degeneration
  6. Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy.
    Siqueira RC, Costa RA, Scott IU, et al. · Acta Ophthalmol Scand · 2007 · Background
    PubMed: PMID 17083555 · NCT00618644 · Retinal Diseases
  7. Evaluation of costs for cystoid macular edema among patients after cataract surgery.
    Schmier JK, Halpern MT, Covert DW, et al. · Retina · 2007 · Background
    PubMed: PMID 17558326 · NCT03832179 (STAMP) · Cataract
  8. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema.
    Nguyen QD, Tatlipinar S, Shah SM, et al. · Am J Ophthalmol · 2007 · Background
    PubMed: PMID 17046701 · NCT02511067 (READ-4)
  9. Bevacizumab and retinal ischemia.
    Neubauer AS, Kook D, Haritoglou C, et al. · Ophthalmology · 2007 · Background
    PubMed: PMID 17980746 · NCT02979665
  10. Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma.
    Mason JO, Albert MA, Persaud TO, et al. · Retina · 2007 · Background
    PubMed: PMID 17891015 · NCT02222610 (RRR)
  11. Visual acuity change after intravitreal triamcinolone in various types of exudative age-related macular degeneration.
    Jonas JB, Strueven V, Kamppeter BA, et al. · J Ocul Pharmacol Ther · 2007 · Background
    PubMed: PMID 17076632 · NCT01552408 (DAVE) · Macular Edema
  12. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.
    Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. · Am J Ophthalmol · 2007 · Background
    PubMed: PMID 17157590 · NCT00727038 (NVG) · Retinal Vein Occlusion
  13. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Fung AE, Lalwani GA, Rosenfeld PJ, et al. · Am J Ophthalmol · 2007 · Background
    PubMed: PMID 17386270 · NCT00590694 (DETAIL) · Macular Degeneration
  14. Anti-vascular endothelial growth factor bevacizumab (avastin) for radiation retinopathy.
    Finger PT, Chin K · Arch Ophthalmol · 2007 · Background
    PubMed: PMID 17562985 · NCT02222610 (RRR)
  15. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema.
    Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, et al. · Ophthalmology · 2007 · Background
    PubMed: PMID 17698196 · NCT01552408 (DAVE) · Macular Edema
  16. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial.
    Chaudhary V, Mao A, Hooper PL, et al. · Ophthalmology · 2007 · Background
    PubMed: PMID 18054638 · NCT01243086 (STAR) · Macular Degeneration
  17. Pharmacokinetics of intravitreal bevacizumab (Avastin).
    Bakri SJ, Snyder MR, Reid JM, et al. · Ophthalmology · 2007 · Background
    PubMed: PMID 17467524 · NCT04539106 · Retinopathy of Prematurity
  18. Pharmacokinetics of intravitreal ranibizumab (Lucentis).
    Bakri SJ, Snyder MR, Reid JM, et al. · Ophthalmology · 2007 · Background
    PubMed: PMID 18054637 · NCT04539106 · Retinopathy of Prematurity
  19. Current concepts and techniques in pterygium treatment.
    Ang LP, Chua JL, Tan DT, et al. · Curr Opin Ophthalmol · 2007 · Background
    PubMed: PMID 17568207 · NCT02342392 · Pterygium

2006 (27 papers)

  1. Ranibizumab: Phase III clinical trial results.
    Rosenfeld PJ, Rich RM, Lalwani GA, et al. · Ophthalmol Clin North Am · 2006 · Trial result
    PubMed: PMID 16935211 · NCT02291887 · Macular Degeneration
  2. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Rosenfeld PJ, Heier JS, Hantsbarger G, et al. · Ophthalmology · 2006 · Trial result
    PubMed: PMID 16581423 · NCT02291887 · Macular Degeneration
  3. Ranibizumab for neovascular age-related macular degeneration.
    Rosenfeld PJ, Brown DM, Heier JS, et al. · N Engl J Med · 2006 · Trial result
    PubMed: PMID 17021318 · NCT02328209
  4. Promising new treatments for neovascular age-related macular degeneration.
    Michels S, Schmidt-Erfurth U, Rosenfeld PJ, et al. · Expert Opin Investig Drugs · 2006 · Trial result
    PubMed: PMID 16787141 · NCT02291887 · Macular Degeneration
  5. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
    Heier JS, Antoszyk AN, Pavan PR, et al. · Ophthalmology · 2006 · Trial result
    PubMed: PMID 16483659 · NCT02291887 · Macular Degeneration
  6. Dynamics of retinal function after multiple photodynamic therapies in age-related macular degeneration: a report of cases.
    Feigl B, Brown B, Lovie-Kitchin J, et al. · Doc Ophthalmol · 2006 · Trial result
    PubMed: PMID 16523231 · NCT02291887 · Macular Degeneration
  7. Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
    Brown DM, Kaiser PK, Michels M, et al. · N Engl J Med · 2006 · Trial result
    PubMed: PMID 17021319 · NCT00061594 · Macular Degeneration
  8. Optical coherence tomography demonstration of macular infarction in sickle cell retinopathy.
    Witkin AJ, Rogers AH, Ko TH, et al. · Arch Ophthalmol · 2006 · Background
    PubMed: PMID 16682603 · NCT00618644 · Retinal Diseases
  9. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
    VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, D'Amico DJ, Masonson HN, et al. · Ophthalmology · 2006 · Background
    PubMed: PMID 16647134 · NCT00390208 (PDEX) · Macular Degeneration
  10. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization.
    Tong JP, Chan WM, Liu DT, et al. · Am J Ophthalmol · 2006 · Background
    PubMed: PMID 16490490 · NCT02976194 (CyPov) · Polypoidal Choroidal Vasculopathy
  11. Rationale for combination therapies for choroidal neovascularization.
    Spaide RF · Am J Ophthalmol · 2006 · Background
    PubMed: PMID 16386991 · NCT01810042 · Macular Degeneration
  12. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
    Spaide RF, Laud K, Fine HF, et al. · Retina · 2006 · Background
    PubMed: PMID 16603955 · NCT00390208 (PDEX) · Macular Degeneration
  13. Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium.
    Prabhasawat P, Tesavibul N, Leelapatranura K, et al. · Ophthalmology · 2006 · Background
    PubMed: PMID 16730066 · NCT02342392 · Pterygium
  14. Diabetic cataract removal: postoperative progression of maculopathy--growth factor and clinical analysis.
    Patel JI, Hykin PG, Cree IA, et al. · Br J Ophthalmol · 2006 · Background
    PubMed: PMID 16540489 · NCT03832179 (STAMP) · Cataract
  15. Occult with no classic choroidal neovascularization secondary to age-related macular degeneration treated by intravitreal triamcinolone and photodynamic therapy with verteporfin.
    Nicolò M, Ghiglione D, Lai S, et al. · Retina · 2006 · Background
    PubMed: PMID 16395140 · NCT00390208 (PDEX) · Macular Degeneration
  16. Vision loss in younger patients: a review of choroidal neovascularization.
    Miller DG, Singerman LJ · Optom Vis Sci · 2006 · Background
    PubMed: PMID 16699445 · NCT03042871 (SMILE) · Choroidal Neovascularization
  17. Influence of treatment parameters on selectivity of verteporfin therapy.
    Michels S, Hansmann F, Geitzenauer W, et al. · Invest Ophthalmol Vis Sci · 2006 · Background
    PubMed: PMID 16384987 · NCT00423189 · Macular Degeneration
  18. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment.
    Maturi RK, Bleau LA, Wilson DL, et al. · Retina · 2006 · Background
    PubMed: PMID 16508425 · NCT00390208 (PDEX) · Macular Degeneration
  19. Testing intravitreal toxicity of bevacizumab (Avastin).
    Manzano RP, Peyman GA, Khan P, et al. · Retina · 2006 · Background
    PubMed: PMID 16508423 · NCT00390208 (PDEX) · Macular Degeneration
  20. Intravitreal bevacizumab in a patient with neovascular glaucoma.
    Kahook MY, Schuman JS, Noecker RJ, et al. · Ophthalmic Surg Lasers Imaging · 2006 · Background
    PubMed: PMID 16583637 · NCT00727038 (NVG) · Retinal Vein Occlusion
  21. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.
    Fung AE, Rosenfeld PJ, Reichel E, et al. · Br J Ophthalmol · 2006 · Background
    PubMed: PMID 16854824 · NCT00727038 (NVG) · Retinal Vein Occlusion
  22. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection.
    Davidorf FH, Mouser JG, Derick RJ, et al. · Retina · 2006 · Background
    PubMed: PMID 16508439 · NCT00727038 (NVG) · Retinal Vein Occlusion
  23. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema.
    Chun DW, Heier JS, Topping TM, et al. · Ophthalmology · 2006 · Background
    PubMed: PMID 17011952 · NCT02511067 (READ-4)
  24. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.
    Avery RL · Retina · 2006 · Background
    PubMed: PMID 16508438 · NCT00618644 · Retinal Diseases
  25. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Avery RL, Pieramici DJ, Rabena MD, et al. · Ophthalmology · 2006 · Background
    PubMed: PMID 16458968 · NCT00390208 (PDEX) · Macular Degeneration
  26. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration.
    Augustin AJ, Schmidt-Erfurth U · Am J Ophthalmol · 2006 · Background
    PubMed: PMID 16564797 · NCT00390208 (PDEX) · Macular Degeneration
  27. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study.
    Arias L, Garcia-Arumi J, Ramon JM, et al. · Ophthalmology · 2006 · Background
    PubMed: PMID 16996600 · NCT00930189 · Macular Degeneration

2005 (16 papers)

  1. Improvement of visual acuity in eyes with diabetic macular edema after treatment with pars plana vitrectomy.
    Jahn CE, Töpfner von Schutz K, Richter J, et al. · Ophthalmologica · 2005 · Trial result
    PubMed: PMID 15564755 · NCT02447185 (aiRTo-PDR)
  2. Pegaptanib for neovascular age-related macular degeneration.
    Gragoudas ES, Adamis AP, Cunningham ET, et al. · N Engl J Med · 2005 · Trial result
    PubMed: PMID 15625332 · NCT00813891 · Macular Degeneration
  3. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina.
    Tamura H, Miyamoto K, Kiryu J, et al. · Invest Ophthalmol Vis Sci · 2005 · Background
    PubMed: PMID 15790913 · NCT00390208 (PDEX) · Macular Degeneration
  4. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization.
    Spaide RF, Sorenson J, Maranan L, et al. · Ophthalmology · 2005 · Background
    PubMed: PMID 15691567 · NCT00390208 (PDEX) · Macular Degeneration
  5. Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma.
    Shields CL, Demirci H, Dai V, et al. · Retina · 2005 · Background
    PubMed: PMID 16205566 · NCT02222610 (RRR)
  6. Global data on visual impairment in the year 2002.
    Resnikoff S, Pascolini D, Etya'ale D, et al. · Bull World Health Organ · 2005 · Background
    PubMed: PMID 15640920 · NCT00813891 · Macular Degeneration
  7. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia.
    Nguyen QD, Shah S, Tatlipinar S, et al. · Br J Ophthalmol · 2005 · Background
    PubMed: PMID 16170134 · NCT03042871 (SMILE) · Choroidal Neovascularization
  8. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema.
    Funatsu H, Yamashita H, Sakata K, et al. · Ophthalmology · 2005 · Background
    PubMed: PMID 15878060 · NCT03784443 (CASSIE) · Macular Edema
  9. Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapy.
    Finger PT, Kurli M · Br J Ophthalmol · 2005 · Background
    PubMed: PMID 15923510 · NCT02222610 (RRR)
  10. Vascular endothelial growth factor: basic science and clinical progress.
    Ferrara N · Endocr Rev · 2005 · Background
    PubMed: PMID 15294883 · NCT00727038 (NVG) · Retinal Vein Occlusion
  11. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown.
    Edelman JL, Lutz D, Castro MR, et al. · Exp Eye Res · 2005 · Background
    PubMed: PMID 15670803 · NCT00390208 (PDEX) · Macular Degeneration
  12. Choroidal neovascularisation in pathological myopia: an update in management.
    Chan WM, Ohji M, Lai TY, et al. · Br J Ophthalmol · 2005 · Background
    PubMed: PMID 16234465 · NCT03042871 (SMILE) · Choroidal Neovascularization
  13. Macular infarction a presentation of sickle cell crisis.
    Chalam KV, Shah VA · Eye (Lond) · 2005 · Background
    PubMed: PMID 15105819 · NCT00618644 · Retinal Diseases
  14. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
    Azab M, Boyer DS, Bressler NM, et al. · Arch Ophthalmol · 2005 · Background
    PubMed: PMID 15824216 · NCT00423189 · Macular Degeneration
  15. Prolactins are natural inhibitors of angiogenesis in the retina.
    Aranda J, Rivera JC, Jeziorski MC, et al. · Invest Ophthalmol Vis Sci · 2005 · Background
    PubMed: PMID 16043870 · NCT03161652 · Macular Edema
  16. Angiogenic pathways in diabetic retinopathy.
    Aiello LP · N Engl J Med · 2005 · Background
    PubMed: PMID 16120866 · NCT03784443 (CASSIE) · Macular Edema

2004 (12 papers)

  1. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies.
    Ciulla TA, Amador AG, Zinman B, et al. · Diabetes Care · 2004 · Trial result
    PubMed: PMID 12941734 · NCT02140411 · Macular Degeneration
  2. Computer-assisted measurement of retinal vessel diameters in the Beaver Dam Eye Study: methodology, correlation between eyes, and effect of refractive errors.
    Wong TY, Knudtson MD, Klein R, et al. · Ophthalmology · 2004 · Background
    PubMed: PMID 15177969 · NCT01810042 · Macular Degeneration
  3. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.
    Wild S, Roglic G, Green A, et al. · Diabetes Care · 2004 · Background
    PubMed: PMID 15111519 · NCT02140411 · Macular Degeneration
  4. Epidemiology of age-related maculopathy: a review.
    van Leeuwen R, Klaver CC, Vingerling JR, et al. · Eur J Epidemiol · 2004 · Background
    PubMed: PMID 14561043 · NCT00500344 (CAPTAIN) · Macular Degeneration
  5. The epidemiology of age-related macular degeneration.
    Klein R, Peto T, Bird A, et al. · Am J Ophthalmol · 2004 · Background
    PubMed: PMID 15013873 · NCT00500344 (CAPTAIN) · Macular Degeneration
  6. Prevalence and causes of visual impairment in an elderly Chinese population in Taiwan: the Shihpai Eye Study.
    Hsu WM, Cheng CY, Liu JH, et al. · Ophthalmology · 2004 · Background
    PubMed: PMID 14711715 · NCT02810808 (ARTIS)
  7. Pathogenesis of lesions in late age-related macular disease.
    Holz FG, Pauleikhoff D, Klein R, et al. · Am J Ophthalmol · 2004 · Background
    PubMed: PMID 15013875 · NCT00813891 · Macular Degeneration
  8. Prevalence of age-related macular degeneration in the United States.
    Friedman DS, O'Colmain BJ, Muñoz B, et al. · Arch Ophthalmol · 2004 · Background
    PubMed: PMID 15078675 · NCT00813891 · Macular Degeneration
  9. Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases.
    Di Girolamo N, Chui J, Coroneo MT, et al. · Prog Retin Eye Res · 2004 · Background
    PubMed: PMID 15094131 · NCT02342392 · Pterygium
  10. Causes and prevalence of visual impairment among adults in the United States.
    Congdon N, O'Colmain B, Klaver CC, et al. · Arch Ophthalmol · 2004 · Background
    PubMed: PMID 15078664 · NCT00813891 · Macular Degeneration
  11. Age-related macular degeneration is the leading cause of blindness..
    Bressler NM · JAMA · 2004 · Background
    PubMed: PMID 15108691 · NCT00813891 · Macular Degeneration
  12. Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema.
    Audren F, Tod M, Massin P, et al. · Invest Ophthalmol Vis Sci · 2004 · Background
    PubMed: PMID 15452046 · NCT01552408 (DAVE) · Macular Edema

2003 (10 papers)

  1. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results.
    Eyetech Study Group · Ophthalmology · 2003 · Trial result
    PubMed: PMID 12750101 · NCT02291887 · Macular Degeneration
  2. Myopic choroidal neovascularization: a 10-year follow-up.
    Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. · Ophthalmology · 2003 · Background
    PubMed: PMID 12867382 · NCT03042871 (SMILE) · Choroidal Neovascularization
  3. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor.
    Schmidt-Erfurth U, Schlötzer-Schrehard U, Cursiefen C, et al. · Invest Ophthalmol Vis Sci · 2003 · Background
    PubMed: PMID 14507895 · NCT00390208 (PDEX) · Macular Degeneration
  4. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier.
    Saishin Y, Saishin Y, Takahashi K, et al. · J Cell Physiol · 2003 · Background
    PubMed: PMID 12652651 · NCT00813891 · Macular Degeneration
  5. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization.
    Rakic JM, Lambert V, Devy L, et al. · Invest Ophthalmol Vis Sci · 2003 · Background
    PubMed: PMID 12824270 · NCT00813891 · Macular Degeneration
  6. Risk factors for age related maculopathy in a Japanese population: the Hisayama study.
    Miyazaki M, Nakamura H, Kubo M, et al. · Br J Ophthalmol · 2003 · Background
    PubMed: PMID 12642312 · NCT02810808 (ARTIS)
  7. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema.
    Funatsu H, Yamashita H, Ikeda T, et al. · Ophthalmology · 2003 · Background
    PubMed: PMID 13129863 · NCT03784443 (CASSIE) · Macular Edema
  8. Intravitreal dexamethasone effectively reduces postoperative inflammation after vitreoretinal surgery.
    Chalam KV, Malkani S, Shah VA, et al. · Ophthalmic Surg Lasers Imaging · 2003 · Background
    PubMed: PMID 12757090 · NCT00390208 (PDEX) · Macular Degeneration
  9. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11.
    Bressler NM, Bressler SB, Congdon NG, et al. · Arch Ophthalmol · 2003 · Background
    PubMed: PMID 14609922 · NCT00813891 · Macular Degeneration
  10. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.
    Blinder KJ, Blumenkranz MS, Bressler NM, et al. · Ophthalmology · 2003 · Background
    PubMed: PMID 12689884 · NCT03042871 (SMILE) · Choroidal Neovascularization

2002 (10 papers)

  1. Retinal angiomatous proliferation in age-related macular degeneration.
    Yannuzzi LA, Negrão S, Iida T, et al. · Retina · 2002 · Background
    PubMed: PMID 11642370 · NCT00813891 · Macular Degeneration
  2. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes.
    Verteporfin Roundtable 2000 and 2001 Participants, Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group principal investigators, Verteporfin in photodynamic therapy (VIP) study group principal investigators, et al. · Retina · 2002 · Background
    PubMed: PMID 11884872 · NCT00813891 · Macular Degeneration
  3. Plasma level of interleukin-6 is an indicator for predicting diabetic macular edema.
    Shimizu E, Funatsu H, Yamashita H, et al. · Jpn J Ophthalmol · 2002 · Background
    PubMed: PMID 11853719 · NCT02511067 (READ-4)
  4. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes.
    Otani A, Takagi H, Oh H, et al. · Microvasc Res · 2002 · Background
    PubMed: PMID 12074642 · NCT00813891 · Macular Degeneration
  5. Intravitreal triamcinolone for refractory diabetic macular edema.
    Martidis A, Duker JS, Greenberg PB, et al. · Ophthalmology · 2002 · Background
    PubMed: PMID 11986098 · NCT01552408 (DAVE) · Macular Edema
  6. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.
    Krzystolik MG, Afshari MA, Adamis AP, et al. · Arch Ophthalmol · 2002 · Background
    PubMed: PMID 11879138 · NCT00813891 · Macular Degeneration
  7. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19.
    Jampol LM, Moy CS, Murray TG, et al. · Ophthalmology · 2002 · Background
    PubMed: PMID 12466159 · NCT02222610 (RRR)
  8. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
    Bressler NM, Arnold J, Benchaboune M, et al. · Arch Ophthalmol · 2002 · Background
    PubMed: PMID 12427056 · NCT00390208 (PDEX) · Macular Degeneration
  9. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion.
    Boyd SR, Zachary I, Chakravarthy U, et al. · Arch Ophthalmol · 2002 · Background
    PubMed: PMID 12470137 · NCT01710839 (WAVE) · Macular Edema
  10. Vascular endothelial growth factor causally contributes to the angiogenic response upon ultraviolet B irradiation in vivo.
    Blaudschun R, Sunderkötter C, Brenneisen P, et al. · Br J Dermatol · 2002 · Background
    PubMed: PMID 11966687 · NCT02342392 · Pterygium

2001 (8 papers)

  1. Prevention of photoreceptor apoptosis by activation of the glucocorticoid receptor.
    Wenzel A, Grimm C, Seeliger MW, et al. · Invest Ophthalmol Vis Sci · 2001 · Background
    PubMed: PMID 11381074 · NCT00390208 (PDEX) · Macular Degeneration
  2. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.
    Verteporfin in Photodynamic Therapy Study Group · Ophthalmology · 2001 · Background
    PubMed: PMID 11320011 · NCT03042871 (SMILE) · Choroidal Neovascularization
  3. Risk factors for age-related macular degeneration: Pooled findings from three continents.
    Smith W, Assink J, Klein R, et al. · Ophthalmology · 2001 · Background
    PubMed: PMID 11297486 · NCT02810808 (ARTIS)
  4. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma.
    Sivak-Callcott JA, O'Day DM, Gass JD, et al. · Ophthalmology · 2001 · Background
    PubMed: PMID 11581047 · NCT00727038 (NVG) · Retinal Vein Occlusion
  5. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium.
    Schwesinger C, Yee C, Rohan RM, et al. · Am J Pathol · 2001 · Background
    PubMed: PMID 11238064 · NCT00813891 · Macular Degeneration
  6. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16.
    Melia BM, Abramson DH, Albert DM, et al. · Ophthalmology · 2001 · Background
    PubMed: PMID 11158813 · NCT02222610 (RRR)
  7. Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia.
    Lee DH, Cho HJ, Kim JT, et al. · Cornea · 2001 · Background
    PubMed: PMID 11588427 · NCT02342392 · Pterygium
  8. Sickle cell disease presenting with extensive peri-macular arteriolar occlusions in a nine-year-old boy.
    Al-Abdulla NA, Haddock TA, Kerrison JB, et al. · Am J Ophthalmol · 2001 · Background
    PubMed: PMID 11228315 · NCT00618644 · Retinal Diseases

2000 (3 papers)

  1. Prevalence and risk factors for refractive errors in adult Chinese in Singapore.
    Wong TY, Foster PJ, Hee J, et al. · Invest Ophthalmol Vis Sci · 2000 · Background
    PubMed: PMID 10937558 · NCT03042871 (SMILE) · Choroidal Neovascularization
  2. Visual outcomes following the use of intravitreal steroids in the treatment of postoperative endophthalmitis.
    Shah GK, Stein JD, Sharma S, et al. · Ophthalmology · 2000 · Background
    PubMed: PMID 10711885 · NCT00390208 (PDEX) · Macular Degeneration
  3. Histopathologic study of presumed parafoveal telangiectasis.
    Gass JD · Retina · 2000 · Background
    PubMed: PMID 10783967 · NCT00457145 · Telangiectasis

1999 (4 papers)

  1. The UKPDS. A model for gathering the evidence for the management of chronic diseases. UK Prospective Diabetes Study Group.
    Watkins P · J R Coll Physicians Lond · 1999 · Background
    PubMed: PMID 9881303 · NCT01552408 (DAVE) · Macular Edema
  2. [Continuing education provided by the Diabetes Society. Results of the UKPDS (United Kingdom Diabetes Society) and therapeutic guidelines concerning diabetes type II].
    Lüddeke HJ · Fortschr Med · 1999 · Background
    PubMed: PMID 9889462 · NCT01552408 (DAVE) · Macular Edema
  3. Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma.
    Gündüz K, Shields CL, Shields JA, et al. · Arch Ophthalmol · 1999 · Background
    PubMed: PMID 10326957 · NCT02222610 (RRR)
  4. Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey.
    Friedman DS, Katz J, Bressler NM, et al. · Ophthalmology · 1999 · Background
    PubMed: PMID 10366070 · NCT02810808 (ARTIS)

1998 (5 papers)

  1. The Hong Kong vision study: a pilot assessment of visual impairment in adults.
    Van Newkirk MR · Trans Am Ophthalmol Soc · 1998 · Background
    PubMed: PMID 9440191 · NCT03042871 (SMILE) · Choroidal Neovascularization
  2. Microvascular density in terms of number and length of microvessel segments per unit tissue volume in mammalian angiogenesis.
    Norrby K · Microvasc Res · 1998 · Background
    PubMed: PMID 9473408 · NCT04878835
  3. The 14-year incidence of visual loss in a diabetic population.
    Moss SE, Klein R, Klein BE, et al. · Ophthalmology · 1998 · Background
    PubMed: PMID 9627648 · NCT03784443 (CASSIE) · Macular Edema
  4. The efficacy of focal laser therapy in radiation-induced macular edema.
    Hykin PG, Shields CL, Shields JA, et al. · Ophthalmology · 1998 · Background
    PubMed: PMID 9709753 · NCT02222610 (RRR)
  5. VEGF localisation in diabetic retinopathy.
    Boulton M, Foreman D, Williams G, et al. · Br J Ophthalmol · 1998 · Background
    PubMed: PMID 9713066 · NCT00685503 · Neovascularization, Pathologic

1997 (10 papers)

  1. Abnormal expression of the p53 tumor suppressor gene in the conjunctiva of patients with pterygium.
    Tan DT, Lim AS, Goh HS, et al. · Am J Ophthalmol · 1997 · Background
    PubMed: PMID 9063255 · NCT02342392 · Pterygium
  2. Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision.
    Tan DT, Chee SP, Dear KB, et al. · Arch Ophthalmol · 1997 · Background
    PubMed: PMID 9338666 · NCT02342392 · Pterygium
  3. Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision.
    Prabhasawat P, Barton K, Burkett G, et al. · Ophthalmology · 1997 · Background
    PubMed: PMID 9186439 · NCT02342392 · Pterygium
  4. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization.
    Okamoto N, Tobe T, Hackett SF, et al. · Am J Pathol · 1997 · Background
    PubMed: PMID 9212753 · NCT00813891 · Macular Degeneration
  5. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.
    Arch Ophthalmol · 1997 · Background
    PubMed: PMID 9109757 · NCT01710839 (WAVE) · Macular Edema
  6. Histopathologic features of neovascularization in sickle cell retinopathy.
    McLeod DS, Merges C, Fukushima A, et al. · Am J Ophthalmol · 1997 · Background
    PubMed: PMID 9323937 · NCT00618644 · Retinal Diseases
  7. Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease.
    Manski TJ, Heffner DK, Glenn GM, et al. · JAMA · 1997 · Background
    PubMed: PMID 9145719 · NCT00089765 · Macular Edema
  8. Increased expression of angiogenic growth factors in age-related maculopathy.
    Kliffen M, Sharma HS, Mooy CM, et al. · Br J Ophthalmol · 1997 · Background
    PubMed: PMID 9059252 · NCT00813891 · Macular Degeneration
  9. Physical activity and the risk of progression of retinopathy or the development of proliferative retinopathy.
    Cruickshanks KJ, Moss SE, Klein R, et al. · Ophthalmology · 1997 · Background
    PubMed: PMID 9097744 · NCT01552408 (DAVE) · Macular Edema
  10. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report.
    Ophthalmology · 1997 · Background
    PubMed: PMID 9097789 · NCT01710839 (WAVE) · Macular Edema

1996 (4 papers)

  1. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes.
    Lopez PF, Sippy BD, Lambert HM, et al. · Invest Ophthalmol Vis Sci · 1996 · Background
    PubMed: PMID 8603870 · NCT00813891 · Macular Degeneration
  2. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor.
    Kvanta A, Algvere PV, Berglin L, et al. · Invest Ophthalmol Vis Sci · 1996 · Background
    PubMed: PMID 8759365 · NCT00813891 · Macular Degeneration
  3. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes.
    Frank RN, Amin RH, Eliott D, et al. · Am J Ophthalmol · 1996 · Background
    PubMed: PMID 8794712 · NCT00813891 · Macular Degeneration
  4. A prospective study of cigarette smoking and risk of age-related macular degeneration in men.
    Christen WG, Glynn RJ, Manson JE, et al. · JAMA · 1996 · Background
    PubMed: PMID 8827967 · NCT01710839 (WAVE) · Macular Edema

1995 (4 papers)

  1. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group.
    Arch Ophthalmol · 1995 · Background
    PubMed: PMID 7487614 · NCT00727038 (NVG) · Retinal Vein Occlusion
  2. Hyperglycemia and microvascular and macrovascular disease in diabetes.
    Klein R · Diabetes Care · 1995 · Background
    PubMed: PMID 7729308 · NCT02511067 (READ-4)
  3. Retinal microaneurysm counts and 10-year progression of diabetic retinopathy.
    Klein R, Meuer SM, Moss SE, et al. · Arch Ophthalmol · 1995 · Background
    PubMed: PMID 7487599 · NCT01552408 (DAVE) · Macular Edema
  4. Prevention and treatment of the complications of diabetes mellitus.
    Klein M · N Engl J Med · 1995 · Background
    PubMed: PMID 7643896 · NCT01552408 (DAVE) · Macular Edema

1994 (5 papers)

  1. Diseases of the retina.
    D'Amico DJ · N Engl J Med · 1994 · Trial result
    PubMed: PMID 8208273 · NCT02291887 · Macular Degeneration
  2. DCCT and us: how far are we from implementation?
    Muggeo M · Acta Diabetol · 1994 · Background
    PubMed: PMID 8111068 · NCT01552408 (DAVE) · Macular Edema
  3. Pterygium recurrence time.
    Hirst LW, Sebban A, Chant D, et al. · Ophthalmology · 1994 · Background
    PubMed: PMID 8152771 · NCT02342392 · Pterygium
  4. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration.
    Amin R, Puklin JE, Frank RN, et al. · Invest Ophthalmol Vis Sci · 1994 · Background
    PubMed: PMID 7519180 · NCT00685503 · Neovascularization, Pathologic
  5. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.
    Aiello LP, Avery RL, Arrigg PG, et al. · N Engl J Med · 1994 · Background
    PubMed: PMID 7526212 · NCT01748292 (T-REX) · Macular Degeneration

1993 (1 paper)

  1. Diode laser photocoagulation for threshold retinopathy of prematurity. A randomized study.
    Hunter DG, Repka MX · Ophthalmology · 1993 · Background
    PubMed: PMID 8437833 · NCT04539106 · Retinopathy of Prematurity

1992 (2 papers)

  1. Continued breakdown of the blood aqueous barrier following cataract surgery.
    Ferguson VM, Spalton DJ · Br J Ophthalmol · 1992 · Background
    PubMed: PMID 1390524 · NCT03832179 (STAMP) · Cataract
  2. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.
    de Vries C, Escobedo JA, Ueno H, et al. · Science · 1992 · Background
    PubMed: PMID 1312256 · NCT01710839 (WAVE) · Macular Edema

1991 (3 papers)

  1. Laser photocoagulation for stage 3+ retinopathy of prematurity.
    McNamara JA, Tasman W, Brown GC, et al. · Ophthalmology · 1991 · Background
    PubMed: PMID 2062488 · NCT04539106 · Retinopathy of Prematurity
  2. Laser photocoagulation for threshold retinopathy of prematurity.
    Iverson DA, Trese MT, Orgel IK, et al. · Arch Ophthalmol · 1991 · Background
    PubMed: PMID 1929909 · NCT04539106 · Retinopathy of Prematurity
  3. Evaluation of a single intravitreal injection of dexamethasone phosphate in vitrectomy surgery for diabetic retinopathy complications.
    Blankenship GW · Graefes Arch Clin Exp Ophthalmol · 1991 · Background
    PubMed: PMID 2004725 · NCT00390208 (PDEX) · Macular Degeneration

1990 (2 papers)

  1. Electroretinography in central retinal vein occlusion. Correlation of electroretinographic changes with pupillary abnormalities.
    Hayreh SS, Klugman MR, Podhajsky P, et al. · Graefes Arch Clin Exp Ophthalmol · 1990 · Background
    PubMed: PMID 2483144 · NCT01710839 (WAVE) · Macular Edema
  2. Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor.
    Conn G, Bayne ML, Soderman DD, et al. · Proc Natl Acad Sci U S A · 1990 · Background
    PubMed: PMID 2320579 · NCT01710839 (WAVE) · Macular Edema

1989 (2 papers)

  1. Human vascular permeability factor. Isolation from U937 cells.
    Connolly DT, Olander JV, Heuvelman D, et al. · J Biol Chem · 1989 · Background
    PubMed: PMID 2584205 · NCT01710839 (WAVE) · Macular Edema
  2. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis.
    Connolly DT, Heuvelman DM, Nelson R, et al. · J Clin Invest · 1989 · Background
    PubMed: PMID 2478587 · NCT01710839 (WAVE) · Macular Edema

1988 (1 paper)

  1. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group.
    Arch Ophthalmol · 1988 · Background
    PubMed: PMID 2895630 · NCT04539106 · Retinopathy of Prematurity

1987 (1 paper)

  1. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group.
    Ophthalmology · 1987 · Background
    PubMed: PMID 3658348 · NCT01552408 (DAVE) · Macular Edema

1986 (1 paper)

  1. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.
    Arch Ophthalmol · 1986 · Background
    PubMed: PMID 2866759 · NCT01552408 (DAVE) · Macular Edema

1985 (1 paper)

  1. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema.
    Klein R, Klein BE, Moss SE, et al. · Ophthalmology · 1985 · Background
    PubMed: PMID 6521986 · NCT01610557

1983 (1 paper)

  1. Complications of vitreous surgery for diabetic retinopathy. II. Postoperative complications.
    Schachat AP, Oyakawa RT, Michels RG, et al. · Ophthalmology · 1983 · Background
    PubMed: PMID 6192378 · NCT02647515 · Diabetic Retinopathy

1979 (2 papers)

  1. From the NIH: Study identifies four factors in diabetic retinopathy associated with high risk of severe visual loss.
    JAMA · 1979 · Background
    PubMed: PMID 581885 · NCT01552408 (DAVE) · Macular Edema
  2. Four risk factors for severe visual loss in diabetic retinopathy. The third report from the Diabetic Retinopathy Study. The Diabetic Retinopathy Study Research Group.
    Arch Ophthalmol · 1979 · Background
    PubMed: PMID 426679 · NCT01552408 (DAVE) · Macular Edema

1969 (1 paper)

  1. Ocular pressure and visual fields. A ten-year follow-up study.
    Armaly MF · Arch Ophthalmol · 1969 · Background
    PubMed: PMID 5763217 · NCT01710839 (WAVE) · Macular Edema

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Tue, 02 Jun 2026 16:35:49 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).